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Summary 
Characterising the role of TET2 in oestrogen receptor positive breast cancer 
Rebecca Elizabeth Broome 
 
The activity of the transcription factor oestrogen receptor  (ER) drives tumour 
development and metastasis in ER positive (ER+) breast cancer. This subtype constitutes 
up to three-quarters of breast cancer cases, and treatments directly targeting ER are 
currently the standard of care. ER operates as part of a signalling complex, co-ordinating 
with several other proteins to regulate gene expression. GATA3 is a transcription factor 
that has been closely linked to ER function, although its precise contribution to ER biology 
is not fully understood. The initial aim of this thesis was to further investigate the role of 
GATA3 in ER signalling. In doing so, GATA3 was shown to regulate the participation of 
the dioxygenase enzyme TET2 in the ER complex. The remainder of the thesis 
investigates the contribution of TET2 to ER biology.  
 
Quantitative multiplexed rapid immunoprecipitation mass spectrometry of endogenous 
proteins (qPLEX-RIME) was used to assess changes to the ER complex in response to 
GATA3 knockdown. Upon GATA3 silencing, and its loss from the ER complex, TET2 stood 
out as the only additional protein that was significantly depleted as an ER interactor, whilst 
several proteins were significantly enriched in the ER complex, including the transcription 
factors LHX4 and ZBTB34. LHX4 and ZBTB34 are thought to be capable of binding 
methylated DNA, whilst TET2 is also implicated in DNA methylation pathways through its 
iterative conversion of methylated DNA to several additional DNA modifications, 5-
hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine. These results implied 
a potential role for GATA3 in modulating reading and writing of DNA modifications as part 
of the ER complex. In the context of the recently developing focus on TET2 in 
transcriptional regulation, the association between ER and TET2 was investigated further. 
  
As few studies have successfully mapped endogenous TET2-chromatin interactions using 
chromatin immunoprecipitation (ChIP), the performance of various TET2 antibodies was 
evaluated using both ChIP and non-quantitative RIME. A commerical antibody was 
identifed that performed robustly in both techniques, and TET2 binding events were 
subsequently shown to constitute a near-total subset of ER binding events in both ER+ 
breast cancer cell lines and patient-derived xenograft models. ER was shown to bind at 
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several sites upstream of the TET2 promoter, supporting multiple existing studies 
proposing TET2 as an ER target gene. A key role for TET2 in the ER complex was further 
reinforced using non-quantitative RIME, where it was shown that TET2 associates not 
only with ER and GATA3, but additionally with several other key ER-associated proteins 
such as FOXA1, GREB1 and RARα. It was hypothesised that TET2, as an ER-regulated 
component of the ER complex, may help to sustain ER-regulated transcription in breast 
cancer. 
 
Consistent with a role for TET2 in mediating the proper activity of the ER complex, loss of 
TET2 correlated with a depletion of global ER binding. This was associated with 
dysregulated expression of both ER and GATA3 target genes. The genes most markedly 
regulated by loss of TET2 in ER+ breast cancer cells included those related to cell cycle 
control, and providing functional evidence of this, growth of ER+ MCF7 cells was inhibited 
by TET2 knockdown. To investigate the TET2-ER relationship in more detail, the role of 
TET2 in regulating DNA modifications in ER+ breast cancer cells was examined. TET2 
knockdown did not appear to induce changes in global DNA methylation, and whilst 
preliminary data suggested TET2 may modulate DNA methylation levels specifically at ER 
binding regions, this remains to be fully determined. However, additional studies showed 
that TET2 robustly regulates oxidation of methylated DNA to 5-hydroxymethylcytosine in 
ER+ breast cancer cells, indicating a role for this enzyme in the production and 
maintenance of 5-hydroxymethylcytosine at ER sites. The conclusion to this thesis puts 
the work presented into perspective and provides an outlook for future studies. 
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Introduction 
1.1 Breast cancer 
Breast cancer accounts for one in four female cancers, with 1.67 million new cases 
diagnosed globally in 2012. It is the leading cause of cancer-related death amongst 
women in less developed regions of the world, and in more developed regions, is second 
only to lung cancer (Ferlay et al. 2015). Breast cancer can also occur in men, although 
this constitutes less than 1% of all cases (Korde et al. 2010). In the UK, ~55,000 new 
cases are diagnosed yearly (2014-2016 statistics, Cancer Research UK). Risk factors for 
breast cancer include both environmental and hereditary components. Mutations in the 
BRCA1 and BRCA2 genes are known to significantly increase the probability of 
developing breast cancer, and are associated with 5% of all cases (Ripperger et al. 2009). 
Other factors contributing to breast cancer risk include age and hormone exposure. In 
women, the latter can be linked to the number of full-term pregnancies a woman 
undergoes and the age at which full-term pregnancy first occurs, as well as the use of 
hormone replacement therapy (Key et al. 2001). 
1.1.1 Breast cancer classification 
Breast cancer is a heterogeneous disease that can be grouped into several different 
subtypes. Classifications are based on both the cell type of origin and the presence or 
absence of several key molecular markers. Tumours can arise from either the ductal or 
lobular epithelial tissue of the breast, with ductal malignancies being the most common (Li 
2003). A hormonal component to breast cancer has long been established, since the 
demonstration by Beatson that removal of the ovaries, the major sex hormone-producing 
tissue in females, reduced tumour burden in a patient suffering with breast cancer 
Chapter 1 
2 
 
(Beatson 1896). As such, the molecular classification of breast cancers is largely based 
on the presence or absence of the hormone receptor oestrogen receptor α (ERα) (Sorlie 
et al. 2001). ERα negative tumours constitute three main subtypes, characterised either 
by high expression of keratins and laminin (basal-like), elevated expression of human 
epidermal growth factor receptor 2 (HER2+), or the broad expression of adipose and other 
non-epithelial cell genes (normal breast-like). In contrast, ERα positive tumours 
recapitulate many characteristics of the luminal epithelial cells of the breast, including 
expression of the transcription factors GATA binding protein 3 (GATA3), X-box binding 
protein 1 (XBP1), and hepatocyte nuclear factor 3α, also known as Forkhead box protein 
A1 (FOXA1) (Sorlie et al. 2001; Perou et al. 2000). Of the ERα positive and ERα negative 
classes, ERα positive tumours are by far the most common, accounting for over two-thirds 
of all breast cancer cases.  
 
Molecular classification of breast cancer can help predict both risk of recurrence and 
treatment response. For example, the PAM50 classification is a gene expression assay 
which measures differential expression of 50 key genes to accurately classify breast 
tumours according to the subtypes described above (Parker et al. 2009; Ellis et al. 2011), 
and can be used to predict the benefit of hormonal therapy and chemotherapy across all 
breast cancer subtypes. More recently, genome-wide analysis of large patient datasets 
has facilitated further subclassifcation of breast cancers into 11 different integrative 
(IntClust) subtypes. This classification is based on a combination of genomic copy-number 
alterations and gene expression. The integrative clusters each have different prognostic 
values and may provide more accurate predictions of disease recurrence, facilitating more 
effective treatment and monitoring (Curtis et al. 2012; Ali et al. 2014; Rueda et al. 2019). 
 
1.2 The oestrogen receptor (ER) 
ER is a nuclear hormone receptor that acts as a ligand-dependent transcription factor. In 
the canonical mechanism of ER signalling, ER binds to its ligand, most commonly 17β-
oestradiol (E2), a metabolite of oestrogen. This induces conformational changes leading 
to receptor homodimerisation, which facilitates ER binding at oestrogen response 
elements (EREs) where it regulates gene expression (Kumar et al. 1987). There are two 
subtypes of the oestrogen receptor, ERα and ERβ, encoded by different genes. These 
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proteins share some structural homology (Kuiper et al. 1996) and are both expressed in 
hormone-responsive tissues such as the ovaries, prostate, testis, and breast. However, 
ERα and ERβ display differing cellular distributions in the mammary gland (Speirs et al. 
2002), indicative of their potentially divergent functions. ERβ has been proposed to have 
a growth suppressive rather than growth stimulatory role in the breast, and may 
antagonise the effects of ERα in both normal development and cancer (Speirs et al. 2002). 
Despite the potential of a role for ERβ in breast cancer, of the two subtypes, ERα 
(hereafter ER) is far more directly implicated in this disease, and has formed the basis of 
the majority of investigations into breast cancer aetiology and treatment. 
1.2.1 ER in normal physiology and cancer 
The activity of ER in both the normal breast and in cancer is driven primarily by oestrogens, 
a group of female sex hormones that play a fundamental role in mammary gland 
development. There are three major naturally-occurring oestrogens in women: oestrone, 
oestradiol, and oestriol. An additional oestrogen, oestetrol, is produced only during 
pregnancy. Oestradiol is the major circulating oestrogen during reproductive years, and is 
also the most potent of all four oestrogens (Baker 2013). As all these hormones act 
through ER, these four forms will henceforth be collectively referred to as oestrogen. 
Oestrogen drives ductal elongation, branching and lactational differentiation of the 
mammary gland after puberty, and is subsequently associated with epithelial proliferation 
in the breast during the menstrual cycle and in pregnancy (Brisken & O’Malley 2010). Mice 
possessing a mutated, oestrogen-unresponsive ER are developmentally viable but suffer 
reproductive defects (Lubahn et al. 1993), and selective ablation of ER in the mammary 
gland arrests its development at the prepubertal stage (Feng et al. 2007). ER acts in 
synchrony with several other hormones such as progesterone and prolactin to regulate 
these diverse developmental processes in a timely and co-ordinated manner (Brisken & 
Ataca 2015). However, whilst in the normal breast, ER expression is restricted to a subset 
(~7%) of cells (Shoker et al. 1999), during malignancy its activities in regulating cell 
proliferation are co-opted by cancer cells. As such, the majority of breast tumours exhibit 
ER expression as a key feature. In breast cancer, ER continues to regulate cell growth by 
driving expression of genes related to the cell cycle and proliferation, however these 
processes gradually escape normal control mechanisms, and oestrogen becomes a driver 
for tumour development (Carroll 2016). ER positive (ER+) breast cancers tend to have a 
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better prognosis than ER negative (ER-) subtypes, partly due to the fact that ER presents 
a tractable target for therapeutic intervention (Parker et al. 2009). However, even within 
the ER+ class, tumours possess marked heterogeneity and differ in their treatment 
response (Lacroix & Leclercq 2004; Curtis et al. 2012). 
1.2.2 ER structure 
ER is a 66 kDa protein, with a structure similar to other members of the nuclear receptor 
superfamily, such as the progesterone receptor, the androgen receptor, and the 
glucocorticoid receptor (Huang et al. 2010). ER possesses three major domains: an N-
terminal domain, a DNA-binding domain (DBD), and a ligand-binding domain (LBD). 
Within this, the protein is divided into six functional domains, classified as A-F (Figure 1.1). 
Functional domains A and B make up Activation Function domain 1 (AF-1). This region 
acts in a ligand-independent manner and is important for ER dimerisation prior to DNA 
binding. Functional domain C constitutes the DBD, where ER-DNA interactions are 
mediated through two zinc finger motifs (Klinge 2001). Domain D contains a nuclear 
localisation signal and is the hinge region of the protein. Domains E and F contain both 
the LBD, and a second Activation Function domain, AF-2. In the LBD, 12 alpha helices 
(H1-H12) create a structure that facilitates the docking of oestrogen (Brzozowski et al. 
1997), whilst AF-2 possesses both a nuclear localisation signal and a further dimerisation 
domain. Importantly, both AF-1 and AF-2 are key mediators of the interactions between 
ER and its cofactors, proteins recruited by the receptor that help it to achieve its 
transcriptional functions. AF-1 and AF-2 can act either independently or synergistically to 
recruit cofactors, with the hinge region (domain C) shown to aid this synergistic recruitment 
(Zwart et al. 2010). 
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Figure 1.1. Structure of ER. 
The N-terminus of ER (functional domains A/B) comprises activation function domain 1 
(AF-1). Functional domain C contains the DNA binding domain (DBD), where two zinc 
finger motifs facilitate ER-DNA interactions. Domain D is the hinge region, whilst domains 
E and F comprise activation function domain 2 (AF-2), and the ligand binding domain 
(LBD), where endogenous ER ligands bind. 
 
1.2.3 Oestrogen response elements (EREs) 
Where present in the cytoplasm, ER is capable of indirectly affecting gene expression 
through non-genomic routes, for example through interacting with tyrosine kinases that 
co-ordinate intracellular signalling cascades (Madak-Erdogan et al. 2008). However, the 
majority of ER-regulated gene expression occurs through its ligand-activated assembly of 
transcription-regulating complexes at specific genomic regions. ER DNA binding motifs 
are known as oestrogen response elements (EREs). The canonical ERE is a 13-bp 
palindromic motif with the consensus sequence GGTCAnnnTGACC (Klinge 2001), and 
ER binds as a homodimer to this sequence. In vitro studies have showed that ER binding 
is preserved in the presence of minor variations in the canonical ERE (Schwabe et al. 
1995), and chromatin immunoprecipitation followed by sequencing (ChIP-seq) to map ER-
chromatin interactions has demonstrated that in many cases, only half this sequence is 
required for ER-DNA interactions (Joseph et al. 2010; Lin et al. 2007; Bourdeau et al. 
2004). Whilst variations within the ERE can affect ER binding affinity, differences in the 
sequence of flanking regions can also influence the strength of ER binding (Anolik et al. 
1995). Conferring further diversity on the mechanisms and affinity of ER binding, ER can 
also tether to DNA via protein-protein interactions with other transcription factors 
(discussed below) (Kushner et al. 2000; Safe 2001; Lin et al. 2007), which in some cases 
may mitigate the requirement of an ERE for effective oestrogen-mediated gene regulation. 
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1.2.4 ER acts mainly from enhancers 
Transcription factors exert their effects on gene expression through interacting with 
different regulatory elements within the genome, including promoters, enhancers, 
insulators and boundary elements (Fulton et al. 2009; Palstra & Grosveld 2012). ChIP-
seq has shown that ER predominantly associates with distal regulatory elements, and only 
~3-5% of ER binding events occur in promoter-proximal regions (within 1-5 kb of the 
transcription start site, TSS) (Carroll et al. 2005; Carroll et al. 2006; Lin et al. 2007). 
Although the function of these promoter-distal ER binding sites was initially unknown, 
subsequent experiments confirmed these as enhancers, genomic regions where 
regulatory factors assemble to modulate gene expression at various distances from their 
target promoter (or promoters) (Pennacchio et al. 2013). Therefore, whilst a number of ER 
target genes (including ESR1 itself) do possess promoter-proximal ER binding sites, most 
ER regulatory sites are distal to the genes they control (Carroll et al. 2006; Laganiere et 
al. 2005). Whilst ER binds primarily at enhancers, transcriptional regulation is effected 
ultimately at promoters, where the basal transcription machinery assembles to initiate 
mRNA assembly. It appears that the influence of ER function on promoter activity is 
mediated through chromatin looping that connects transcriptional regulatory complexes 
assembled at enhancers with their target promoters, translating the effects of ER at distal 
sites to TSSs (Fullwood et al. 2009; Kadauke & Blobel 2009; Pan et al. 2008). 
 
Although different studies report varying numbers of ER binding events (even within the 
same cell line), it is generally concluded that there are many more ER binding sites in the 
genome than there are differentially regulated genes. This is partly consistent with the 
enhancer model, whereby multiple enhancers may regulate a single gene (Karnuta & 
Scacheri 2018). However, this could also imply that some of these ER sites might not have 
a transcriptional function in the cell types in which they are observed, and/or under the 
experimental conditions in which they are detected. Some of these apparently 
transcriptionally non-functional ER sites may exert transcriptional influences in different 
cell types or under different conditions (Carroll et al. 2006). Overall, enhancers appear to 
be poorly conserved, both across different species, and different tissue types (Pennacchio 
et al. 2013), suggestive of a role in regulating cell type-specific expression (Heintzman et 
al. 2009; Heinz et al. 2015). Taken together, these factors render it difficult to link 
enhancers directly to their target genes.  
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Several techniques have facilitated mapping of specific ER-regulated enhancer-promoter 
interactions, with the rationale that physical association between specific chromatin 
domains may provide evidence of a functional connection between these regions. 
Chromosome conformation capture (3C) (Dekker et al. 2002) has been used to identify, 
in a targeted manner, ER enhancers physically associated with the promoters of several 
key oestrogen-regulated genes, including TFF1 (trefoil factor 1), PGR (progesterone 
receptor), and GREB1 (growth regulation by estrogen in breast cancer 1) (Bonéy-Montoya 
et al. 2010; Deschênes et al. 2007; Pan et al. 2008). The subsequent development of a 
genome-wide approach to mapping factor-specific enhancer-promoter interactions, ChIA-
PET (chromatin interaction analysis by paired-end tag sequencing) allowed Fullwood et 
al. (2009) to probe ER-mediated chromatin looping in MCF7 cells. This demonstrated that 
the majority (86%) of ER-mediated chromatin loops anchoring two regulatory sites occur 
in the range of 10-100 kb. However, it was shown that overall, ER-mediated loops tend to 
connect more than two regulatory sites at once, highlighting the potentially diverse and 
complex nature of ER-regulated gene expression. More recently, Hi-C (high-throughput 
chromosome conformation capture), an unbiased technique for examining overall 
chromatin architecture, has been used to show that oestrogen induces a global 
reorganisation of chromatin structure in MCF7 cells (Mourad et al. 2014). Specifically, this 
showed that gene-rich chromosomes and areas of open and highly transcribed chromatin 
are brought into closer proximity by oestrogen treatment in these cells, presumably 
triggering interplay between the transcriptional regulatory machinery assembled at 
enhancers, and the promoters of target genes. Accordingly, analysis of these differentially-
regulated loci showed an enrichment of oestrogen-induced genes and those related to 
proliferative control.  
 
An additional phenomenon that may be useful in connecting distal enhancers to regulation 
of potential target promoters is the expression of enhancer RNAs (eRNAs). These are 
non-coding RNAs transcribed as a result of RNA polymerase II activity at enhancers. 
Oestrogen-induced eRNAs have been suggested to be important in ER-mediated gene 
expression through interactions with promoters, and may themselves have a role in 
oestrogen-induced chromatin looping (Li et al. 2013; Hah et al. 2013), although this is a 
contentious issue requiring further research. More recent attempts to infer functional links 
between specific cis-regulatory elements and their regulated genes have utilised CRISPR-
based approaches, systematically disrupting transcription factor binding sites in 
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combination with studying the effect on the expression of nearby genes (for example Fei 
et al. 2019). The approaches described above, when used in combination, may can help 
narrow down those cell type-specific ER binding events that display functionality with 
respect to gene expression. 
 
1.3  The ER complex 
ER does not function in isolation, but co-operates with numerous proteins to achieve its 
transcriptional functions. Some of these proteins, known as cofactors, help the receptor to 
access its target sites, and some function as adapters mediating further protein-protein 
interactions. Additionally, others possess intrinsic enzymatic activity and can faciliate, for 
example, modification of histones and chromatin remodelling. Several of these key 
processes are described in the next sections. 
1.3.1 ER-associated transcription factors 
1.3.1.1 Pioneer factors  
Although ER mediates its transcriptional actions predominantly through binding to DNA, it 
cannot achieve independent access to compacted chromatin. Pioneer factors are proteins 
that can associate with condensed chromatin and enable ATP-independent remodelling 
to facilitate the binding of further transcription factors (Zaret & Carroll 2011). The first 
pioneer factor characterised in relation to ER was FOXA1 (Carroll et al. 2005) which 
achieves its remodelling functions partly through its ability to displace linker histones 
(Cirillo et al. 1998; Cirillo et al. 2002). FOXA1 expression is considered a key marker of 
ER+ luminal tumours (Perou et al. 2000; Sorlie et al. 2001). ChIP-seq has shown that 
~50% of ER binding events are co-occupied by FOXA1 in ER+ breast cancer cell lines 
(Hurtado et al. 2011), yet FOXA1 silencing results in decreased ER-chromatin occupancy 
even at sites where FOXA1 is not initially detected, suggesting it is capable of stabilising 
ER binding in both a direct and indirect manner. Depletion of FOXA1 in ER+ breast cancer 
cell lines has profound effects on oestrogen-regulated gene expression and results in 
impaired proliferation (Hurtado et al. 2011; Laganiere et al. 2005), indicative of its key role 
in ER-mediated transcription. Genomic binding of FOXA1 is not dependent on oestrogen 
treatment, suggesting that this factor demarcates regulatory sites prior to ER recruitment 
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to DNA, and hence determines the ER pathways that are regulated upon ligand stimulation 
(Glont et al. 2019; Hurtado et al. 2011). In line with this, differing distributions of ER binding 
are observed between primary tumours with good versus poor outcomes, and this is 
thought to be mediated by FOXA1 (Ross-Innes et al. 2012). Why FOXA1 behaves 
differently in terms of its binding distribution in cancers with different outcomes remains 
under investigation. 
 
FOXA1 is not the only protein that provides pioneer functions for ER. The transcription 
factor transducin-like enhancer of split 1 (TLE1), shown to interact with histones but 
previously thought to mediate chromatin condensation (Palaparti et al. 1997; Sekiya & 
Zaret 2007), is important for ER binding at a subset of sites in ER+ breast cancer cells. 
Loss of TLE1 alters recruitment of RNA polymerase II at ER sites, associated with impared 
proliferation (Holmes et al. 2012). Other proteins possessing pioneer factor-like activity in 
relation to ER include pre-B-cell leukemia transcription factor 1 (PBX1) and activating 
enhancer-binding protein 2 gamma (AP2-γ), both of which also co-occupy ~50% of ER 
binding sites in ER+ breast cancer cell lines and are important for oestrogen-regulated 
gene expression and cell growth (Magnani et al. 2011, 2015; Tan et al. 2011). Analysis of 
FOXA1, PBX1 and AP2-γ binding events in the MCF7 genome showed that despite their 
potentially similar roles, these three proteins co-associate at ~30% of ER binding events, 
implying that in some instances they may act co-operatively in mediating ER access to 
chromatin (Jozwik & Carroll 2012). 
1.3.1.2 GATA3  
Another transcription factor that is consistently implicated in ER+ breast cancer is GATA3. 
Along with FOXA1, GATA3 is one of the minimal gene markers of ER+ tumours (Perou et 
al. 2000; Sorlie et al. 2001), and, similarly to FOXA1 motifs, GATA3 motifs are enriched 
around ER binding sites in MCF7 cells, implying a functional interplay between these three 
proteins (Carroll et al. 2005; Lin et al. 2007; Serandour et al. 2013). ER and GATA3 
overlap at ~45% of ER binding events in E2-stimulated MCF7 cells, and co-expression of 
ER, GATA3 and FOXA1 together was shown to be required to confer oestrogen-
responsive growth in an ER negative, oestrogen-unresponsive cell line (Kong et al. 2011). 
Eeckhoute et al. (2007) also showed a key role for GATA3 in oestrogen-mediated growth, 
demonstrating that GATA3 knockdown in ER+ T47D cells reduces their proliferative 
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response to oestrogen stimulation. Much like ER, GATA3 plays a fundamental role in 
mammary gland development, and conditional deletion of GATA3 results in severe 
maturation defects of the mouse mammary ductal tree during puberty (Kouros-Mehr et al. 
2006). In breast cancer, loss of GATA3 is associated with a higher histologic grade, poor 
differentiation, and positive lymph nodes, concurrent with loss of ER expression (Chou et 
al. 2010; Mehra et al. 2005; Perou et al. 2000; Sorlie et al. 2001; Sorlie et al. 2003). 
Notably, GATA3 is mutated in more than 10% of all breast cancers. These mutations are 
markedly enriched in luminal cancers, which are typically ER+, compared to basal 
cancers, which are typically ER- (~15% versus ~2% of cases) (Cancer Genome Atlas 
Network 2012). These mutations cluster in the second zinc finger of GATA3, but are 
diverse and result in varying changes to the overall protein, including both truncations and 
elongations (Cancer Genome Atlas Network 2012; Emmanuel et al. 2018; Usary et al. 
2004). Despite studies on the effects of certain mutants in breast cancer cell lines 
(Adomas et al. 2014; Gustin et al. 2017; Takaku et al. 2018), the association between 
mutant GATA3 and clinical outcome is unclear (Du et al. 2015; Liu et al. 2016), and it is 
possible that the various GATA3 mutations may each have different functional 
consequences. It has been suggested that GATA proteins may also possess pioneer 
factor-like activities (Cirillo et al. 2002; Takaku et al. 2016). However, although loss of 
GATA3 in MCF7 cells does affect ER binding, this appears to be a context-dependent 
modulation, with equivalent numbers of stronger and weaker ER binding sites observed 
(Theodorou et al. 2013). Therefore, although GATA3 demonstrates a clear and 
undeniable connection to ER+ disease, this connection may be complex, and further 
investigations are required to determine its precise contribution to ER signalling. 
1.3.1.3 Tethering proteins  
Additional transcription factors often found enriched at ER sites include activator protein 
1 (AP-1, a heterodimer consisting of proteins belonging to the c-Jun and c-Fos families) 
and specificity protein 1 (Sp1). Experiments have shown that these factors likely mediate 
tethering of ER to the DNA, through the finding that ER deficient in its DNA-binding 
capacity can still efficiently modulate oestrogen-regulated transcription at ER/AP-1 and 
ER/Sp1 co-occupied sites (Porter et al. 1997; Jakacka et al. 2001). More recent studies 
investigating the genome-wide binding profile of an ER DBD mutant have shown that the 
transcription factor runt-related transcription factor 1 (RUNX1) may also have a role in 
tethering ER to the DNA at certain regions (Stender et al. 2010). 
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1.3.2 Co-regulators mediating ER target gene activation and repression 
1.3.2.1 Histone modifiers 
Histone modifications are highly implicated in the co-ordinated regulation of transcription. 
Through altering histone-DNA interactions, they primarily serve to regulate chromatin 
accessibility, modulating the assembly of transcriptional complexes to regulate gene 
expression in a context-dependent manner. In addition, histone marks may also act as 
binding sites for transcriptional co-regulators (Zhou et al. 2011; Shlyueva et al. 2014). 
Different types of histone modifications are associated with gene activation, whilst others 
correlate with gene repression, and the dynamic regulation of these marks achieved by 
the ER complex as a whole is diverse and wide-ranging. Focusing on proteins immediately 
and directly recruited to the activated ER complex, many of these coordinate changes in 
histone modifications. These include members of the p160 family, such as nuclear 
receptor co-activators NCOA1 (SRC1), NCOA2 (SRC2 or GRIP1) and NCOA3 (SRC3 or 
AIB1) (Anzick et al. 1997; Hong et al. 1997; Onate et al. 1995). Whilst these factors do not 
have intrinsic enzymatic capacity, they act as adapter proteins for the recruitment of 
histone acetyltransferases (HATs), which modify histone N-terminal tails through the 
addition of acetyl groups (Rollins et al. 2015). The p160 proteins interact with ER via their 
central nuclear receptor interaction domain, where LXXLL motifs facilitate interactions with 
the AF-2 domain of ER (Heery et al. 1997). This provides a platform for the recruitment of 
HATs such as CREB-binding protein (CBP), p300 and pCAF (p300/CBP-associated 
factor). These enzymes acetylate histones, which weakens DNA-histone interactions, 
decondensing chromatin and facilitating the recruitment of further transcriptional co-
regulators. As evidence of the importance of this process, histone acetylation, in particular 
at lysine 27 of histone H3 (H3K27ac) is a key mark associated with active enhancers 
(Zhou at al. 2011), and increases at many ER-regulated enhancers in response to 
oestrogen treatment (Hah et al. 2013; Lupien et al. 2009). HATs CBP and p300 can also 
mediate interactions with active RNA polymerase II, providing a connection to the general 
transcription machinery (Neish et al. 1998; Rollins et al. 2015).  
 
Additional histone modifiers that are recruited to the activated ER complex and positively 
regulate transcription include histone methyltransferases (HMTs) such as protein arginine 
methyltransferases 1 (PRMT1) and 4 (PRMT4, also known as CARM1). Whilst HATs CBP 
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and p300 are recruited to the ER complex through interactions with the activation domain 
1 (AD1) of p160 family proteins, PRMT1 and CARM1 can be recruited through a separate 
activation domain, AD2 (Koh et al. 2001). Through methylating arginine residues of 
histones H3 and H4, CARM1 and PRMT4 act synergistically with CBP and p300 to 
decondense chromatin and enhance ER-mediated transcription (Chen et al. 2000; Ma et 
al. 2001; Wagner et al. 2006).  
 
Whilst ER is most often discussed in the context of gene activation, about half of ER-
regulated genes are repressed in response to oestrogen (Carroll et al. 2006). The precise 
mechanisms that determine whether ER represses or activates transcription remain 
unclear. It has been suggested that ER binding correlates less strongly with the TSSs of 
oestrogen-downregulated genes than with the TSSs of oestrogen-upregulated genes, 
implying that ER-mediated repression may more frequently involve distal or secondary 
regulation compared to ER-mediated induction (Carroll et al. 2006). Mechanistically, it is 
likely that ER achieves gene repression through a variety of means. This may include 
indirect methods such as displacement of co-activators, or rate-limiting competition for co-
activators, known as squelching. However, ER is also known to interact with a number of 
transcriptional co-repressors, implying a role for ER in mediating direct oestrogen-
stimulated repression of some of its target genes (Zubairy & Oesterreich, 2005). Similarly 
to ER-mediated induction, this ER-mediated repression is also thought to involve changes 
in histone modifications, for example through adapter-mediated recruitment of histone 
deacetylases (HDACs). These enzymes counter the effects of HATs by removing 
activating histone acetylation marks, leading to a more condensed chromatin state. 
Receptor-interacting protein 140 (RIP140), repressor of estrogen receptor activity (REA) 
and the nuclear receptor co-repressor (NCOR) family proteins are some of the cofactors 
that can direct ER-mediated gene repression through their interactions with HDACs 
(Castet et al. 2004; Delage-Mourroux et al. 2000; Lazar 2003; Stossi et al. 2006; 
Varlakhanova et al. 2010). As many of these co-repressors, like the p160 co-activators, 
also interact with ER via its AF-2 domain, co-activator and co-repressor recruitment are 
often mutually exclusive (Watson et al. 2012). This implies that competition between 
functionally opposing co-regulators can contribute to the distinct activating or repressing 
actions of ER, and indeed it has been shown that REA and NCOA1 compete for binding 
to the ER AF-2 domain (Delage-Mourroux et al. 2000). Nevertheless, certain HDACs may 
also be capable of interacting with ER directly (Leong et al. 2005). 
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1.3.2.2 ATP-dependent chromatin remodellers  
In addition to the changes in chromatin structure induced by ER-directed histone 
modifications, ATP-dependent chromatin remodelling complexes also have a role in 
oestrogen-activated gene expression. These complexes alter the spatial organisation of 
nucleosomes. This is achieved either through repositioning nucleosomes along DNA, 
restructuring them through exchanging their histone components for different variants, or 
mediating their expulsion or disassembly (Wang et al. 2007). All of these processes may 
render chromatin more or less accessible to transcription factors. Brahma-Related Gene 
1 (BRG1) and BRG1-associated factor 57 (BAF57), both members of the SWItch/Sucrose 
Non-Fermentable (SWI/SNF) chromatin remodelling complex, have been shown to 
Figure 1.2. The ER complex recruits co-activators regulating histone modifications. 
ER binds at enhancers in conjunction with other key transcription factors, such as the 
pioneer factor FOXA1, and ER-associated protein GATA3. The recruitment of p160 
adapters to the activated ER provides a platform for interactions with histone 
acetyltransferases such as p300, and histone methyltransferases such as CARM1. The 
histone modifications mediated by these enzymes decondense chromatin and facilitate 
activation of transcription by RNA polymerase II (Pol II). H3K27ac = acetylation of histone 
H3 lysine 27; H3R17me = methylation of histone H3 arginine 17. 
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interact with ER via its AF-2 domain, and appear important for oestrogen-mediated gene 
expression (Belandia et al. 2002; DiRenzo et al. 2000; García-Pedrero et al. 2006). More 
specifically, DiRenzo et al. (2000) showed that BRG1-mediated co-activation of ER activity 
is dependent on its ATPase function, indicating that active chromatin remodelling is a key 
component of ER transcriptional regulation. 
1.3.2.3 DNA methylation  
The chemical composition of DNA itself can also undgero epigenetic changes, and it 
appears that DNA modifications may also play a role in ER-regulated transcription. 
Methylation of the 5’ carbon of cytosine by DNA methyltransferases (DNMTs) results in 5-
methylcytosine (5mC), an epigenetic mark thought to play a role in transcriptional 
regulation (Moore et al. 2013). Several studies have demonstrated a link between ER 
signalling, methylation, and transcriptional regulation at specific loci. For example, 
oestrogen treatment induces methylation of the CYP1A1 promoter and silencing of 
CYP1A1 expression in MCF7 cells (Marques et al. 2013). In a broader study, Ariazi et al. 
(2017) proposed ER may repress a subset of its target genes, including tumour 
suppressors and genes relating to basal-like phenotypes, through directing methylation of 
regulatory sites. In contrast, studies by Leu et al. (2004) and Stone et al. (2012) both 
showed that dysregulation of ER signalling (via silencing or antihormone treatment, 
respectively) resulted in downregulation of the ER target gene PGR. This could not be 
reversed by reactivation of ER signalling alone, but also required demethylation of the 
PGR promoter via DNMT inhibition, implying that loss of ER activity may promote 
methylation-induced silencing. More recently, Wang et al. (2018) similarly demonstrated 
that ER-directed DNA demethylation may have a role in oestrogen-mediated gene 
expression. Finally, Kangaspeska et al. (2008) and Métivier et al. (2008) have shown in 
MDA-MB-231 cells stably expressing ER that the promoter of TFF1 (pS2), an oestrogen-
regulated gene, undergoes cyclical changes in methylation in response to oestrogen. 
Blocking this process inhibited TFF1 expression, implying that whilst stable changes in 
DNA methylation might contribute to ER transcriptional control, the dynamics of these 
changes may also be important in defining their effects. 
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1.4  Targeted therapies for ER positive breast cancer 
Given that ER is the driving transcription factor in the majority of breast cancers, numerous 
treatment strategies centre around targeting either ER itself, or oestrogen as its activating 
ligand. Three main classes of these drugs, discussed here, are selective oestrogen 
receptor modulators (SERMs) such as tamoxifen, selective oestrogen receptor degraders 
(SERDs) such as fulvestrant, and aromatase inhibitors (AIs). Whilst SERDs act as pure 
antioestrogens and have only antagonist activity in relation to ER, SERMs are 
distinguished from both full ER agonists and antagonists in that they may have 
antioestrogenic activity in some tissues whilst providing oestrogenic activity in others. In 
contrast, AIs act upstream of ER by blocking oestrogen synthesis. 
1.4.1 Tamoxifen 
Originally and unsuccessfully designed as a contraceptive pill, a role for tamoxifen in 
treating breast cancer was first identified in 1971 (Cole et al. 1971). Tamoxifen has since 
been in use for more than 40 years for the effective treatment of ER+ disease (Jordan 
2003). Illustrating the success of this drug, recent analyses have shown that five years’ 
tamoxifen treatment halves the 10-year recurrence rate for ER+ breast cancer, 
corresponding to an approximately one-third decrease in mortality (Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) et al. 2011). In breast cancer, the actions of 
tamoxifen are two-fold. Firstly, tamoxifen competes with endogenous oestrogens for 
binding to the ER LBD. Secondly, tamoxifen induces conformational changes in ER that 
impair its association with co-activating p160 proteins, and consequently with 
transcriptional co-activators such as p300 and CBP. This promotes the interaction of ER 
with co-repressors such as SMRT and NCOR and blocks the expression of genes driving 
tumour growth (Brzozowski et al. 1997; Shang et al. 2000; Shang & Brown 2002; Shiau 
et al. 1998). Whist tamoxifen antagonises ER activity in breast, it can activate ER in other 
tissues, for example in bone, hence its definition as a SERM (Haskell 2003). These tissue-
specific effects are thought to be due to varying local levels of endogenous oestrogens, 
and the differing expression of ER co-activators and co-repressors in different cell types 
(Dutertre & Smith 2000). 
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1.4.2 Aromatase inhibitors 
Aromatase inhibitors (AIs) affect ER activity through blocking oestrogen production. 
Oestrogen is synthesised through conversion from androgen by aromatase, a member of 
the cytochrome P450 (CYP)19 family of enzymes (Cole & Robinson 1990). AIs in use in 
the clinic include letrozole, anastrazole, and exemestane, all of which interact 
competitively with the active site of aromatase and prevent androgen binding (Miller 2003). 
AIs are most appropriate for use in postmenopausal women where oestrogen production 
switches from the ovaries to peripheral tissues including the breast. This is due to the fact 
that in premenopausal women, not only are circulating oestrogen levels much higher, but 
increased hormone synthesis by the ovaries can rapidly counteract any oestrogen-
depleting effects of AIs (Simpson 2003). In contrast, local production of oestrogen can be 
effectively lowered by aromatase inhibition in the postmenopausal setting, facilitating 
reduced activation of ER. 
1.4.3 Fulvestrant 
In contrast to tamoxifen, fulvestrant does not demonstrate any oestrogenic effects, and 
uniformly abrogates ER activity. Its mechanism of action involves high-affinity binding to 
ER leading to conformational changes that inhibit ER dimersation and nuclear 
translocation. In addition to blocking ER transcriptional activity, fulvestrant also triggers 
accelerated degradation of ER, resulting in a rapid depletion of total ER levels (Dauvois 
et al. 1993; Fawell et al. 1990; Wakeling et al. 1991). Due to its orthogonal mode of action, 
fulvestrant can be used as a second-line treatment in breast cancers exhibiting intrinsic or 
acquired tamoxifen resistance. However, unlike tamoxifen and AIs, fulvestrant cannot be 
given orally and is administered by intramuscular injection in the clinic. Although this can 
aid treatment compliance, this renders fulvestrant treatment more expensive than 
tamoxifen or AIs. Given that the performance of AIs and fulvestrant are comparable as 
second-line therapies, AIs are therefore typically favoured for treatment of 
postmenopausal women (Robertson 2007). 
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1.5 TET proteins 
Ten-eleven translocation (TET) proteins were first described with the identification of TET1 
as a fusion partner of the mixed lineage leukaemia (MLL) gene in acute myeloid leukaemia 
(Lorsbach et al. 2003). Subsequent investigations revealed two additional TET family 
members, TET2 and TET3. Through their homology to the trypanosome enzymes J-
binding protein 1 and 2 (JBP1 and JBP2), TET proteins were determined as Fe(II)/α-
ketoglutarate-dependent dioxygenases capable of modifying methylated cytosine (5mC) 
(Tahiliani et al. 2009). Specifically, TETs oxidise 5mC, and in an iterative process, produce 
the further DNA modifications 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC) (He et al. 2011; Ito et al. 2011; Tahiliani et al. 2009), and 
the implication of 5mC in genome stability and transcriptional control has driven interest 
in TET enzymes as dynamic regulators of this epigenetic mark. Emerging evidence that 
the 5mC oxidation products 5hmC, 5fC and 5caC may also have transcriptional roles in 
their own right (discussed in section 1.7 below) has further fuelled research into TET 
proteins, primarily in development, but also more recently, in cancer. 
1.5.1 Structure of TET proteins 
TET proteins are large (∼180 to 230 kDa) multidomain enzymes. Their shared C-terminal 
catalytic domain consists of a double stranded beta helix (DSBH) domain, binding sites 
for Fe(II) and α-ketoglutarate cofactors, and a cysteine-rich (Cys) domain (Figure 1.3). 
Whilst the conserved catalytic domain mediates direct interactions with cytosine residues, 
this does not define the wider DNA sequence preference of these enzymes (Hu et al. 
2013). TET1 and TET3 possess a CXXC domain which facilitates their targeting to CG-
rich regions (Xu et al. 2018). However, TET2 lacks this domain, hence the mechanisms 
by which it is targeted to specific genomic regions remain unclear (Rasmussen & Helin 
2016). It is possible that the less-conserved regions of TET2 provide interfaces for 
interactions with different proteins that may direct its sequence-specific genomic targeting 
(Hu et al. 2013). This basic structural difference provides one feature that distinguishes 
TET2 from its other family members. The remainder of this section will discuss the overall 
functions of TET proteins, with a focus on TET2. 
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Figure 1.3. Structure of TET proteins. 
The core catalytic domain of all three TET enzymes consists of a cysteine-rich (Cys-rich) 
domain, a double stranded beta helix (DSBH) domain, and binding sites for Fe(II) and α-
ketoglutarate cofactors (within the DSBH, not shown). Additionally, TET1 and TET3 
possess an N-terminal CXXC domain facilitating their sequence-specific DNA binding. 
1.5.2 TET2 in development and disease 
Whilst homozygous deletion of TET3 is embryonic lethal in mice (Gu et al. 2011), deletion 
of TET1 or TET2 causes no striking developmental phenotypes, but rather skews the 
differentiation of certain cell lineages. With respect to loss of TET2, this altered cellular 
differentiation occurs specifically in the haematopoietic compartment (Dawlaty et al. 2011; 
Moran-Crusio et al. 2011; Quivoron et al. 2011). In contrast, combined deletion of TET1 
and TET2 in mice results in a more severe phenotype, and most die perinatally (Dawlaty 
et al. 2013). Therefore, whilst TET3 appears to have a unique role in embryonic 
development, TET1 and TET2 may be capable of compensating for one another in this 
setting. 
 
The important role of TET2 in regulating haematopoetic development becomes clearer 
through studies of its involvement in cancer, where it is the most frequently mutated gene 
in a range of haematological malignancies, including chronic myelomonocytic leukaemia 
(CMML, TET2 mutated in 20-58% of cases), acute myeloid leukaemia (AML, 12-32% of 
cases), and T-cell lymphomas (20-83% of cases). Across these malignancies, mutations 
of TET2 appear varied, encompassing missense mutations that result in various changes 
to the amino acid sequence, nonsense mutations causing truncations, frameshift 
deletions/insertions, and also splice site mutations. These events do not localise to a 
specific exon or residue, and there appears no predominant hotspot for these alterations. 
In addition, many patients exhibit more than one TET2 mutation. Overall, this evidence 
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implies TET2 inactivation is the unifying outcome of these mutational occurrences 
(Kosmider et al. 2009; Patnaik et al. 2016). These haematological TET mutations appear 
to be specific to TET2, as TET1 and TET3 are rarely found mutated in these cancers 
(Scourzic et al. 2015).  
 
In contrast to their well-documented role in haematological malignancies, less attention 
has been drawn to the oncogenic potential of TET2 mutations in solid cancers. TET2 
mutations can be identified in many solid tumour types according to data available through 
the online tool CBioPortal (www.cbioportal.org) (Cerami et al. 2012; Gao et al. 2013). 
However, with the exception of a few studies showing moderate levels of TET2 
perturbation in non-small cell lung cancer (Gardner et al. 2017) and skin cancer (Pickering 
et al. 2014), mutational frequencies of TET2 in solid cancers tend to be low, at between 
0.1 – 10%, and TET2 mutations are rare in breast cancer (Scourzic et al. 2015; Stephens 
et al. 2012). Of the infrequent mutations observed in solid tumours, in a similar manner to 
the mutations observed in haematological malignancies, these alterations do not localise 
to one specific region of the protein, and the associated changes to the protein sequence 
vary. Overall, missense mutations appear to be the most common type of alteration to 
TET2 in solid tumours, with truncating mutations second most common. A small number 
of splice site mutations can also be observed in the solid tumour datasets available on 
CBioPortal, and TET2 exhibits fusions with several different loci in a small minority of 
studies. Nevertheless, despite its low mutational frequency, reduced TET2 expression is 
observed in several cancer types, including endometrial, liver and breast cancer 
(Ciesielski et al. 2017; Yang et al. 2013). Linking TET2 levels to clinical outcome, 
Takayama et al. (2015) showed that loss of TET2 is associated with metastasis in prostate 
cancer, and in a mixed cohort of 162 breast cancer patients, Yang et al. (2015) 
demonstrated reduced expression of TET1, TET2, and TET3 mRNAs as associated with 
poor prognosis. Of note, Huang et al. (2016) reported loss of TET2 nuclear localisation 
(although not overall expression) as associated with a more aggressive phenotype in 
colorectal cancer, implying that exclusion of TET2 from the nucleus may play a role in this 
malignancy. 
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1.5.3 TET2 functions 
1.5.3.1 Catalytic functions of TET2 
In terms of its catalytic functions, TET2, like TET1 and TET3, iteratively oxidises 5mC to 
create the further DNA modifications 5hmC, 5fC and 5caC (He et al. 2011; Ito et al. 2011; 
Tahiliani et al. 2009). 5mC is initially formed through methylation of cytosines by DNMTs. 
This typically occurs in the context of CpG dinucleotides, self-complementary DNA 
sequences where a cytosine is followed by a guanine on the same strand. During cell 
division, 5mC can be maintained through the recognition of newly replicated, hemi-
methylated DNA by ubiquitin-like PHD and RING finger domain-containing protein 1 
(UHRF1), which promotes recruitment of the maintenance methyltransferase DNMT1 to 
methylate the newly-synthesised strand in a symmetrical manner (Bostick et al. 2007; 
Hermann et al. 2004). Where UHRF1/DNMT1 do not act to reinstate 5mC in this manner, 
for example through reduced activity of DNMT1, this can result in passive, replication-
dependent loss of 5mC.  
 
The effect that TET-mediated oxidation of 5mC has on the heritability of this mark has 
been studied. Although the DNMT1 interaction partners UHRF1 and UHRF2 can also 
interact with 5hmC (Frauer et al. 2011; Hashimoto et al. 2012; Iurlaro et al. 2013; Spruijt 
et al. 2013; Zhou et al. 2014), the activity of DNMT1 at hemi-hydroxymethylated DNA 
appears to be up to 60-fold less than its activity at hemi-methylated DNA (Hashimoto et 
al. 2012; Ji et al. 2014; Valinluck & Sowers 2007). This has led to the suggestion that TET-
mediated conversion of 5mC to 5hmC may trigger passive loss of DNA modifications, and 
indeed, this process appears to be important both in germ cells and in early 
embryogenesis (Hackett et al. 2013; Inoue & Zhang 2011). However, alternative 
methyltransferases DNMT3A2 and DNMT3B2 may also be involved in mitotic inheritance 
of 5mC, and these enzymes are also capable of methylating hemi-hydroxymethylated 
sites (Hashimoto et al. 2012; Ji et al. 2014). This suggests that the presence of 5hmC may 
not always result in replication-dependent loss of 5mC. Further investigations will be 
necessary to determine the effect of TET-mediated 5hmC generation on the maintenance 
of DNA modifications, however it is possible that this effect may be both cell context- and 
locus-specific.  
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No inheritance mechanism has been described for the final products of TET metabolism, 
5fC and 5caC, thus it appears likely that these marks can also act as intermediates in 
TET-mediated, replication-dependent DNA demethylation. However, in contrast to 5hmC, 
these later oxidised products can also be actively removed from DNA. Specifically, both 
5fC and 5caC are substrates for thymine DNA glycosylase (TDG), an enzyme typically 
mediating DNA mismatch repair (He et al. 2011; Maiti & Drohat 2011; Spruijt et al. 2013). 
TDG-mediated excision of its DNA substrates results in the generation of an abasic site 
which is subsequently replaced with an unmodified cytosine through base excision repair 
(BER) pathways (Lindahl & Wood 1999). In support of this mechanism operating to 
remove 5fC and 5caC, disruption of TDG in embryonic stem cells (ESCs) causes 
accumulation of both of these marks (He et al. 2011; Shen et al. 2013; Song et al. 2013), 
and overexpression of TDG in HEK293T cells results in their depletion (Nabel et al. 2012). 
Notably, TDG displays no in vitro activity towards unmodified cytosine, 5mC or 5hmC, and 
overexpression of TDG appears to have no effect on 5mC and 5hmC levels, indicating 
that these active demethylation pathways are specific to 5fC and 5caC (He et al. 2011; 
Maiti & Drohat 2011; Nabel et al. 2012) Overall, this indicates a key role for TET enzymes 
in DNA demethylation pathways. A summary of these pathways is shown in Figure 1.4.  
 
Of the TET-regulated DNA modifications, 5mC and 5hmC are the most abundant. 5mC is 
typically present as approximately 4-5% of total cytosines, whilst levels of 5hmC range 
between 0.03-0.7% due to wide tissue-specific variation (Globisch et al., 2010; Lister et 
al. 2009; Szwagierczak et al. 2010). Contrastingly, 5fC and 5caC are present at levels at 
least 1000 times lower than 5hmC (Globisch et al. 2010; Ito et al. 2011), and are more 
difficult to reliably detect using current methods. The scarcity of 5fC and 5caC in 
comparison to 5hmC further reinforces that these marks may be actively maintained at 
low levels in the genome through TET/TDG-mediated removal. However, the relative 
abundance of 5hmC may also be due to more efficient production of this mark compared 
to 5fC and 5caC. Specifically, TET-mediated conversion of 5hmC to 5fC appears to be 
~6-fold slower, on average, than the initial conversion of 5mC to 5hmC, whilst the rate of 
oxidation of 5fC to 5caC is ~10-fold reduced compared to the initial 5mC to 5hmC step 
(Hu et al. 2015; Ito et al. 2011; Rasmussen et al. 2016). This suggests that TET enzymes 
stall in their activity after the production of 5hmC. The resultant relative stability of 5hmC 
compared to 5fC and 5caC could indicate a unique cellular role for this mark. Additionally, 
it has been proposed that the main function of all three TET proteins may be to prevent 
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aberrant methylation of non-methylated regions (Jeong et al. 2014; Rasmussen et al. 
2015). Therefore, the finding 5mC appears to be the mark most efficiently converted by 
TET proteins may also support the notion of 5mC suppression as the most important 
biological role of these enzymes. 
 
 
 
Studies in numerous different systems have demonstrated the key role of TET enzymes 
in regulating DNA modifications. Notably, despite the fact that the basic catalytic functions 
of all three TET proteins are broadly similar, several investigations have demonstrated 
that these enzymes may preferentially regulate modifications at different sites, with a role 
for TET2 that appears distinct from the other TET family members. For example, Putiri et 
al. (2014) showed that siRNA-mediated depletion of TETs 1, 2, and 3 in an embryonic 
carcinoma cell line indicated a clear role for all three family members in regulation of 5hmC 
at enhancers. However, of the three TET proteins, TET2 appeared to mediate the most 
robust regulation of this mark at these sites. This finding was corroborated by Hon et al. 
Figure 1.4. The role of TET enzymes in active and passive DNA demethylation. 
Cytosine residues are methylated at the 5’ carbon by DNA methyltransferases (DNMTs), 
resulting in 5-methylcytosine (5mC). This newly-added methyl group can be further 
modified by the addition of a hydroxyl group by TET enzymes to generate 5-
hydroxymethylcytosine (5hmC). 5hmC can be further oxidised by TET enzymes to 
produce, sequentially, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Whilst all 
these modifications may be lost passively through DNA replication as a result of cell 
division, 5fC and 5caC can also be removed through base excision repair pathways 
initiated by thymine DNA glycosylase (TDG). 
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(2014) in mouse embryonic stem cells (mESCs), who showed that loss of both TET1 and 
TET2 resulted in accumulation of 5mC at a range of sites. Whilst the vast majority of these 
hypermethylated sites encompassed enhancers and distal regulatory elements 
(constituting 70% of hypermethylated sites in response to TET1 loss, and 86% of sites in 
response to TET2 loss), the absolute number of sites affected by TET2 was approximately 
8.7 times the number of sites hypermethylated in response to TET1 loss (60,095 versus 
8,455 sites). In the same study, measurements of 5hmC similarly demonstrated that whilst 
loss of both TET1 and TET2 resulted in depletion of this mark at promoters, gene bodies, 
CTCF-bound insulators, and enhancers, the effects of TET2 loss on 5hmC were more 
pronounced that those of TET1 loss. Therefore, whilst knockout studies imply that TET1 
and TET2 may be capable of overlapping effects in the developmental setting, functional 
investigations in mESCs and cancer cell lines show they have distinct roles at the level of 
DNA modifications. Furthermore, it appears TET2 may possess a key role in regulating 
DNA modifications at enhancers. 
1.5.3.2 Additional functions of TET2 
In addition to the catalytic role of TET2, the transcriptional implications of which are 
described in section 1.7 below, several further roles have been described for TET proteins 
that may not rely solely on their dioxygenase capabilities. For example, whilst perturbation 
of TET catalytic activity has an impact on the levels and distribution of 5mC and its oxidised 
forms, it has been suggested that TET proteins may also prevent aberrant 5mC deposition 
at selected genomic regions through physical occupancy of these sites (Wu & Zhang 
2017). Citing a study by Lu et al. (2014), which investigated methylation patterns in 
mESCs in response to knockout of all three TET proteins, Wu & Zhang (2017) proposed 
that the accumulation of 5mC at sites where oxidised forms of 5mC are normally present 
at very low levels implies TET proteins could partly prevent aberrant methylation at these 
sites through blocking access to DNMTs.  
 
TET proteins may also have a role in stabilising or modifying the activity of transcriptional 
complexes, potentially acting as an adapter protein, through associating with histone 
modifying enzymes. For example, all three TET proteins can directly interact with the 
enzyme O-linked β-N-acetylglucosamine transferase (OGT) (Chen et al. 2013; Deplus et 
al. 2013; Vella et al. 2013). OGT can modify histones through O-GlcNAcylation, and has 
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also been linked to processes mediating histone ubiquitination (Deplus et al. 2013; 
Hardivillé & Hart 2014; Lercher et al. 2015). In addition, TET2/OGT interactions have 
been shown to be important for stabilisation of the histone methyltransferase complex 
SET1/COMPASS, with a study by Deplus et al. (2013) demonstrating that the interaction 
between TET2 and OGT is important for H3K4me3 deposition and transcriptional 
activation in HEK293T cells. These examples provide a potential connection between 
TET enzymes and wider epigenetic functions. 
 
Furthermore, several studies have demonstrated that TET catalytic activity may be 
negligible for some of its functions. Specifically to TET2, Zhang et al. (2015) showed that 
TET2-mediated HDAC2 recruitment can repress interleukin 6 (IL-6) expression in mouse 
myeloid cells, and through depletion of wild-type TET2 and overexpression of a TET2 
catalytic mutant, the authors suggested this may be independent of its enzymatic function. 
Similarly, Montagner et al. (2016) showed that in mast cells, hyperproliferation resulting 
from TET2 loss could be rescued by re-expression of either wild-type or catalytically 
inactive TET2.  
 
In terms of the other TET family members, TET1 interacts with the SIN3A histone 
deacetylase complex (Williams et al. 2011), and the histone modifier lysine (K) 
acetyltransferase 8 (KAT8) (Zhong et al. 2017). Additionally, TET3-mediated repression 
of the imprinted SNRPN gene, required for preventing premature differentiation of mouse 
NSCs, is maintained even in the presence of a TET3 catalytic mutant (Montalbán-Loro et 
al. 2019). These recent works imply that further and potentially diverse roles of TET 
proteins remain to be uncovered. 
 
1.6 DNA modifications in transcriptional control 
Due to the role of TET enzymes in regulating the levels of 5mC and its oxidised forms, the 
distribution and function of these epigenetic marks is thought to be key to the biological 
importance of TET proteins. The next two sections will provide a brief overview of the 
suspected role of 5mC and its TET-oxidised intermediates in transcription, touching upon 
the potential dysregulation of these marks in cancer. 
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1.6.1 Distribution and proposed transcriptional roles of DNA 
modifications  
The role of DNA methylation in transcriptional regulation has been investigated in a 
number of systems, with the broad conclusion being that this mark is associated with 
transcriptional repression (Bird & Wolffe 1999; Bird 2002; Klose & Bird 2006; Moore et al. 
2013). DNA methylation occurs primarily at cytosines in the context of CpG dinucleotides. 
Non-CpG modification is also possible, although this is a rarer event (Lister et al. 2009). 
The frequency of CpGs in the genome is overall lower than would be expected by chance, 
partly due to the tendency of 5mC to mutate into thymine. However, the majority of CpG 
dinucleotides (70-80%) throughout the mammalian genome are methylated (Bird 2002). 
DNA methylation is associated with various processes, including X chromosome 
inactivation and genomic imprinting, and a large proportion of DNA methylation is thought 
to be involved in repression of endogenous retrotransposons and viral elements (Beard et 
al. 1995; Jaenisch et al. 1985; Mohandas et al. 1981; Schulz et al. 2006). Of key relevance 
to the role in 5mC in transcription, most (60-70%) promoters contain CpG islands (CGIs). 
These are stretches of DNA that contain a higher frequency of CpG dinucleotides than the 
surrounding genome, but are largely protected from DNA methylation (Illingworth et al. 
2010). Whilst most promoters are therefore depleted of 5mC irrespective of the 
transcriptional activity of the gene they control, where methylation of CGI-containing 
promoters does occur, this is negatively correlated with gene expression (Bird & Wolffe, 
1999).  
 
Two main mechanisms have been proposed for 5mC-directed transcriptional repression. 
Firstly, the presence of 5mC is thought to have a destabilising influence on the DNA 
binding of most transcription factors and DNA-binding proteins, hindering transcriptional 
activation (Yin et al. 2017). Secondly, of the proteins shown to interact directly with 5mC, 
the earliest of these identified were transcriptional repressors, which recruit histone 
deacetylase complexes and catalyse chromatin condensation (Bird & Wolffe 1999; Jones 
et al. 1998; Nan et al. 1998). Examples of these methyl-CpG-binding domain (MBD)-
containing proteins include MeCP1, MeCP2, and MBD1, 2, and 4 (Klose & Bird 2006). In 
addition, the transcriptional repressor Kaiso (ZBTB33) has been shown to bind methylated 
CpG dinucleotides through its zinc-finger domains (Prokhortchouk et al. 2001; Yoon et al. 
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2003), and it is possible that other members of this large protein family may possess 
similar functions (Filion et al. 2006).  
 
Nevertheless, despite this mechanistic evidence for the repressive activity of 5mC, recent 
studies have identified a range of additional proteins capable of interacting with 5mC, not 
all of which are associated with transcriptional repression, and which may have more 
diverse regulatory functions (Iurlaro et al. 2013; Spruijt et al. 2013; Spruijt & Vermeulen 
2014). In addition, the fact that a strong transcriptional activator can trigger transcription 
from a previously silenced, methylated promoter (Thompson et al. 1986), and that genes 
possessing methylated CGIs are expressed in some developmental contexts (Fouse et 
al. 2008), implies that a balance between 5mC and the profile of transcriptional regulators 
that interact with this mark may “fine-tune” gene expression at different loci. It therefore 
appears that further work is required to precisely define the potentially complex 
relationship between 5mC and gene expression.  
 
In terms of levels of 5mC at other regulatory elements, overall, enhancers also appear to 
be depleted of this mark, although less so than promoters (Luo et al. 2018; Stadler et al. 
2011), and at these sites 5mC loss is similarly correlated with positive transcriptional 
activity (Hon et al. 2013; Lister et al. 2009; Stadler et al. 2011; Ziller et al. 2013). 
Importantly, Ziller et al. (2013) examined genome-wide DNA methylation across 30 human 
cell and tissue types through investigation of 42 separate whole genome bisulfite 
sequencing (WGBS) datasets. This analysis showed that dynamic regulation of 
methylation occurred at only 21.8% of CpG sites within a normal developmental context. 
The majority of these dynamic CpGs co-localised with gene regulatory elements, 
particularly enhancers and transcription factor binding sites linked to cell type-specific 
genes. This indicates that regulation of 5mC at enhancers may be a key process in the 
definition of cell phenotypes, with interplay between DNMT-mediated methylation and 
TET-mediated demethylation potentially central to this. As the studies cited in the previous 
section highlight, TET depletion in several systems corroborates this notion, with the 
finding that regulatory elements appear to be the main targets of TET-mediated regulation 
of DNA modifications (Hon et al. 2014; Lu et al. 2014; Stadler et al. 2011). 
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In contrast to 5mC, which is notable in its distribution by the regions from which it is 
excluded, 5hmC is specifically enriched at various genomic regions, including promoters, 
gene bodies, and enhancers (Hahn et al. 2013; Johnson et al. 2016; Pastor et al. 2011; 
Stroud et al. 2011; Wu et al. 2011). Whilst studies show 5hmC at enhancers is typically 
associated with transcriptional activation, its role at promoters remains unclear, with 
several studies proposing 5hmC as an activating mark at these sites (Hahn et al. 2013; 
Madzo et al. 2014; Taylor et al. 2016), and others suggesting it may have a repressive 
role (Neri et al. 2013; Wu et al. 2011). However, as 5mC is required as a substrate for 
conversion to 5hmC, these conflicting findings may be partly due to different basal levels 
of 5mC at these promoters that confound measurement of the effects of 5hmC (Pastor et 
al. 2013). Interestingly, screens conducted by Iurlaro et al. (2013) and Spruijt et al. (2013) 
to identify readers of 5mC and its oxidised derivatives demonstrated that 5hmC interacts 
both with proteins thought to be involved in active DNA demethylation pathways, and 
those involved in transcriptional regulation. This reinforces the idea of 5hmC as a stable 
transcriptional regulatory mark, in addition to being a potential DNA demethylation 
intermediate. Furthermore, in these studies, 5mC and 5hmC were found to attract the 
binding of distinct proteins, with very few proteins capable of interacting with both marks. 
This further fuels the notion of distinct transcriptional roles for these two modifications. 
 
Compared to 5mC and 5hmC, the specific functions of the final products of TET 
metabolism, 5fC and 5caC, have been much less investigated. Nevertheless, the in vitro 
screen performed by Iurlaro et al. (2013) demonstrated that far more specific readers 
bound uniquely to 5fC than to 5mC or 5hmC, and the functions of these proteins strongly 
suggest transcriptional regulatory capabilities. Moreover, in a recent study by the same 
group, genome-wide profiling of 5fC was performed in mouse embryos, through biotin 
labelling of 5fC followed by pull-down and sequencing (Iurlaro et al. 2016). This showed 
that 5fC is enriched at active enhancers in mouse embryos in a tissue-specific manner, 
suggesting a role for this mark in embryonic development. Work in additional systems, 
and the development of further methods to profile both 5fC and 5caC, may reveal further 
insights into the potential transcriptional roles of these products of TET activity. 
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1.6.2 Dysregulation of DNA modifications in cancer  
In addition to their role in normal cells, levels of both 5mC and 5hmC may be dysregulated 
during cancer progression. Many cancers demonstrate a global loss of both 5mC 
(Hernandez-Blazquez et al. 2000; Kulis & Esteller 2010; Paz et al. 2002; Wilson et al. 
2007) and 5hmC (Lian et al. 2012; Kudo et al. 2012; Takayama et al. 2015; Yang et al. 
2013), compared to normal tissue. Despite this, increases in 5mC are observed at some 
sites, and it has long been suggested that hypermethylation of otherwise non-methylated 
tumour suppressor promoters may contribute to their silencing in cancer (Baylin & Jones, 
2016). However, more recent reports have suggested that many of the promoters 
hypermethylated in cancer cells are silenced in non-malignant tissues to begin with 
(Sproul et al. 2012), and that hypermethylation of enhancers may instead be a more 
dominant feature of cancer progression (Bell et al. 2016; Taberlay et al. 2014). Of specific 
relevance to breast cancer, several studies have clustered breast tumours based on their 
differential distribution of 5mC and shown that this stratifies tumours based on ER status 
(Fackler et al. 2011; Hill et al. 2011; Ronneberg et al. 2011). 
 
Changes in 5hmC have been less extensively mapped in normal versus cancer tissues, 
however local gains in 5mC are often associated with 5hmC loss, with Thomson et al. 
(2016) specifically showing depletion of 5hmC concomitant with hypermethylation of 
certain promoters during malignant progression in a mouse model of liver carcinogenesis. 
Broadly speaking, whether 5hmC loss is a cause or consequence of malignancy remains 
a topic of debate (Ficz & Gribben 2014). Nevertheless, this loss of 5hmC often correlates 
with reduced expression of TET proteins (Kudo et al. 2012; Lian et al. 2012; Yang et al. 
2013). Overall, it appears that the role of DNA modifications may be diverse and complex, 
and in particular, examination of the different transcriptional contributions of 5mC versus 
its oxidised intermediates requires significant work. It appears that TET proteins, and 
TET2 in particular, may provide a link between these DNA modifications and gene 
regulatory events at enhancers. 
1.6.3 Aims of the thesis 
Rationale: ER is a transcription factor that is central to breast cancer biology, and 
constitutes the main therapeutic target in ER+ disease. Although several targeted 
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therapies exist for ER+ breast cancer, in many cases patients incur resistance and relapse 
on these treatments. ER co-operates with numerous other proteins that together form the 
ER transcriptional complex. The proteins that co-assemble with the activated ER are 
diverse in function, and their interplay facilitates the precise and dynamic actions of ER in 
regulating gene expression dependent on the cellular context. The overarching aim of this 
thesis is to investigate ER signalling in the context of ER+ breast cancer, with the intention 
of developing a better understanding of how ER functions in the disease setting, primarily 
in terms of its interaction with cofactors that help it achieve its function. 
Aim 1: The transcription factor GATA3 is highly expressed, and frequently mutated, in 
ER+ breast cancers (Cancer Genome Atlas Network 2012; Kouros-Mehr et al. 2006; 
Perou et al. 2000; Sorlie et al. 2001). Oestrogen-induced growth of ER+ breast cancer 
cells appears dependent on GATA3 (Eeckhoute et al. 2007; Kong et al. 2014), and ER 
and GATA3 share a large proportion (~45%) of ER binding sites in ER+ breast cancer 
cells (Kong et al. 2011; Theodorou et al. 2013), therefore it appears that there may be 
functional interplay between these two proteins. The first aim of this thesis constitutes an 
investigation into the contribution of GATA3 to the ER complex using proteomics-based 
approaches. 
Aim 2: Having established the dioxygenase enzyme TET2 as a key GATA3-regulated 
component of the ER complex as part of the investigations addressing Aim 1, the second 
aim of this thesis sets out to further characterise the contribution of TET2 to ER signalling, 
specifically focusing on the relationship between the ER, GATA3 and TET2 signalling 
complexes, and the role of TET2 in ER-mediated gene expression and chromatin binding. 
Aim 3: The third aim of this thesis expands on the efforts detailed in Aim 2 by specifically 
focusing on the role of TET2 in regulating DNA modifications in ER+ breast cancer cell 
lines, and exploring the relationship between these processes and ER-regulated gene 
expression. 
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Materials and Methods  
2.1 Materials 
2.1.1 Cell lines and media 
ER+ luminal breast cancer cell lines MCF7, T47D and ZR75-1 were obtained from ATCC. 
MCF7 cells were grown in DMEM (Gibco), T47D cells and ZR75-1 cells in in RPMI 1640 
(Gibco). All media was supplemented with 10% heat-inactivated foetal bovine serum 
(FBS), 50 U/ml penicillin and 50 g/ml streptomycin (Gibco) and 2 mM L-glutamine 
(Gibco). Cells were genotyped by short-tandem repeat (STR) profiling using the 
PowerPlex 16HS Cell Line panel and analysed using Applied Biosystems Gene Mapper 
ID v3.2.1 software by the external provider Genetica DNA Laboratories (LabCorp 
Specialty Testing Group) at least every six months and around every major experiment. 
Cells were routinely mycoplasma tested using MycoProbe Mycoplasma detection kit 
(R&D). 
2.1.2 Patient-derived xenograft (PDX) material 
PDX material was kindly provided by Carlos Caldas and colleagues (Bruna et al. 2016). 
Frozen PDX tissue was propagated in immune-compromised mice. Briefly, tumour pieces 
(1 mm3) were implanted into the mammary pad of NSG (NOD scid gamma) mice. All mice 
were supplemented with oestrogen, using silastic E2 pellets (made in-house) inserted into 
the dorsal scruff. Tumours were measured twice weekly. Once tumours reached 
~1000 mm3, mice were sacrificed by cervical dislocation under deep, isoflurane-induced 
anaesthesia. Tumours were resected and either snap frozen in liquid nitrogen, fixed in 
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10% neutral buffered formalin solution for subsequent paraffin embedding, embedded in 
Optimal Cutting Temperature compound (OCT), or viably frozen in foetal calf serum (FCS) 
supplemented with 5% dimethyl sulphoxide (DMSO). STG195 possesses a Y537S 
mutation in the ESR1 gene; AB555 is ER wild-type. 
2.1.3 Antibodies 
Antibodies used are listed in Table 2.1. 
 
Protein target Antibody Application 
β-actin Cell Signaling #4970 Western blot 
ERα 
Novocastra, Leica NCL-L-
ER-6F11 
Western blot 
Abcam ab3575 ChIP, RIME 
Millipore 06-935 ChIP, RIME 
GATA3 
Santa Cruz sc268 Western blot, RIME 
Abcam ab106625 RIME 
TET2 
Abcam ab94580 ChIP, RIME 
Millipore MABE462 
ChIP, RIME and Western blot 
 
Bethyl A304-247A 
Pierce PA5-3547 
Santa Cruz sc-398535 
Cell Signaling 18950 
Cell Signaling 45010 
 
Table 2.1. List of antibodies used and their applications. 
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2.1.4 Small interfering RNAs and drug compounds 
Control small interfering RNAs (siRNAs) (D-001810-10), and those used to knock down 
GATA3 (L-003781-00), ER (L-003401-00), and TET2 (L-013776-03) were obtained from 
Dharmacon (Horizon Discovery). In order to achieve robust knockdown whilst minimising 
possible off-target effects of specific siRNA sequences, pools of four different siRNA 
sequences were used against each target. Sequences are shown in Table 2.2. Cells were 
transfected with siRNA using Lipofectamine RNAiMax transfection reagent (Invitrogen). 
For cell treatments, fulvestrant (Selleckchem) was used at a final concentration of 100 nM. 
 
Target siRNA sequence 
Non-targeting control 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
ER 
GAUCAAACGCUCUAAGAAG 
GAAUGUGCCUGGCUAGAGA 
GAUGAAAGGUGGGAUACGA 
GCCAGCAGGUGCCCUACUA 
GATA3 
GUACAGCUCCGGACUCUUC 
CCCAAGAACAGCUCGUUUA 
GAAGGCAUCCAGACCAGAA 
CAUCGACGGUCAAGGCAAC 
TET2 
ACAAGAAAGUAGAGGGUAU 
ACACCUAGUUUCAGAGAAU 
CCUCAGAAUAAUUGUGUGA 
CAGCAAAGGUACUUGAUAC 
Table 2.2. Sequences of siRNAs against ER, GATA3 and TET2. 
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2.1.5 Primers for qRT-PCR and ChIP-qPCR 
Sequences of primers for qRT-PCR are shown in Table 2.3. Ubiquitin C (UBC) was used 
as a housekeeping control. Sequences of primers for ChIP-qPCR are shown in Table 2.4. 
 
Target Forward primer (5’-3’) Reverse primer (5’-3’) 
TET2 ATTCTCGATTGTCTTCTCTAGTGAG CATGTTTGGACTTCTGTGCTC 
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
Table 2.3. Primer sequences for qRT-PCR. 
 
ER site Forward primer (5’-3’) Reverse primer (5’-3’) 
RARα GCTGGGTCCTCTGGCTGTTC CCGGGATAAAGCCACTCCAA 
GREB1 GAAGGGCAGAGCTGATAACG GACCCAGTTGCCACACTTTT 
MYC GCTCTGGGCACACACATTGG GGCTCACCCTTGCTGATGCT 
Negative 
control region 
GCCACCAGCCTGCTTTCTGT CGTGGATGGGTCCGAGAAAC 
Table 2.4. Primer sequences for ChIP-qPCR at ER binding sites. 
 
 
2.2 Methods 
2.2.1 Mammalian cell culture methods 
2.2.1.1 Thawing, growing and freezing cells 
Cells were periodically cultured to between 80 and 90% confluence at 37°C with 5% CO2, 
rinsed with sterile phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4), and trypsinised using 0.05% trypsin-EDTA. Trypsin was 
neutralised with DMEM or RPMI-1640 containing 10% FBS, and cells were centrifuged for 
3 min at 1,000 g (Heraeus Megafuge, Thermo Fisher Scientific). The pelleted cells were 
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resuspended in media and replated depending on the initial confluence. To prepare frozen 
stocks, cells were resuspended in 10% DMSO and 90% FBS and frozen to -80°C using a 
Mr. Frosty (Nalgene). To revive frozen cell lines, stocks were thawed rapidly at 37°C, 
growth medium added and cells centrifuged for 3 min at 1,000 g before being resuspended 
in growth medium and placed into flasks. 
2.2.1.2 Small interfering RNA transfections and drug treatments 
Cells were grown in full medium for 24 hours and then transfected using Lipofectamine 
RNAiMAX transfection reagent according to manufacturer’s instructions. Briefly, the 
transfection reagent was diluted in Opti-MEM (Gibco) and incubated for 5 minutes at room 
temperature. Subsequently, siRNA diluted in Opti-MEM was added to the transfection 
reagent/Opti-MEM mix and incubated for a further 20 minutes at room temperature. This 
mixture was added to cells in full growth medium and incubated for the relevant duration. 
For the purposes of obtaining protein, RNA or DNA samples, cells were washed twice in 
cold PBS and harvested in PBS containing protease inhibitors (Roche).  For growth 
assays, cells were left in transfection medium for the duration of the assay. All siRNAs 
were used at a final concentration of 10 nM.  
2.2.1.3 Analysis of cell growth 
Cell growth after siRNA transfection was assessed using the IncuCyte® ZOOM Live Cell 
Analysis System (Essen BioScience). Cells were seeded in 96-well plates and transfected 
in at least quadruplicate as described in section 2.2.1.2, upon which plates were 
immediately placed in the IncuCyte® ZOOM Live Cell Analysis System (37°C with 5% 
CO2) and growth was monitored for at least 120 hours via phase-contrast images taken 
every 3 hours. Confluence was assessed using default settings of the IncuCyte® ZOOM 
software. 
2.2.2 RNA methods 
2.2.2.1 RNA isolation and quantification 
Cells were washed twice in cold PBS and harvested in PBS containing protease inhibitors 
(Roche). Total RNA was extracted using an RNeasy kit (Qiagen) according to 
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manufacturer’s instructions, and quantified using a Qubit 3.0 Fluorometer (Thermo Fisher 
Scientific).  
2.2.2.2 Quantitative real-time PCR 
Total RNA (1 µg) was used for cDNA conversion and qRT-PCR analysis. cDNA was 
synthesised using the SuperScript III Reverse Transcriptase kit (Invitrogen) according to 
manufacturer’s instructions. For subsequent qPCR analysis, cDNA was diluted 1:10. 
Reactions were performed in triplicate, run on the BioRad CFX Connect RealTime System 
and analysed using BioRad CFX Maestro software version 1.1. Each reaction mixture 
contained 1X Power SYBR® Green PCR Master Mix (Applied Biosystems), forward and 
reverse primers (final concentration 10 µM each) and 2 µl diluted DNA template, with 
nuclease-free H2O to a final volume of 15 μl.  The hot-start Taq polymerase was heat-
activated at 95°C for 10 minutes, followed by 45 cycles of 15 seconds at 95°C and 
30 seconds at 60°C. The fluorescence was read in each cycle.  A melt curve was 
constructed by increasing the temperature from 65 to 95°C and continuously reading the 
fluorescence. Expression relative to UBC as a housekeeping control was determined 
using the delta-delta Ct method (Livak and Schmittgen 2001). 
2.2.2.3 RNA sequencing (RNA-seq) 
2.2.2.3.1 Library preparation and sequencing 
Library preparation and sequencing was carried out by the Genomics Core Facility 
(CRUK-CI). RNA libraries were prepared using the TruSeq stranded mRNA library prep 
kit (Illumina) and samples were sequenced on a HiSeq 4000 to approximately 30 million 
reads per sample.  
2.2.2.3.2 RNA-seq data processing and bioinformatic analysis 
RNA-seq data processing and bioinformatic analysis was performed by Dr Igor 
Chernukhin. 50 bp single-end reads were aligned to the Human Reference Genome 
(assembly hg38) using STAR version 2.5.2b (Dobin & Gingeras 2015). Read counts were 
normalised and tested for differential gene expression using DESeq2 (Love et al. 2014). 
Chapter 2 
36 
 
2.2.3 DNA methods 
2.2.3.1 DNA isolation and quantification 
Cells were washed twice in cold PBS and harvested in PBS containing protease inhibitors 
(Roche). DNA was extracted using a DNeasy Blood and Tissue Kit (Qiagen) according to 
manufacturer’s instructions. DNA was RNase (Sigma) treated on-column (20 µl of 20 
mg/mL) for 15 minutes at room temperature. Purified DNA was quantified using a Qubit 
3.0 Fluorometer (Thermo Fisher Scientific). 
2.2.3.2 Mass spectrometry measurements of 5mC and 5hmC 
Mass spectrometry analysis and data processing was performed by Dr Shiqing Mao 
(CRUK-CI). Cells were harvested and DNA isolated as described in section 2.2.3.1. 
Subsequently, 5mC and 5hmC were measured according to Bachman et al. (2014). 
Briefly, genomic DNA or ChIP DNA was incubated with 5 U DNA Degradase Plus (Zymo 
Research) for 4 hours at 37°C. Calibration curves were generated using a mixture of 
synthetic standards 2′-deoxycytidine (Sigma), 5-methyl- and 5-hydroxymethyl-2′-
deoxycytidine (Berry & Associates), in the ranges 0.01–100 µM, 0.0005–5 µM and 
0.0001–1 µM for C, 5mC and 5hmC, respectively. Samples and synthetic standards were 
spiked with an isotopically labelled mix that contained 1 µM 2′-deoxycytidine-(15N,d2), 5-
methyl-2′-deoxycytidine-(d3) and 5-hydroxymethyl- 2′-deoxycytidine-(d3) (Toronto 
Research Chemicals) as internal standards. Nucleotides were quantified using a Thermo 
Q-Exactive mass spectrometer. The quantitation was based on the peak area ratio of the 
analytes compared to their corresponding isotope-labelled internal standards, and the 
calibration curves. 5mC levels are expressed as a percentage of total cytosines. 
2.2.3.3 Methyl Midi-seq (MMS) 
2.2.3.3.1 DNA extraction, sample preparation and sequencing 
Library preparation, sequencing and initial data processing for genomic analysis of 5mC 
was undertaken using the Methyl Midi-seq (MMS) service provided externally by Zymo 
Research (Irvine, California). Cells were harvested and DNA isolated as described in 
section 2.2.3.1. Subsequently, libraries were prepared from 500 ng of genomic DNA 
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sequentially digested with 60 U of TaqαI and 30 U of MspI (NEB) and then extracted with 
a DNA Clean & Concentrator kit (Zymo Research). Fragments were ligated to pre-
annealed adapters containing 5’-methylcytosine instead of cytosine according to Illumina’s 
specified guidelines (http://www.illumina.com). Adapter-ligated fragments of 150–250 bp 
and 250–350 bp were recovered from a 2.5% NuSieve 1:1 agarose gel using a Zymoclean 
Gel DNA Recovery Kit (Zymo Research). The fragments were then bisulfite-treated using 
the EZ DNA Methylation-Lightning Kit (Zymo Research). Preparative-scale PCR was 
performed and the resulting products were purified using a DNA Clean & Concentrator kit 
(Zymo Research) for sequencing on an Illumina HiSeq. Sequence reads from bisulfite-
treated EpiQuest libraries were identified using standard Illumina basecalling software and 
then analysed using a Zymo Research proprietary analysis pipeline, which is written in 
Python and uses Bismark to perform the alignment  (Krueger & Andrews 2011). Index files 
were constructed using the bismark_genome_preparation command and the entire 
reference genome. The --non_directional parameter was applied while running Bismark. 
All other parameters were set to default. Filled-in nucleotides were trimmed off when doing 
methylation calling. The methylation level of each sampled cytosine was estimated as the 
number of reads reporting a C, divided by the total number of reads reporting a C or T.  
2.2.3.3.2 Methyl Midi-Seq bioinformatic analysis 
Subsequent bioinformatic analysis was carried out by Dr Kamal Kishore (Bioinformatics 
Core Facility, CRUK-CI). The genome was partitioned into non-overlapping tiles of length 
1 kb and 5mC was profiled within these tiles. Regions with low read coverage (less than 
4 reads in any sample) were discarded from the analysis. The differential 5mC analysis 
was carried out by methylKit using Fisher Exact test (Akalin et al. 2012). For site-specific 
5mC/5hmC analysis, shared ER/TET2 regions were defined using the intersect function 
in R to generate completely overlapping regions. 
2.2.3.4 Reduced Representation Hydroxymethylation Profiling (RRHP) 
DNA extraction, sample preparation and sequencing 
Library preparation, sequencing and initial data processing for genomic analysis of 5hmC 
was undertaken using the Reduced Representation Hydroxymethylation Profiling (RRHP) 
service provided externally by Zymo Research (Irvine, California), as described in 
Petterson et al. (2014). Cells were harvested and DNA isolated as described in section 
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2.2.3.1. Subsequently, genomic DNA was fragmented overnight at 37°C with a 
hydroxymethyl-insensitive enzyme, MspI, and purified using the DNA Clean & 
Concentrator kit (Zymo Research). Modified Illumina TruSeq P5 and P7 adapters 
containing 5’-CG overhangs were ligated onto the digested DNA using T4 DNA ligase (2 
hours at 16°C). Libraries were then strand extended at 72°C with Taq DNA Polymerase. 
The adapters were designed to regenerate the 5’-CCGG site at the P5 junction while the 
P7 adapter generates a 5’-TCGG junction, making it insensitive to MspI digestion. 
Adapterised libraries were treated with β-glucosyltransferase to label 5-hmC modifications 
and purified using a DNA Clean & Concentrator kit (Zymo Research). The glucosylated 
libraries were then subjected to an overnight MspI digestion at 37°C, cutting any fragments 
not containing a glucosyl-5hmC site at the P5 CCGG junction. After incubation, the 
libraries were size-selected from 100 bp to 500 bp and purified using a Zymoclean Gel 
DNA Recovery Kit (Zymo Research). The fragments were amplified using OneTaq 2X 
Master Mix (NEB), with PCR conditions including an initial denaturation of 94°C for 30 
seconds followed by 12 cycles of 94°C for 30 seconds, 58°C for 30 seconds, and 68°C for 
1 minute. Fragments containing 5hmC were positively selected during PCR amplification 
with adapter-specific indexing primers whereas fragments lacking glucosylated-5hmC at 
the P5 junction were cleaved and, therefore, not amplified by PCR. Amplified libraries 
were purified using the DNA Clean and Concentrator kit, and multiplexed using equal 
volumes of the libraries. All adapters and primers used were synthesized by Integrated 
DNA Technologies. Sequence reads from RRHP libraries were first processed to trim off 
the low quality bases and the P7CG adapter at the 3’ end of the reads. Reads were then 
aligned to the reference genome using bowtie (Langmead & Salzberg 2012) default 
parameters and the ‘–best’ setting. Aligned reads with the MspI tag (CCGG) were counted. 
The correlation analysis between different RRHP libraries was performed by comparing 
the presence of the tagged reads at each profiled MspI site, and Pearson’s coefficient was 
calculated accordingly.  
2.2.3.4.1 Reduced Representation Hydroxymethylation Profiling bioinformatic analysis 
Subsequent bioinformatic analysis was carried out by Dr Kamal Kishore (Bioinformatics 
Core Facility, CRUK-CI). The genome was partitioned into non-overlapping tiles of length 
1 kb and 5hmC was profiled within these tiles. Regions with low read coverage (those with 
less than 10 reads in any sample) were discarded from the analysis. The differential 5hmC 
analysis was carried out using DESeq2 (Love et al. 2014). For site-specific 5mC/5hmC 
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analysis, shared ER/TET2 regions were defined using the intersect function in R to 
generate completely overlapping regions. 
2.2.4 Protein methods 
2.2.4.1 Western blot 
Cells were harvested in RIPA buffer (Pierce) and the lysate sonicated using a Bioruptor 
Plus (Diagenode) for 2 minutes (30 seconds on/30 seconds off) to degrade the DNA. 
Protein was then quantified using a Direct Detect Spectrometer (Millipore). Samples were 
incubated at 70°C for 10 minutes in the presence of 1X LDS sample buffer (Invitrogen) 
and 1X NuPage sample reducing agent (Invitrogen) and loaded on NuPAGE 4-12% bis-
Tris gels (Invitrogen). A Precision Plus Protein Standards molecular weight marker 
(BioRad) was used for determination of protein sizes.  The gel tank apparatus was filled 
with 1X MOPS-SDS (3-(N-morpholino)propanesulfonic acid-sodium dodecyl suphate) 
running buffer (Invitrogen) and a voltage of 120 V applied for varying durations depending 
on the target protein size. Proteins were then transferred to nitrocellulose membranes 
using the iBlot® 2 Dry Transfer System (Invitrogen), or an overnight wet transfer (for 
TET2). The membrane was blocked using Odyssey Blocking Buffer (Li-Cor) for 1 hour at 
room temperature, and incubated with primary antibody overnight at 4°C. All primary 
antibodies (listed in Table 2.1) were used at a concentration of 1:1000, aside from the 
ERα antibody which was used at a concentration of 1:100. The membrane was then 
washed in Tris-buffered saline (50 mM Tris, 150 mM NaCl) containing 0.1% Tween-20 
(TBS-T), incubated with fluorescent secondary antibodies (IRDye® 800 CW Goat anti-
Mouse IgG 1:5,000 or IRDye® 680LT Goat anti-Rabbit 1:20,000, both Li-Cor) for 45 
minutes at room temperature, and washed once more in TBS-T before imaging using the 
Odyssey CLx Imaging System (Li-Cor). Images were taken with the automated capture 
option of the Image Studio Version 4.0 software. 
2.2.4.2 Parallel Reaction Monitoring (PRM) 
2.2.4.2.1 Sample preparation and mass spectrometry  
PRM sample preparation, method development and mass spectrometry (MS) analysis 
were performed by Dr Carmen Gonzalez Tejedo (Proteomics Core Facility, CRUK-CI). 
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Surrogate peptides unique to the target proteins of interest (ER, TET2, GATA3 and Actin) 
were chosen and stable-isotope-labelled versions of these peptides were synthesised as 
SpikeTides™ peptides by JPT Peptide Technologies, GmbH (Berlin, Germany). Cells 
were washed twice in cold PBS and harvested in PBS containing protease inhibitors 
(Roche). Cells were lysed and peptides digested with trypsin, and a mix of stable isotope-
labelled peptide standards was added to the mixture. Mixtures were desalted using either 
Ultra-Micro C18 Spin Columns (Harvard Apparatus) or cartridges from an iST Sample 
Preparation Kit (Preomics) and reconstituted in either 3% acetonitrile/0.1% formic acid or 
the iST Sample Preparation Kit load buffer (Preomics). A Pierce Peptide Retention Time 
Calibration Mixture containing 15 synthetic heavy peptides mixed at an equimolar ratio 
(Thermo Scientific) was added to each sample at a final concentration of 20 fmol of 
peptides per 2 µg of total protein to assess chromatography performance and optimise 
scheduled MS acquisition windows. Diluted peptide mixtures were analysed by liquid 
chromatography mass spectrometry (LC-MS) on a Dionex Ultimate 3000 UHPLC system 
coupled to a Q-Exactive HF mass spectrometer (Thermo Fisher Scientific). Scheduled 
PRM transitions used a retention time window of 120 seconds. All samples were analysed 
in triplicate in the mass spectrometer. 
2.2.4.2.2 PRM data processing and bioinformatic analysis 
Data processing and bioinformatic analysis of PRM data was performed by Dr Carmen 
Gonzalez Tejedo (Proteomics Core Facility, CRUK-CI). All raw files were processed using 
Skyline-daily software v.19.0.9.190 (MacCoss Lab, University of Washington) for the 
generation of extracted-ion chromatograms and peak integration. Peak integrations were 
reviewed manually and transitions from analyte peptides were confirmed by the same 
retention times of the endogenous peptides and heavy stable isotope-labelled peptides 
time in a pre-selected retention time window. At least three transition ion peak area 
intensities were integrated and summed for each peptide (heavy and endogenous). The 
ratio of endogenous/heavy peak areas was calculated and the average of three 
independent injections of every sample was calculated to obtain a final quantification value 
for each peptide. Data were exported from Skyline for analysis and plotting using an in-
house R script to calculate fold changes and p-values between different experimental 
conditions. Quantitative values obtained for actin peptides were used to normalise the 
data between different conditions. 
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2.2.4.3 Full proteome analysis 
2.2.4.3.1 Sample preparation and mass spectrometry  
Full proteome analysis was carried out by the Proteomics Core Facility (CRUK-CI),  as 
described in Papachristou et al. (2018). Briefly, cells were washed twice in cold PBS and 
harvested in PBS containing protease inhibitors (Roche). Cells were sonicated in 200 μl 
of 0.1 M tetraethylammonium bromide (TEAB), 0.1% SDS (sodium dodecyl suphate) 
buffer followed by probe sonication and boiling at 95 °C. Protein concentration was 
estimated using a Bradford assay (BIO-RAD-Quick start) according to manufacturer’s 
instructions. For each sample, 90 μg of total protein was reduced for 1 hour at 60°C by the 
addition of 2 μl 50 mM tris-2-carboxyethyl phosphine (TCEP, Sigma). Cysteines were 
blocked for 10 minutes at room temperature with the addition of 1 μl 200 mM methyl 
methanethiosulfonate (MMTS, Sigma). Proteins were digested overnight at 37°C in trypsin 
(Pierce) solution, added at a ratio of ~30:1 protein:trypsin. The following day peptides were 
labelled using the TMT (tandem mass tag) 11plex reagents (Thermo Scientific) with a 
randomised design. Peptides were fractionated on a Dionex Ultimate 3000 system at high 
pH using the X-Bridge C18 column (Waters) with 1% gradient. UV signal was recorded at 
280 and 215 nm and fractions were collected in a peak-dependent manner. Peptide 
fractions were analysed on a Dionex Ultimate 3000 UHPLC system coupled with a nano-
ESI Fusion Lumos (Thermo Scientific).  
2.2.4.3.2 Full proteome data processing and bioinformatic analysis 
Data processing of full proteome results was carried out by the Proteomics Core Facility 
(CRUK-CI) according to Papachristou et al. (2018). Raw MS data was processed with the 
SequestHT search engine on the Proteome Discoverer 2.1 software for peptide and 
protein identifications. The node for SequestHT included the following parameters: 
Precursor Mass Tolerance 20 ppm, Fragment Mass Tolerance 0.5 Da. Dynamic 
Modifications were Oxidation of M (+15.995 Da), Deamidation of N, Q (+0.984 Da) and 
Static Modifications were TMT6plex at any N-Terminus, K (+229.163 Da), Methylthio at C 
(+45.988). The Reporter Ion Quantifier node included a TMT 6plex (Thermo Scientific 
Instruments) Quantification Method. Further bioinformatic analysis was carried out by Dr 
Kamal Kishore (Bioinformatics Core Facility, CRUK-CI). Pre-processed quantitative 
datasets (peptide or protein-level intensities) generated by Proteome Discoverer were 
imported into R and data analysed using the qPLEXanalyzer tool (Papachristou et al. 
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2018), which uses analysis based on limma (an R/Bioconductor package) to identify 
differentially abundant proteins. 
2.2.5 Chromatin Immunoprecipitation (ChIP)  
2.2.5.1 Chromatin preparation and immunoprecipitation 
ChIP was performed as described by Papachristou et al. (2018). Briefly, cells were 
crosslinked at room temperature by incubating with 2 mM disuccinimidyl glutarate (DSG) 
for 20 min followed by 1% formaldehyde for 10 min before crosslinking was quenched with 
0.1 M glycine for 10 min. Cells were then washed twice in cold PBS and harvested in cold 
PBS containing protease inhibitors (Roche). Crosslinked cells were incubated with lysis 
buffer 1 (LB1, 50 mM Hepes–KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 
0.5% NP-40/Igepal CA-630, 0.25% Triton X-100) for 10 min followed by 5 min in LB2 (10 
mM Tris–HCL, pH8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) before resuspending 
in LB3 (10 mM Tris–HCl, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na–
Deoxycholate, 0.5% N-lauroylsarcosine). Chromatin was sonicated using the Bioruptor 
Plus (Diagenode) for 15 min (30 seconds on/30 seconds off) to generate DNA fragments 
of around 100-800 bp. Beads were pre-bound with antibody overnight at 4°C, with 5 μg of 
the appropriate antibody (or 2.5 μg each of ERα Abcam ab3575 and ERα Millipore 06-935 
where these antibodies were used in a 1:1 combination) and 50 μl of Protein A Dynabeads 
(Invitrogen) was used for each immunoprecipitation. After washing to remove unbound 
antibody, chromatin and beads were combined and samples were immunoprecipitated 
overnight at 4°C. The following day, beads were washed 10 times in RIPA buffer (50mM 
HEPES pH 7.6, 1mM EDTA, 0.7% Na-deoxycholate, 1% NP-40, 0.5M LiCl) followed by 2 
washes in Tris-EDTA (10mM Tris-HCl, 1mM EDTA). Chromatin was eluted and 
decrosslinked by incubating samples in elution buffer (50mM TrisHCl, pH8, 10mM EDTA, 
1% SDS) for 6-18 hours at 65°C. Eluted DNA was treated with RNase A (20 ng/ml) for 1 
hour followed by proteinase K (200 ng/ml) for 2 hours before DNA was purified by phenol-
chloroform extraction and taken forward for either qPCR (section 2.2.5.2) or sequencing 
(section 2.2.5.3).  
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2.2.5.2 ChIP-qPCR 
ChIP DNA was used neat and input DNA diluted 1:10 for qPCR analysis. Reactions were 
performed as described in section 2.2.2.2, using the primers listed in Table 2.4. Relative 
enrichment was determined as % of input. 
2.2.5.3 ChIP-seq library preparation and sequencing 
Library preparation was performed using the ThruPlex DNA-seq kit (Rubicon Genomics), 
and DNA was subjected to next generation sequencing on a HiSeq 4000 (Illumina) to 
reach approximately 30 million reads per sample. Sequencing was carried out by the 
Genomics Core Facility (CRUK-CI). 
2.2.5.4 ChIP-seq data processing and bioinformatic analysis 
ChIP-seq data processing and bioinformatic analysis was performed by Dr Igor 
Chernukhin. 50bp single-end reads were aligned to the Human Reference Genome 
(assembly hg38) using bowtie2 v.2.2.6 (Langmead & Salzberg 2012). Aligned reads with 
a mapping quality of less than 5 were filtered out. The read alignments from all replicates 
were combined into a single library and peaks were called using MACS2 version 
2.0.10.20131216 (Zhang et al. 2008) with sequences from chromatin extracts from the 
same cell line or PDX used as a background input control. The peaks yielded with a 
MACS2 q-value ≤ 1e-3 were selected for downstream analysis. 
2.2.5.4.1 Venn diagrams and differential binding analysis 
For Venn diagrams, shared sites were defined as peaks overlapping by at least 1 bp, 
generated using bedtools v.2.29.0 (Quinlan & Hall 2010). Differential binding analysis was 
performed as described previously using DiffBind (Stark & Brown 2013). For heatmaps, 
MA plots, and average plots visualising tag density and signal distribution, consensus 
peak sets across the compared conditions were determined using DiffBind. Heatmaps and 
average plots were generated with the read coverage in a window of ± 5 kb flanking the 
tag midpoint using a bin size of 1/100 of the window length. MA plots were generated in 
R v.3.5.1 or later, and average plots, boxplots and heatmaps were generated using 
MATLAB. 
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2.2.5.4.2 Motif analysis 
MEME Suite (v.4.9.1) tools were used for motif analysis. FIMO (Grant et al. 2011) was 
used to search all known transcription factor motifs from the JASPAR database (JASPAR 
CORE 2016 vertebrates) in tag-enriched sequences. Peak size-matched, randomly 
selected open chromatin regions based on an MCF7 MNase dataset (EBI Array Express 
E-MTAB-1958) were used as background controls. The motif frequencies for both tag-
enriched and control sequences were calculated as the sum of motif occurrences adjusted 
with MEME q-value. Motif enrichment analysis was performed by calculating the odds of 
finding an overrepresented motif among MACS2-defined peaks by fitting Student’s t-
cumulative distribution to the ratios of motif frequencies between tag-enriched and 
background sequences. Yielded p-values were further adjusted using Benjamini-
Hochberg correction. MEME (Bailey & Elkan 1994) and DREME (Bailey 2011) were used 
to perform de novo motif analysis on sequences corresponding to ChIP-seq peak regions 
and the resulting position weight matrix was compared to the JASPAR, Transfac and 
UNIPROBE databases by the TOMTOM application (Gupta et al. 2007). A p-value 0.0001 
was used as a threshold to define the presence of a motif. 
2.2.6 Rapid Immunoprecipitation Mass-spectrometry of Endogenous 
Proteins (RIME) 
2.2.6.1 Chromatin preparation and immunoprecipitation 
Chromatin preparation and immunoprecipitation was performed as described in section 
2.2.5.1, until the bead washing step after overnight immunoprecipitation. At this point, 
beads were washed 10 times in RIPA buffer (50mM HEPES pH 7.6, 1mM EDTA, 0.7% 
Na-deoxycholate, 1% NP-40, 0.5M LiCl) followed by two washes in 100 mM ammonium 
hydrogen carbonate (AMBIC). Washed beads were frozen at -20C prior to peptide 
digestion and RIME analysis (section 2.2.6.2). 
2.2.6.2 RIME sample preparation and mass spectrometry  
RIME sample preparation and analysis was performed by the Proteomics Core Facility 
(CRUK-CI) as described in Glont et al. (2019) and Papachristou et al. (2018). Briefly, 
tryptic digestion of bead-bound protein was performed by addition of 10 μl trypsin solution 
(15 ng/μl) (Pierce) in 100 mM AMBIC followed by overnight incubation at 37 °C. A second 
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digestion step was performed the next day for 4 h. After tryptic digestion tubes were placed 
on a magnetic stand to allow removal of the supernatant after acidification by the addition 
of 2 μl 5% formic acid. Digested peptide mixes were cleaned using Ultra-Micro C18 Spin 
Columns (Harvard Apparatus) according to manufacturer’s instructions. For non-
quantitative RIME, digested peptide mixtures were diluted 1/10 with loading buffer (0.1% 
formic acid, 2% acetonitrile (ACN), water) and analysed on an LTQ Velos-Orbitrap MS 
(Thermo Scientific) coupled to an Ultimate RSLCnano-LC system (Dionex). For 
quantitative RIME (qPLEX-RIME), digested, cleaned peptide samples were dried using a 
speedvac, reconstituted in 100 μl 0.1 M TEAB and labelled using TMT 10plex reagents 
(Thermo Fisher) with a randomised design. The peptide mixture was fractionated with 
Reversed-Phase cartridges at high pH (Pierce). Nine fractions were collected using 
different elution solutions in the range of 5–50% ACN. Peptide fractions were analysed on 
a Dionex Ultimate 3000 UHPLC system coupled with a nano-ESI Fusion Lumos (Thermo 
Scientific). 
2.2.6.3 RIME data processing and bioinformatic analysis 
2.2.6.3.1 Non-quantitative RIME 
Data processing of RIME results was carried out by the Proteomics Core Facility (CRUK-
CI) according to Papachristou et al. (2018). The raw MS files were processed with the 
SequestHT search engine on Proteome Discoverer 2.1 software for peptide and protein 
identifications. The node for SequestHT included the following parameters: Precursor 
Mass Tolerance 20ppm, Maximum Missed Cleavages sites 2, Fragment Mass Tolerance 
0.02Da. Dynamic Modifications were Oxidation of M (+15.995Da) and Deamidation of N, 
Q (+0.984Da). The coverage plots were created using the qPLEXanalyzer tool 
(Papachristou et al. 2018). Further bioinformatic analysis was carried out by Dr Kamal 
Kishore (Bioinformatics Core Facility, CRUK-CI) according to Papachristou et al. (2018). 
Specific interactors were considered as those occurring in at least two out of three 
independent replicates. Any proteins that appeared in any one of the three IgG control 
RIME experiments were excluded. 
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2.2.6.3.2 Quantitative RIME 
Data processing of RIME results was carried out by the Proteomics Core Facility (CRUK-
CI) according to Papachristou et al. (2018). The raw MS files were processed with the 
SequestHT search engine on the Proteome Discoverer 2.1 software for peptide and 
protein identifications. The node for SequestHT included the following parameters: 
Precursor Mass Tolerance 20 ppm, Fragment Mass Tolerance 0.5 Da, Dynamic 
Modifications were Oxidation of M (+15.995 Da), Deamidation of N, Q (+0.984 Da) and 
Static Modifications were TMT6plex at any N-Terminus, K (+229.163 Da). The Reporter 
Ion Quantifier node included a TMT 6plex (Thermo Scientific Instruments) Quantification 
Method. Further bioinformatic analysis was carried out by Dr Kamal Kishore 
(Bioinformatics Core Facility, CRUK-CI). Pre-processed quantitative datasets (peptide or 
protein-level intensities) generated by Proteome Discoverer were imported into R and data 
analysed using the qPLEXanalyzer tool (Papachristou et al. 2018), which uses analysis 
based on limma (an R/Bioconductor package) to identify differentially abundant proteins. 
2.2.7 Survival analysis 
For analysis of relapse free survival, Kaplan-Meier plotter (http://kmplot.com) was used. 
The data and methods used for the analysis are described in Györffy et al. (2010). Briefly, 
patients were stratified into high or low expression groups according to the median level 
of the gene probe selected (TET2 JetSet probe 227624_at). ER+ and ER- cohorts were 
analysed separately, with the “ER status derived from GE data” option selected. All other 
parameters were left as default. 
2.2.8 Additional software and statistical tests 
All analysis additional to that described in the method-specific sections above was 
performed using either MS Excel, GraphPad Prism v.8 or R v.3.5.1. Significance was 
assessed using Student’s t-test or Welch’s t-test. Only values with a p-value less than 0.05 
were considered statistically significant. Error bars represent standard deviation (SD). 
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The effect of GATA3 depletion on the ER 
complex, and the identification of TET2 as 
a key ER interactor 
3.1 Introduction 
ER drives tumour development in ER+ breast cancer in co-operation with numerous other 
proteins that together form the ER transcriptional complex. Although there are many key 
players that participate in the ER complex whose function is well understood, the roles of 
many other ER cofactors remain to be fully characterised, and it is likely there are yet 
further ER co-operating proteins yet to be found. These studies are important for 
developing a clearer picture of the molecular mechanisms driving the development and 
progression ER+ breast cancer, towards the aim of more effective targeted therapies.  
 
GATA3 is a transcription factor fundamental to mammary gland development that is highly 
expressed, and frequently mutated, in ER+ breast cancers (Cancer Genome Atlas 
Network 2012; Kouros-Mehr et al. 2006; Perou et al. 2000; Sorlie et al. 2001). Oestrogen-
induced growth of ER+ breast cancer cells appears dependent on GATA3 (Eeckhoute et 
al. 2007; Kong et al. 2014), and at the molecular level, GATA3 motifs are enriched around 
ER binding sites (Carroll et al. 2005; Lin et al. 2007; Serandour et al. 2013). ER and 
GATA3 co-localise at a large proportion (~45%) of ER binding sites in ER+ breast cancer 
cells (Kong et al. 2011; Theodorou et al. 2013), therefore it appears that there may be 
direct functional interplay between these two proteins that contributes to the breast cancer 
phenotype.  
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In terms of the mechanisms behind this potential co-operativity, GATA factors have been 
shown to interact directly with nucleosomes in vitro (Cirillo et al. 2002; Takaku et al. 2016) 
implying pioneer factor-like activities, as have been shown for FOXA1 in the context of 
ER. However, although overexpression of GATA3 in MBA-MD-231 cells demonstrates 
GATA3-induced chromatin remodelling at a subset of sites, rather than appearing an 
activity intrinsic to GATA3, this instead correlates with its capacity to recruit ATP-
dependent chromatin remodellers such as BRG1 (Takaku et al. 2016). Moreover, 
silencing of GATA3 in ER+ breast cancer cells affects the distribution of ER binding, but 
with equal proportions of both stronger and weaker ER binding events observed 
(Theodorou et al. 2013). Nevertheless, these effects are associated with oestrogen-
independent changes in FOXA1, p300, H3K4me1 and H3K27ac distribution that correlate 
with gene expression changes upon subsequent oestrogen stimulation, implying that the 
importance of GATA3 in ER biology may be partly due to a role in regulating enhancer 
accessibility. In the same study, GATA3 loss was further implicated in ER signalling 
through the examination of chromatin loops at the promoters of the oestrogen-regulated 
genes TFF1 and TFF3. At these sites, loss of GATA3 resulted in changes in chromatin 
looping that were associated with increased expression of these ER-regulated genes. This 
paints a complex picture of the role of GATA3 in ER biology, where, despite their putative 
functional connection and similar developmental roles, GATA3 may not always reinforce 
ER activity, but may instead fine-tune its effects on transcription. Importantly, whilst these 
observations of the contribution of GATA3 to ER signalling are themselves complex, the 
potential mechanisms behind them remain unclear. In particular, given that GATA3 
appears to lack intrinsic enzymatic or chromatin remodelling capabilities, investigating the 
proteins that are recruited to the ER complex by GATA3 could shed further light on its 
role.  
 
Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) is a 
method that has previously been used to study the composition of the ER complex, and 
to identify novel ER-interacting proteins (Mohammed & Carroll 2013). This technique 
involves antibody-based purification of endogenous protein complexes, with 
formaldehyde and disuccinimidyl glutarate (DSG) crosslinking performed prior to 
immunoprecipitation to enhance the scope of interactions that can be detected. A 
quantitative version of RIME (quantitative multiplexed rapid immunoprecipitation mass 
spectrometry of endogenous proteins, qPLEX-RIME) involves tandem mass tag (TMT) 
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labelling of samples prior to peptide fractionation and subsequent mass spectrometry. 
This facilitates precise quantitation of changes in chromatin-associated protein 
interactomes between different experimental conditions. For example, this technique has 
recently been used to investigate changes in the composition of the ER complex in 
response to tamoxifen treatment (Papachristou et al. 2018). To gain insights into the 
contribution of GATA3 to ER signalling, qPLEX-RIME was employed to evaluate the ER 
complex under control and GATA3-depleted conditions. The aim of this approach was to 
either detect mediators of GATA3 action that may be lost as a result of its absence from 
the ER complex, or to identify compensatory factors that could provide an indication of 
GATA3 activity, to gain further insights the potential contribution of this protein to ER-
regulated transcription. 
 
3.2 Results 
3.2.1 GATA3 knockdown affects the composition of the ER complex 
GATA3 was robustly depleted in MCF7 cells after 48 hours of siRNA-mediated 
knockdown, with no effect on total ER protein levels, as confirmed by Western Blot (Figure 
3.1A). ER qPLEX-RIME was then conducted comparing the ER interactome under control 
or GATA3-silenced conditions. As expected, GATA3 was observed as the most 
significantly depleted ER interactor, validating the knockdown approach (Figure 3.1B). 
Beyond this, and notably, given the implied functional link between GATA3 and ER, only 
a small number of significant changes were observed in response to GATA3 knockdown. 
The proteins significantly enriched in the ER complex in response to loss of GATA3 were 
the transcription factors LIM-homeobox 4 (LHX4) and zinc finger and BTB domain 
containing protein 34 (ZBTB34). The protein GREB1L (growth regulation by estrogen in 
breast cancer 1-like protein), which is of unknown function but has been implicated as a 
co-activator for the retinoic acid receptor (RAR) (Brophy et al. 2017; Herlin et al. 2019), 
was also enriched. Concurrent with this, the only protein that was significantly depleted in 
response to GATA3 knockdown (other than GATA3 itself) was the dioxygenase enzyme 
TET2. RNA-seq demonstrated that these changes to the ER complex in response to 
GATA3 knockdown are likely due to altered expression of these proteins (Figure 3.2), 
suggesting that the decreased TET2-ER interactions might result from downregulation of 
Chapter 3 
50 
 
TET2 levels in response to GATA3 loss, and the increased presence of LHX4, ZBTB34 
and GREB1L may be linked to their protein-level upregulation. Interestingly, it has been 
suggested that both LHX4, and the BTB/POZ protein family (of which ZBTB34 is a 
member) may be capable of binding to methylated DNA (Filion et al. 2006; Qi et al. 2006; 
Yin et al. 2017). TET2 also has a link to DNA methylation through its capacity to regulate 
DNA modifications, mediating the conversion of 5mC to 5hmC, followed by iterative 
oxidation of 5hmC to 5fC and 5caC (He et al. 2011; Ito et al. 2011; Tahiliani et al. 2009). 
These results suggest a potential role for GATA3 in modulating reading and writing of DNA 
modifications as part of the ER complex. 
 
 
 
Figure 3.1. GATA3 knockdown alters the composition of the ER complex.  
A) Western blot for GATA3 and ER after 48 hours’ treatment with either non-targeting 
control siRNA (siNT), or siRNA targeting GATA3 (siGATA3), demonstrating robust GATA3 
depletion with no effect on total ER levels. β-actin is used as a loading control. B) ER 
qPLEX-RIME in MCF7 cells showing changes to the ER complex after GATA3 knockdown 
(48 hours). Four replicates of ER RIME and one pooled IgG control RIME for each 
condition were included in each 10plex TMT MS run. Significantly enriched or depleted 
proteins according to the adjusted p-value are highlighted in red (p adj ≤ 0.05 after multiple 
testing correction using Benjamini-Hochberg procedure). 
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Figure 3.2. Protein-level changes in the ER complex correspond to gene expression 
changes induced by GATA3 knockdown.  
For the five significantly changing proteins identified in Figure 3.1, significance in ER 
qPLEX-RIME (p-value, left y axis, red data points) and RNA-seq (p-value, right y axis, 
blue data points) were plotted against log2 fold change, showing that changes in the 
expression levels of these genes in response to GATA3 knockdown likely contribute to 
their altered levels in the ER complex. 
3.2.2 TET2 and GATA3 antibody testing using RIME 
Given the capacity of TET2 for regulating DNA modifications, and the developing focus 
on the role of this factor in transcriptional regulation (Chen et al. 2018; Li et al. 2017; 
Rasmussen et al. 2015, 2019; Wang et al. 2018; Wang et al. 2015), its loss from the ER 
complex in response to GATA3 depletion warranted further investigation. Due to the lack 
of robust, commercially available IP-grade antibodies for TET2, several groups have 
circumvented the resultant challenges associated with mapping endogenous TET2-
chormatin interactions through generating custom TET2 antibodies, or by overexpressing 
TET2 tagged with additional epitopes more easily detectable using ChIP (Rasmussen et 
al. 2019; Wang et al. 2015; Wang et al. 2018). RIME provides an unbiased and sensitive 
approach for assessing the specificity and efficacy of antibodies for immunoprecipitation, 
so for this study, a selection of commercially available TET2 antibodies were tested using 
this method. To allow assessment of the reciprocal interaction between TET2 and GATA3, 
antibody candidates against GATA3 were also evaluated. 
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Non-quantitative RIME was performed on untreated, asynchronous MCF7 cells.   
Antibodies were assessed through measuring protein sequence coverage in terms of the 
unique peptides detected by mass spectrometry. RIME using species-matched IgG 
antibodies as negative controls was performed in parallel to discriminate specific from 
non-specific interactions. As shown in Figure 3.3A, the TET2 protein was 
immunoprecipitated with varying efficiencies using the different antibody candidates. 
Given that cell lysates are crosslinked for RIME, this antibody validation also provided the 
potential to explore TET2-associated proteins. The two antibodies achieving the highest 
TET2 sequence coverage were Abcam ab94580 and Bethyl A304-247A (Figure 3.3A), so 
to assess the consistency of the TET2 interactors detected using these two reagents, the 
lists of proteins detected in each of these RIME experiments were overlapped with one 
another, as shown in Figure 3.4A. Proteins detected in the IgG negative control are also 
illustrated in the Venn diagram to provide an indication of antibody specificity. Both 
antibodies resulted in the detection of similar numbers of proteins (648 interactors using 
Figure 3.3. Coverage plots for TET2 and GATA3 antibodies tested using RIME. 
To assess the efficiency of each antibody to immunoprecipitate its target protein, plots 
showing the peptide sequence coverage of the bait protein were generated for A) TET2 
and B) GATA3. Plots show the location of unique peptides identified with high confidence 
across the protein sequence. The corresponding percentage coverage and number of 
unique peptides is detailed above each plot. Data are the results of one replicate, used 
as a quick way of assessing multiple antibodies prior to more detailed experimental work. 
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Abcam ab94580 and 587 interactors using Bethyl A304-247A), with 396 of these proteins 
common to both antibodies. Of these, 97 (~25%) were also detected in the IgG negative 
control, leaving 299 of these shared interactors as specific to TET2. Bethyl A304-247A 
and Abcam ab94580 antibodies thus appeared similar both in their ability to purify TET2, 
and in terms of the interactors co-purified, and Abcam antibody ab94580 was selected for 
use in future work. 
 
As shown in Figure 3.3B, GATA3 was also immunoprecipitated with varying efficiencies 
using the four different antibodies tested against this protein. The two antibodies achieving 
the highest sequence coverage were Santa Cruz sc268 and Abcam ab106625, both 
resulting in detection of 15.58% of the GATA3 protein. To compare the GATA3 interactors 
co-purified using each of these antibodies, the lists of detected interactors were 
overlapped, shown in Figure 3.4B. Proteins detected in the IgG negative control are also 
illustrated in the Venn diagram. Some consistency was observed between the interactors 
detected using these antibodies, however the number of interactors detected using the 
Santa Cruz antibody was much smaller (110 interactors, versus 525 for Abcam 
ab106625). One explanation for this could be that the polyclonal Abcam ab106625 is less 
susceptible to epitope masking than the monoclonal Santa Cruz sc268, resulting in a more 
robust pull-down and facilitating the detection of a greater number of interactors. The 
overlap of these two sets of interactors with those detected in the IgG negative control 
illustrates their specificity (Figure 3.4B). A proportion of the interactors detected using both 
Santa Cruz sc268 and Abcam ab106625 appeared to be non-specific based on their co-
occurrence in the IgG negative control, however non-specific interactors constituted a 
much larger proportion of the total Santa Cruz sc268 list (73 out of 110 proteins, ~66%) 
than the Abcam ab106625 list (124 out of 525 proteins, ~24%). The increased scope of 
Abcam ab106625 for detecting specific GATA3 interacting proteins thus prompted the 
selection of this reagent for GATA3 RIME. 
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Figure 3.4. Venn diagrams of TET2 and GATA3 interactors detected using different 
antibodies in RIME.  
Lists of Uniprot IDs of all interactors identified using selected A) TET2 and B) GATA3 
antibodies were overlapped. The proportion of unique interactors detected by each 
antibody is indicated by overlap with lists of interactors detected using species-matched 
IgG negative controls. Antibody species: TET2 Abcam ab94580 (rabbit); TET2 Bethyl 
A304-247A (rabbit); GATA3 Abcam ab106625 (rabbit); GATA3 Santa Cruz sc268 (mouse). 
For the GATA3 Venn diagram, a combined list of proteins detected in both rabbit and 
mouse IgG RIME was used. 
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3.2.3 ER, GATA3 and TET2 form a complex, and share common 
interacting proteins 
Using the antibodies selected for GATA3 and TET2 RIME in section 3.2.2, and the 
antibody combination previously optimised for ER immunoprecipitation by Glont et al. 
(2019), RIME for ER, GATA3 and TET2 was performed in MCF7 cells. Biological triplicates 
were performed for each factor, including an IgG negative control. Specific interactors for 
each protein were defined as those detected in at least two out of three independent 
replicates, and absent from all three replicates of the IgG negative control. ER, GATA3 
and TET2 were reciprocally detected as interactors of one another, implying that these 
proteins interact closely at the core of the ER complex. In addition, ER, GATA3 and TET2 
demonstrated a large number of common interactors (379 proteins). The Venn diagram in 
Figure 3.5B demonstrates the overlap of the specific interactors detected for ER, GATA3 
and TET2, whilst Figure 3.6 shows the full list of interactors common to all three proteins. 
ER, GATA3 and TET2 common interactors included several other key ER-associated 
proteins such as FOXA1, GREB1, RARα, and ER co-activators NCOA3 and CARM1 
(Anzick et al. 1997; Chen et al. 2000; Deschênes et al. 2007; Mohammed et al. 2013; 
Ross-Innes et al. 2010), demonstrating that TET2 interacts with central components of the 
ER machinery. The sequence coverage achieved for ER, GATA3 and TET2 in these 
experiments is shown in Figure 3.5A, demonstrating that each bait protein was robustly 
detected using RIME. Additionally, the sequence coverage and corresponding number of 
unique peptides obtained for ER, GATA3 and TET2 in all three RIME experiments are 
shown in Figure 3.7. 
 
ER RIME performed in this manner has been described previously, and the list of ER 
interactors identified in this experiment matched up well with existing results (Glont et al. 
2019; Papachristou et al. 2018). Though GATA3 RIME has not been published, GATA3 
is consistently identified as an ER interactor in published ER RIME datasets in MCF7 cells 
(Mohammed et al. 2016; Glont et al. 2019; Papachristou et al. 2018), thus the detection 
of many key ER interactors in the GATA3 RIME validates the GATA3 antibody used for 
this approach. Additionally, amongst the proteins identified in the GATA3 RIME was the 
known GATA3-interacting protein Friend of GATA1 (FOG1), also known as ZFPM1 
(Cantor & Orkin 2005), further confirming that this antibody captures direct interactors of 
GATA3. 
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Figure 3.5. ER, GATA3 and TET2 form a complex, and share common interacting 
proteins. 
A) Non-quantitative RIME in MCF7 cells yielded robust coverage of the three bait proteins 
ER, GATA3 and TET2, indicated by coverage diagrams showing the unique peptides 
identified with high confidence across the protein sequence. The number of unique 
peptides and corresponding % sequence coverage is shown above each plot. Each 
diagram provides a representative example of three biological replicates.  B) Overlap of 
lists of Uniprot IDs of specific interactors for ER, GATA3 and TET2. Specific interactors 
were defined as those occurring in at least two out of three independent replicates. 
Proteins that appeared in any one of the three IgG control RIME experiments were 
excluded. ER, GATA3 and TET2 shared a total of 379 common interactors by RIME. 
Several key ER complex proteins were amongst these, highlighted in the central portion 
of the diagram. ER, GATA3 and TET2 common interactors are listed in full in Figure 3.6. 
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Figure 3.6. Full list of ER, GATA3 and TET2 common interactors from RIME in MCF7 
cells. 
Specific interactors were considered as those occurring in at least two out of three 
independent replicates. Any proteins that appeared in any one of three IgG negative 
control RIME experiments were excluded. 
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Figure 3.7. Protein coverage and unique peptides for reciprocal detection of ER, 
GATA3 and TET2 in RIME. 
Barplots depicting the % peptide sequence coverage for ER, GATA3 and TET2 in 
separate RIME experiments, indicating that these three proteins are reciprocally detected 
as interactors of one another using RIME. Results represent mean ± SD (n=3). The 
number of unique peptides detected for each protein (the average of three biological 
replicates) is indicated above each bar. 
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TET2 has been identified previously as an ER interactor in RIME datasets from MCF7 
cells (Papachristou et al. 2018), however this is the first time RIME for TET2 itself has 
been described. Again, given the detection of TET2 as an ER interactor, the robust overlap 
between the ER and TET2 interactomes provides some validation to the TET2 antibody 
used. Further confirming the capacity of the TET2 antibody to detect known TET2 
interactors, published co-immunoprecipitation data has shown that TET2 interacts with 
p300 (Zhang et al. 2017), OGT (Chen et al. 2013; Deplus et al. 2013; Vella et al. 2013), 
and HDAC2 (Zhang et al. 2015), and all three of these proteins were co-purified with TET2 
in RIME. 
 
Beyond this, several additional interactors were detected in the RIME data that could shed 
light on the dynamic interplay between ER, GATA3 and TET2, and the potential 
contribution of TET2 to ER transcription. Amongst the other proteins detected as common 
interactors of ER, TET2 and GATA3 were the ER co-repressor proteins NCOR1 and 
NCOR2, and the scaffolding protein AKAP8. Common interactors of ER and TET2 
included APEX1, an apurinic/apyrimidinic (AP) lyase thought contribute to active DNA 
demethylation through its role in base-excision repair (Hajkova et al. 2010), and several 
members of the MCM family of DNA helicases important for DNA replication during the 
cell cycle (MCM3 and 7). Collectively, these proteins may implicate TET2 in various 
processes including transcriptional control, scaffolding/mediation of protein-protein 
interactions, active regulation of DNA modifications (or DNA repair), and DNA replication 
during the cell cycle, all potentially as part of the ER complex.  
 
Given the large overlap between the ER, GATA3 and TET2 interactomes, examination of 
proteins detected in each of these RIME experiments individually may also help to 
evaluate the potential co-functionality of these proteins in the ER complex. For example, 
the DNA methyltransferase DNMT1 was was co-purifed with both ER and GATA3, 
furthering the potential association between DNA methylation pathways and ER signalling. 
In relation to TET2, whilst other TET family members TET1 and TET3 are thought to be 
directed to GC-rich target sites via their CXXC domains, TET2 lacks this domain, hence it 
is unclear how it is targeted to specific genomic regions. One mechanism may be though 
interactions with other CXXC domain-containing proteins (Hu et al. 2013), and both 
CXXC4/IDAX and CXXC5/RINF have been shown to facilitate the association of TET2 
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with chromatin (Ko et al. 2013; Ma et al. 2017). CXXC5 was present as an ER interactor, 
suggesting that this protein might help mediate TET2-DNA interactions as part of its role 
in the ER complex. Finally, the E3 ubiquitin ligase UHRF2, shown to enhance interactions 
between TET proteins and hydroxymethylated DNA (Spruijt et al. 2013), was also detected 
in both ER and GATA3 RIME experiments, suggesting that TET2 may interact with 5hmC 
proximal to ER sites. These speculations may be tempered by the absence of CXXC5 and 
UHRF2 from the TET2 RIME, suggesting they might be part of a larger ER/GATA3 
complex, but not necessarily via direct association with TET2 sub-complexes. However, 
the fact that these proteins are not detected as TET2 interactors could also be reflective 
of greater efficiency of the ER antibody compared to the TET2 antibody. Stoichiometry, 
positioning, and expression levels of certain bait proteins compared to others may also 
affect the subsets of interactors detected using different antibodies against proteins 
participating in the same complex, and the profile of interactors detected in the ER RIME 
compared to the TET2 RIME might also reflect these differences. Furthermore, RIME 
provides an aggregate view of all protein complexes immunoprecipitated from a 
heterogeneous population of cells, with no resolution of complex-to-complex variation. 
Whilst detection of the key interactors involved in the majority of complexes will likely be 
retained, resolution of interactions important only at subsets of these complexes may be 
weakened or lost, dependent on the above variables. This highlights how probing the 
same protein complex using several different bait proteins, as has been attempted here, 
may facilitate a more comprehensive picture of the proteins acting together in a cell.  
3.2.4 TET2 antibody testing using ChIP-seq 
Having confirmed that ER and TET2 interact as part of the ER complex, the chromatin 
profile of these interactions was next investigated using ChIP. Despite the similarities 
between the RIME and ChIP-seq protocols, anecdotal observations demonstrate that 
antibodies performing robustly in RIME do not always perform comparably in ChIP. 
Therefore, the TET2 antibodies previously tested using RIME, including several additional 
candidates, were screened in a single replicate of ChIP-seq in asynchronous, untreated 
MCF7 cells. ER ChIP-seq was performed as a control, and peaks were called using MACS 
(Zhang et al. 2008). The ER control ChIP-seq detected a robust number of binding events 
(34,692), demonstrating high signal and low background (Figure 3.8A, bottom track). 
Based on the RIME data indicating TET2 as a central member of the ER complex, and 
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the identical nature of the crosslinking conditions between the ChIP and RIME protocols, 
it was deemed plausible that TET2 binding may be detected at ER sites. This held true, 
and as such, snapshots of ChIP-seq tracks at two key ER-regulated genes, RARA and 
GREB1 (Figure 3.8A) are provided as examples of TET2 antibody performance. Whilst 
Santa Cruz sc398535 was the poorest performer in terms of the number of binding events 
detected (with 975 peaks detected), Diagenode C15410255 (5,755 peaks), Abcam 
ab230358 (6,488 peaks), Bethyl A304-247A (5,521 peaks), and Pierce PA5-35847 (6,508 
peaks) performed comparably. However, a far larger number of peaks (21,359) were 
detected using Abcam ab94580, more than three times those detected by the next-best 
performer, Pierce PA5-35847. Based on ChIP-seq signal, Abcam ab94580 was also the 
top-ranked antibody, displaying coverage approximately ten times that of Abcam 
ab230358, the next-best performer in this respect, at the sites shown in Figure 3.8A.  
 
A Venn diagram indicating positional overlap of peaks for three of the best-performing 
antibodies based on a combination of their ChIP-seq performance and RIME protein 
sequence coverage (refer to Figure 3.4) is shown in Figure 3.8B. Whilst the binding sites 
detected using Pierce PA5-35847 formed a near-total subset of those detected by Abcam 
ab94580, the peaks detected using the Bethyl antibody A304-247A demonstrated a 
smaller overlap, with approximately ~50% of the peaks detected unique to this antibody. 
Although all TET2 antibodies demonstrated very similar binding profiles to ER, particularly 
at the RARA and GREB1 enhancers depicted in Figure 3.8A, for Abcam ab94580 this 
similarity was striking, likely due to the improved coverage and signal-to-background ratio 
of this antibody. Although according to Figure 3.8B, the Bethyl, Pierce and Abcam 
antibodies all detected peaks that overlapped with ER binding, the peaks produced by 
both Abcam ab94580 and Pierce PA5-35847 formed a near-total subset of the total ER 
binding events, with 95% of the Pierce PA5-35847 peaks and 93% of the Abcam ab94580 
peaks co-occupied by ER (corresponding 18% and 57% of ER peaks for each antibody, 
respectively). This high degree of ER and TET2 co-localisation is not unexpected given 
the interaction between ER and TET2 observed in the RIME data, and thus it was 
reasoned that the large number of ER-overlapping peaks detected by Abcam ab94580 
may be valid and specific to TET2. For these reasons, Abcam ab94580 was selected for 
future ChIP-seq studies.  
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Figure 3.8. TET2 antibody testing using ChIP-seq. 
A) UCSC genome browser tracks of ChIP-seq signal near two key ER target genes 
(GREB1 and RARA) for the six TET2 antibodies tested, plus an ER control (performed 
using the ER antibody combination detailed in the Materials and Methods). All tracks are 
representative of one biological replicate, and all samples recieved equivalent (between 
22 and 25 million) sequencing reads. The number of peaks called using MACS are 
indicated. B) Venn diagram showing positional overlap of binding sites for three of the 
best-performing antibodies based on a combination of ChIP-seq performance and RIME 
protein coverage (refer to Figure 3.3). Overlap with ER control peaks is also shown. 
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3.2.5 ER and TET2 co-localise at chromatin in ER+ cell lines and PDX 
models 
The aim of the next investigations was to validate the preliminary findings described 
above, and to explore the interplay between ER and TET2 in several additional ER+ breast 
cancer models. ChIP-seq was first performed in two ER+ cell lines, MCF7 and ZR75-1. 
Asynchronous, untreated cells were used and four biological replicates were performed 
for each cell line. Peaks were called used MACS (Zhang et al. 2008) and only peaks 
occurring in all four independent replicates were considered in further analysis. This 
resulted in the identification of 16,884 and 13,423 TET2 binding sites in MCF7 and ZR71-
1 cells, respectively (Figure 3.9). Comparison of TET2 and ER ChIP-seq in both cell lines 
confirmed the robust overlap of ER and TET2 binding observed in the preliminary 
experiments, with TET2 binding sites constituting a near-total subset of ER binding sites 
in both cell lines (Figure 3.9A). UCSC genome browser screenshots in Figure 3.9B 
demonstrate the overlap of ER and TET2 binding at regulatory sites for two key ER target 
genes, RARA and GREB1. Motif analysis of TET2 binding regions further confirmed the 
association between TET2 and ER, with ER and FOXA1 motifs the two most significantly 
enriched sequences within TET2 peaks (Figure 3.10).  
 
The co-localisation of ER and TET2 was next validated in two ER+ patient-derived 
xenograft (PDX) models (Bruna et al. 2016). In these models, TET2 sites again formed a 
subset of ER binding sites (Figure 3.11A), with ER and TET2 co-bound in proximity to ER-
regulated genes, as in the cell line models (Figure 3.11B). PDX model STG195 possesses 
an ER mutation (Y537S), suggested to promote constitutive ER activity and resistance to 
antihormone therapies (Harrod et al. 2017). The proportion of ER sites co-occupied by 
TET2 in this model was comparable to the proportion of ER sites bound by both factors in 
wild-type model AB555, implying that this mutation does not alter the interaction of TET2 
with the ER complex. The high degree of genomic co-localisation of ER and TET2, and 
the near-absence of ER-independent TET2 binding sites is thus observed across all four 
independent ER+ breast cancer models. 
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Figure 3.9. TET2 and ER interact at chromatin in ER+ breast cancer cell lines. 
A) Venn diagrams indicate positional overlap of ER and TET2 ChIP-seq peaks in ER+ 
breast cancer cell lines MCF7 and ZR75-1. The heatmaps below each Venn diagram 
illustrate the ChIP-seq signal intensity for ER and TET2 at ER/TET2 shared sites (top), 
and “TET2 low” sites where TET2 peaks were not called (bottom). B) UCSC genome 
browser tracks demonstrate overlap of TET2 and ER peaks at ER target genes RARA 
and GREB1. For the schematics below each track, dotted lines indicate introns, boxes 
indicate exons, and arrowheads indicate direction of transcription. ChIPs were perfomed 
in quadruplicate. 
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Figure 3.10. De novo motif analysis of ER and TET2 peak regions reveals 
enrichment of ESR1 and FOXA1 motifs. 
Enrichment analysis was performed using MEME Suite tools (Machanick and Bailey 
2011). The top two enriched motifs according to E-value (determined by significance of 
the motif according to the discovery program reporting the motif) are shown in column 2. 
Column 4 shows the distribution of the best matches to the enriched motif within the peak 
regions analysed (the vertical line corresponds to the centre of the sequences). Mean, 
median, and range (in bp) for inputted sequences for each ChIP-seq are (in order): MCF7 
ER – 605, 527, 4160; MCF7 TET2 – 421, 505, 4631; ZR75-1 ER – 592, 505, 4631; ZR75-
1 TET2 – 403, 352, 2688. Specific identities of motifs bearing similarity to those in column 
2 are displayed in column 5, demonstrating that these motifs represent ER and FOXA1 
binding regions. 
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Figure 3.11. TET2 and ER interact at chromatin in ER+ PDX models. 
A) Venn diagrams indicate positional overlap of ER and TET2 ChIP-seq peaks in two ER+ 
PDX models, STG195 and AB555. The heatmaps below each Venn diagram illustrate the 
ChIP-seq signal intensity for ER and TET2 at ER/TET2 shared sites (top), and “TET2 low” 
sites where TET2 peaks were not called (bottom). B) UCSC genome browser tracks 
demonstrate overlap of TET2 and ER peaks at ER target genes RARA and GREB1. For 
the schematics below each track, dotted lines indicate introns, boxes indicate exons, and 
arrowheads indicate direction of transcription. ChIPs were perfomed in quadruplicate. 
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When cross-comparing ChIP-seq between different factors, variations in antibody 
efficiency and specificity (discussed in the context of RIME in section 3.2.3) can limit 
definitive conclusions about true patterns of genomic overlap. Validation of the TET2 
antibody used here against several other candidates in both ChIP and RIME suggests it 
is specific and effective. However, it is likely that TET2 interacts with chromatin at a wider 
range of sites than those detected in the above models, but that these are lower affinity 
sites and hence are not captured using ChIP. While it is important to bear in mind the 
caveats of antibody-based techniques, the lack of robust numbers of ER-independent 
TET2 sites could also suggest a role for ER in targeting TET2 to chromatin. As described 
previously, TET2 lacks the CXXC domain possessed by other TET family members, hence 
how it is directed to specific genomic regions is uncertain. Investigations in several model 
systems have proposed different proteins that may determine site-specificity of TET2-
chromatin interactions (Chen et al. 2018; Hassan et al. 2017; Wang et al. 2015). From 
these studies, it seems likely that if TET2 does require intermediate proteins to facilitate 
its targeting to specific sites, these mediators are likely to vary with both cell, and 
potentially genomic, context. These ChIP-seq results, demonstrating close association of 
the TET2 chromatin binding profile with that of ER, build on the RIME findings and imply 
ER may help target TET2-chromatin interactions in an ER+ breast cancer context. This 
idea is explored further in Chapter 4. 
 
In all four models (two cell lines and two PDX tumour samples), genomic annotation of ER 
sites (Figure 3.12) revealed binding of ER mainly to promoter-distal sites, as expected 
(Carroll et al. 2006). TET2 embodied this preference for distal sites even further, exhibiting 
a smaller fraction of promoter-proximal binding sites than ER in all four models. This 
finding that TET2 may preferentially associate with enhancers is consistent with recent 
literature (Rasmussen et al. 2015, 2019), a turning point from previous paradigms where, 
in the absence of high-quality TET2 ChIP-seq data, it was assumed TET2 occupancy 
would bias towards promoters, in line with observations for TET1 and TET3 (Jin et al. 
2016; Williams et al. 2011; Wu & Zhang 2011). These endogenous TET2 mapping 
approaches show that in ER+ breast cancer cells, the binding of TET2 tracks that of the 
driving transcription factor, ER.  
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Figure 3.12. Genomic annotation of ER and TET2 sites indicates binding to a large 
fraction of promoter-distal regions. 
Pie charts show classification of ER and TET2 binding sites according to genomic location 
for all the models tested. Promoters were defined as regions inclusive of 1 kb downstream 
and 2 kb upstream of the TSS. 
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In addition to confirming that ER and TET2 co-bind at key ER target genes, two examples 
of which (GREB1 and RARA) are shown in Figures 3.9B and 3.11B, inspection of 
individual ChIP-seq tracks indicated that the TET2 gene itself possesses ER binding sites 
20-30 kb upstream of its TSS in all four ER+ breast cancer models (Figure 3.13). This 
indicates that TET2 may be an ER target gene in ER+ breast cancer, and is supported by 
recent studies in MCF7 cells demonstrating that TET2 expression is induced by oestrogen 
(Wang et al. 2018) and robustly repressed by tamoxifen (Papachristou et al. 2018). In 
combination with the finding that TET2 expression is reduced by GATA3 knockdown, 
these results indicate that TET2 is a common target gene of both ER and GATA3 that is 
a central component of the ER complex on chromatin.  
  
Figure 3.13. ChIP-seq shows ER binding sites distal to the TET2 promoter. 
UCSC genome browser tracks demonstrating ER binding sites upstream of the TET2 TSS 
in two ER+ breast cancer cell lines (MCF7 and ZR75-1) and two ER+ PDX models 
(STG195 and AB555). ChIPs were performed in quadruplicate. 
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3.2.6 TET2 expression is associated with outcome in breast cancer 
As described in Chapter 1, TET2 is rarely mutated in breast cancer (Scourzic et al. 2015; 
Stephens et al. 2012). Nevertheless, reduced TET2 expression is observed in breast 
tumours compared to matched normal tissue (Yang et al. 2013), and examination of a 
cohort of 162 breast cancer samples by Yang et al. (2015) revealed that lower levels of 
TET1, TET2, and TET3 mRNAs are associated with poor prognosis. However, neither of 
these studies discriminated breast cancers based on molecular subtype. To investigate 
whether TET2 associates with clinical outcome specifically in ER+ breast cancer, the 
online tool KM plotter (Györffy et al. 2010) was used to assess the relationship between 
TET2 mRNA expression and relapse-free survival (RFS) in ER+ and ER- breast cancer 
patients (Figure 3.14). Higher expression of TET2 was significantly associated with 
improved relapse-free survival in the ER+ cohort, but not in the ER- cohort. Although 
further validation using additional datasets would be required to confirm this observation 
(for example to match the numbers of ER+ and ER- patients assessed), this demonstrates 
that TET2 predicts clinical outcome when ER+ disease is assessed exclusively. 
  
Figure 3.14. Higher TET2 mRNA expression is associated with improved relapse-
free survivial in ER+ breast cancer. 
Kaplan-Meier plotter (Győrffy et al. 2013) was used to assess relapse-free survival (RFS) 
in ER+ and ER- breast cancer patients. HR = hazard ratio. 
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3.3 Summary 
Through the use of qPLEX-RIME, a recently developed proteomic tool for investigating 
endogenous interacting proteins, the findings in this chapter indicate that GATA3 
regulates the composition of the ER complex, shedding new light on its role in ER biology. 
Amongst the proteins significantly enriched in the ER complex upon loss of GATA3 were 
the transcription factors LHX4 and ZBTB34, whilst the dioxygenase enzyme TET2 was 
significantly depleted. It has been suggested that LHX4 and ZBTB34 are capable of 
interacting with methylated DNA (5mC) (Filion et al. 2006; Qi et al. 2006; Yin et al. 2017), 
and the dioxygenase TET2 has a role in DNA methylation pathways through its function 
in oxidising 5mC to further DNA modifications, a process thought to be central to DNA 
demethylation. The common functional thread unifying these proteins thus suggests that 
GATA3 may have an indirect role in regulating levels of both DNA methylation and 
oxidised forms of this mark, and how these modifications are interpreted by the ER 
complex. The fact that TET2 was depleted from the ER complex in response to GATA3 
knockdown presented it as a more tractable target to study in relation to breast cancer 
than the enriched factors LHX4, ZBTB34 or GREB1L, which are not detected as ER 
interactors under normal conditions in these cells. In addition, the presence of a wide body 
of existing research on TET2 and its functions, in particular the developing research on its 
role in transcription, prompted further investigation of the role of this factor in the ER 
complex. This work forms the basis of the remainder of this thesis. 
 
Due to the lack of well-optimised, commercially available antibodies for 
immunoprecpiptation of TET2, both RIME and ChIP-seq were used to evaluate a range of 
antibody options. Upon selection of a candidate for robust detection of TET2, TET2 was 
confirmed as central to the ER complex through detection of its reciprocal interaction with 
both ER and GATA3 in RIME. This was further evidenced by the extensive overlap 
between TET2, GATA3 and ER interactors, including many factors salient to ER biology 
such as FOXA1, RARα and CARM1. ChIP-seq in several ER+ breast cancer models, 
representing both cell line models and PDX tissue, demonstrated that TET2 binds to a 
subset of ER regulatory sites, and additionally that TET2 itself appears to be an ER target 
gene, with a putative ER enhancer 20-30 kb upstream of its TSS. This reinforces the 
notion of a functional role for TET2 with regards to ER signalling, as it has been shown 
that the ER complex can regulate its own activity through controlling transcription of its 
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core components. For example, GREB1 and RARα, both proteins linked to ER function, 
are also ER-regulated genes (Mohammed et al. 2013; Liu et al. 2014; Ross-Innes et al. 
2010). Furthermore, the strong link between ER and TET2 chromatin occupancy, and the 
observation of very few ER-independent TET2 binding sites, suggest a possible role for 
ER in targeting TET2 to chromatin. This idea is explored further in Chapter 4. 
 
The suggestion of a functional link between ER and TET2 is a novel concept in the ER 
field. Whilst this work was in progress, Wang et al. (2018) established a link between ER 
and TET2, showing that these proteins co-localise on chromatin in MCF7 cells, and 
proposing that TET2 has a role in the expression of ER target genes. The work in this 
chapter builds on this ER-TET2 connection by demonstrating that the participation of TET2 
in the ER complex is regulated by the key ER cofactor GATA3. This work also shows, 
using RIME, that ER, GATA3 and TET2 interact as part of a protein complex, and 
reinforces the connection between TET2 and ER through demonstrating their interaction 
at chromatin in several additional ER+ breast cancer models. In terms of the importance 
of TET2 in breast cancer, existing studies have linked increased TET2 expression with 
improved prognosis (Wang et al. 2018; Yang et al. 2015). The findings that TET2 forms a 
key part of the ER complex, and itself appears to be an ER target gene, suggest this 
improved prognosis may be partly due to a requirement of TET2 for the formation of a fully 
functional ER complex that is sensitive therapeutic targeting. Further in-depth studies will 
be required to validate this observation.  
 
For the work in this chapter, RIME analysis was performed by the Proteomics Core 
Facility, with further bioinformatic analysis performed by Dr Kamal Kishore of the 
Bioinformatics Core Facility. Sequencing was performed by the Genomics Core Facility, 
and RNA-seq and ChIP-seq data processing and analysis was performed by Dr Igor 
Chernukhin. 
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The role of TET2 in gene expression, and 
the interdependence of ER/TET2-
chromatin interactions 
4.1 Introduction 
The work in Chapter 3 demonstrated TET2 as a key component of the ER complex, and 
showed that ER and TET2 co-localise at chromatin in a range of breast cancer models, 
implying that there may be a functional relationship between these two proteins. Breast 
cancers driven by ER are associated with improved clinical outcome compared to ER- 
subtypes, partly due to fact that the ER complex presents a tractable target for 
antihormone therapies (Parker et al. 2009). The hypothesis that TET2 might be important 
for the proper functioning of the ER complex is corroborated by the finding that lower levels 
of TET2 are associated with poor prognosis in breast cancer (Yang et al. 2015), similar to 
the association between ER expression and outcome. 
 
Based on these findings, the potential relationship between ER and TET2 in transcriptional 
control was explored further. Firstly, the TET2-regulated gene programme was 
investigated in ER+ breast cancer cells to determine whether this links to aspects of the 
ER programme known to contribute to a malignant phenotype. Reports in the literature 
combined with the work in Chapter 3 show that TET2 is an ER-regulated gene 
(Papachristou et al. 2018; Wang et al. 2018), and several oestrogen-regulated members 
of the ER complex have been shown to be important for ER-chromatin interactions and 
expression of ER target genes, including FOXA1, GREB1 and NCOA3 (AIB1) (Hurtado et 
al. 2011; Mohammed et al. 2013; Tikkanen et al. 2000). Based on this, and given the 
observation that ER and TET2 co-localise at chromatin at a large fraction of ER sites as 
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observed in Chapter 3, the requirement of TET2 for ER-chromatin interactions was also 
examined. 
 
As mentioned in Chapter 1, TET1 and TET3 possess CXXC domains, structural features 
known to direct targeting of proteins to various CG-rich sequences (Xu et al. 2018). 
Uniquely to the TET family, TET2 lacks this domain, hence how it is targeted to specific 
regions of the genome remains a topic of research. It has been suggested that other CXXC 
domain-containing proteins may instead co-operate with TET2 to direct its chromatin 
interactions. One such protein, CXXC5, shown to facilitate recruitment of TET2 to 
promoters in plasmacytoid dendritic cells (pDCs) (Ko et al. 2013), was detected as a 
component of the ER complex in Chapter 3, implying a potential association between 
TET2 and CXXC5 with respect to ER signalling. Nevertheless, TET2 appears to 
preferentially target enhancers, in contrast to TETs 1 and 3 which favour promoters (Jin 
et al. 2016; Rasmussen et al. 2015, 2019; Williams et al. 2011). This distinction, coupled 
with the particular importance of enhancers in cell type-specific functions, further 
reinforces that TET2 may rather employ context-dependent, and potentially CXXC-
independent mechanisms to access its target sites. Several studies have revealed insights 
into how TET2 might be recruited to chromatin, with Wang et al. (2015) showing that the 
transcription factor WT1 recruits TET2 to regulate gene expression in the human 
leukaemia cell line HL-60. Furthermore, Chen et al. (2018) showed a role for SNIP1 in 
bridging the interaction between TET2 and the transcription factor c-MYC, aiding 
expression of c-MYC target genes in U2OS cells. This implies that TET2-chormatin 
interactions may be co-ordinated by several intermediary proteins at once. The extent of 
the TET2 and ER genomic co-localisation observed in Chapter 3 implies that ER itself 
might have a role in targeting of TET2 to chromatin in the ER+ breast cancer context. A 
potential role for ER in directing and stabilising TET2-chromatin interactions was therefore 
also explored in this chapter. 
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4.2 Results 
4.2.1 siRNA-mediated TET2 knockdown in MCF7 cells 
To examine the role of TET2 in ER+ breast cancer cells, its expression was silenced using 
siRNA. Asychronous MCF7 cells were transfected with siRNA targeting TET2, or a non-
targeting siRNA control, and TET2 knockdown was confirmed as effective and stable at 
the mRNA level over a time course of 96 hours after a single transfection (Figure 4.1). 
 
4.2.2 Assessment of TET2 protein levels after TET2 knockdown 
To confirm effective TET2 knockdown at the protein level, antibodies were tested for TET2 
Western blot. Although several publications demonstrate Western blotting for TET2, a 
range of different antibodies have been used across the literature, probing TET2 in various 
different cell lines, so several candidates were assessed in order to find the best approach 
Figure 4.1. Confirmation of depletion of TET2 mRNA in MCF7 cells. 
MCF7 cells were treated with an siRNA pool (10 nM) targeting TET2 (siTET2), or a non-
targeting control (siNT). Cells were harvested at 48, 72 and 96 hours after transfection 
and TET2 mRNA levels were assessed using qRT-PCR. Results represent mean ± SD of 
enrichment relative to a housekeeping control gene (UBC) (n=2). * = p ≤ 0.05, ** = p ≤ 
0.01. 
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for detecting TET2 in MCF7 cells. In total, seven antibodies were tested (see Materials 
and Methods), and multiple transfer methods applied, including dry and wet transfers of 
varying durations. However, no TET2-specific band could be detected in either whole-cell 
or nuclear-enriched lysates based on the comparison between control and TET2 
knockdown samples. Figure 4.2A shows selected example Western blots. 
  
Figure 4.2. TET2 isoform expression in MCF7 cells and example TET2 Western 
blots. 
A) Three example Western blots demonstrating the lack of specificity of several of the 
TET2 antibodies tested using MCF7 whole cell lysates. The blots shown were produced 
using the dry transfer system iBlot2 (see Materials and Methods). 50µg protein was 
loaded per blot. β-actin was used as a loading control. B) UCSC genome track of an RNA-
seq library showing expression of TET2 in MCF7 cells. RefSeq schematics for TET2 
isoform A (NM_001127208.2; ~223 kDa) and isoform B (NM_017628.4; ~130 kDa) are 
shown. Lines indicate introns, boxes indicate exons, and arrowheads indicate direction of 
transcription. 
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According to the RefSeq database (O’Leary et al. 2016), both the canonical long isoform 
of TET2 (isoform A, ~223 kDa) and a short isoform proposed to lack the TET catalytic 
domain (isoform B, ~130 kDa) (Lou et al. 2019) are expressed from the TET2 locus. 
According to the ER qPLEX-RIME data from Chapter 3, TET2 peptides depleted from the 
ER complex in response to GATA3 loss in MCF7 cells included those exclusive to the 
longer isoform of TET2, indicating this as the primary isoform of interest in these 
investigations (data not shown), and RNA-seq data further confirmed expression of this 
longer isoform at the RNA level in MCF7 cells (Figure 4.2B). As this longer isoform of 
TET2 has a high molecular weight (223 kDa), it is possible that this property might impair 
its transfer from gel to membrane. However, the use of multiple blotting approaches 
suggest that low expression of TET2 in MCF7 cells combined with the lack of specificity 
of these antibodies in Western blot are likely to have limited the effective detection of this 
protein. Given that TET2 was successfully immunoprecipitated for RIME and ChIP-seq 
using Abcam antibody ab94580, an alternative approach could have been to enrich for 
TET2 using this method prior to Western blotting. However, it was reasoned that improved 
sensitivity and accuracy in detection of TET2 might be achieved through collaboration with 
the Proteomics Core Facility at CRUK-CI. Both full proteome and protein-targeted mass 
spectrometry measurements offer improved sensitivity and accuracy over Western 
blotting, particularly for proteins exhibiting low expression (Liebler & Zimmerman 2013). 
Therefore, a combination of these techniques was applied to assess the protein-level 
effects of TET2 knockdown. TMT full proteome analysis, similar to qPLEX-RIME, relies 
on TMT labelling allowing quantitative comparisons between experimental conditions, but 
in an antibody-independent manner. Using this method, robust depletion of TET2 protein 
levels was confirmed in response to 72 hours of TET2 siRNA treatment, with no effect 
measured on total ER or GATA3 levels (Figure 4.3). For all subsequent assessments of 
TET2 protein levels in this work, Parallel Reaction Monitoring (PRM) was employed. This 
targeted proteomics approach allows quantification of proteins based on the measurement 
of specific peptides, unique to the protein of interest, using tandem mass spectrometry. 
Peptides are fragmented to generate a characteristic ion fragmentation pattern that 
indicates the targeted peptide sequence with high specificity. The signal intensity of these 
resulting fragments is compared to that of stable isotope-labelled reference peptide 
standards, and this serves as the basis for quantitative comparison of protein levels across 
different biological samples. 
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4.2.3 TET2 depletion affects proliferative pathways in MCF7 cells  
To identify TET2-regulated genes, RNA-seq was performed following 48 hours of TET2 
knockdown in asynchronous MCF7 cells. This revealed repression of 2,269 genes and 
activation of 2,144 genes (p ≤ 0.05) (Figure 4.4). GATA3 mRNA expression was 
unaffected by TET2 silencing. ER mRNA expression was modestly repressed, although 
proteomic analysis after 72 hours of TET2 knockdown (Figure 4.3) suggested that this 
does not translate into an effect on total protein levels. To compare the gene regulatory 
programme of TET2 with those of ER and GATA3, RNA-seq was also performed 48 hours 
after knockdown of either ER or GATA3 in MCF7 cells. ER and GATA3 mRNA levels were 
robustly depleted, with ER transcripts reduced to 11% of control levels and GATA3 
transcripts reduced to 20% of control levels by their respective silencing. As expected, 
TET2 mRNA levels were robustly and significantly repressed by both ER and GATA3 
knockdown (to 23% of control levels by ER knockdown, and 43% of control levels by 
GATA3 knockdown). Overall, 60% of the genes significantly regulated by TET2 
knockdown (2,656 out of 4,413 genes, p ≤ 0.05) were also significantly regulated by both 
GATA3 and ER silencing. Given that TET2 appears to behave as a target gene of both 
Figure 4.3. TET2 knockdown significantly depletes TET2 protein levels in MCF7 
cells, with no effect on total ER or GATA3 protein levels. 
MCF7 cells were treated with an siRNA pool (10 nM) targeting TET2 (siTET2) or a non-
targeting control (siNT). Cells were harvested at 72 hours after transfection and full 
proteome analysis performed. Four replicates of each condition were included in an 
11plex TMT MS run. Results represent mean ± SD protein intensity, the aggregate of 
intensities of the individual unique peptides identified for each protein. **** = p ≤ 0.0001. 
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ER and GATA3, some of the concordance between the ER, GATA3 and TET2 gene 
regulatory profiles is therefore likely to be due to secondary effects as a result of TET2 
depletion after ER and GATA3 silencing. Taking the 500 most induced and 500 most 
repressed genes in response to TET2 silencing (in terms of log2 fold change), 60% of 
these most differentially regulated genes were modulated in the same direction following 
ER knockdown (visually depicted in the heatmaps in Figure 4.5A). This included 
repression of key ER target genes such as PGR, CCND1, XBP1, and CXCL12. 
Importantly, ER/TET2 shared binding sites were enriched adjacent to TET2 target genes 
(Figure 4.6), further implying genomic co-operation between these two proteins. 
Interestingly, similar enrichment of ER/TET2 shared sites was observed both at genes 
induced by TET2 knockdown and those repressed by TET2 knockdown, implying that 
TET2 may be capable of both activating and repressive transcriptional activity as part of 
the ER complex. However, more detailed functional analysis would be required to confirm 
this observation. 
 
To assess whether the genes regulated by TET2 show a tendency towards modulation of 
any particular pathway, gene ontology (GO) analysis was performed using DAVID 
(Database for Annotation, Visualization and Integrated Discovery) (Huang et al. 2007; 
Huang et al. 2009). Genes repressed by TET2 knockdown showed significant enrichment 
of six functional categories linked to cell division and cell cycle processes (Figure 4.5B). 
In contrast, the genes induced by TET2 knockdown demonstrated significant enrichment 
of only two functional categories, linked to cell communication and signal transduction. 
When examining solely the TET2-regulated genes that also changed in response to 
GATA3 and ER knockdown, enrichment of the same functional categories was observed 
(Figure 4.5C). This demonstrates that the pathways most strongly affected by loss of TET2 
in these cells are those converged on by GATA3 and ER regulatory processes, and are 
related to the cell cycle and proliferation. To place these findings into a functional setting, 
proliferation of MCF7 cells was assessed over a 4-day period after TET2 knockdown. 
Consistent with repression of cell cycle gene programs, MCF7 growth was inhibited by 
TET2 knockdown (Figure 4.7).  
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Figure 4.4. TET2 knockdown affects gene expression in MCF7 cells. 
siRNA-mediated TET2 silencing (48 hours) resulted in repression of 2,269 genes and 
activation of 2,144 genes compared to control (n=6, p ≤ 0.05, significantly regulated genes 
highlighted in red). 
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Figure 4.5. TET2 depletion affects gene pathways related to the cell cycle. 
A) Heatmaps depict the top 500 induced and top 500 repressed TET2-regulated genes 
according to log2 fold change. Colour scale represents the relative expression (z-score) 
of genes across the two conditions (control and knockdown), calculated separately within 
each comparison (siTET2 vs siNT, siESR1 vs siNT and siGATA3 vs siNT). Hierarchical 
clustering of genes in the leftmost (siTET2) heatmap is preserved across all three 
heatmaps. Columns represent independent biological replicates (n=6). B) Barplot 
displaying –log10(FDR) for GO analysis of the top 500 induced and top 500 repressed 
TET2-regulated genes according to log2 fold change. Only categories with FDR ≤ 0.05 
(threshold indicated by dotted line) are shown. C) Barplot displaying –log10(FDR) for GO 
analysis of the top 500 induced and top 500 repressed TET2-regulated genes according 
to log2 fold change, sub-selected from genes also significantly (p ≤ 0.05) regulated by 
both GATA3 and ER silencing. The top 6 enriched categories are shown for repressed 
genes, and the top 2 for induced genes. Dotted line indicates FDR 0.05. Enriched 
processes were identified using the Biological Process category level 3 of the GO 
hierarchy (GOTERM_BP_3). 
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Figure 4.6. ER/TET2 shared sites are enriched in the vicinity of TET2-regulated 
genes compared to unchanging genes. 
Graph shows the cumulative fraction of total ER/TET2 shared binding sites (n = 15,442, 
MCF7 cells) within up to 100 kb of the TSSs of three groups of genes: genes upregulated 
by TET2 knockdown (n = 2,144, red line), genes downregulated by TET2 knockdown (n 
= 2,269, blue line) (p ≤ 0.05), and genes unchanging in response to TET2 knockdown 
(constant genes, grey lines). Constant genes were randomly selected from those with p 
> 0.5 and mean expression > 1.0. Grey lines indicate analysis based on constant genes: 
the dotted line indicates analysis matched to the number of downregulated genes, and 
the solid line indicates analysis matched to number of upregulated genes. 
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Figure 4.7. TET2 knockdown inhibits MCF7 cell growth. 
Cell growth is expressed as mean ± SD of % confluence, assessed using the Incucyte 
Zoom™ system. Knockdown was performed at t = 0; cells were seeded 24 hours prior to 
this. Data points represent mean ± SD of ≥ 6 technical replicates (wells). Results for each 
biological replicate are plotted separately. ** = p ≤ 0.01, *** = p ≤ 0.001. siTET2 = TET2 
knockdown, siER = ER knockdown, siNT = non-targeting control-treated cells. A), B) and 
C) show growth experiment replicates 1 to 3 demonstrating the effect of TET2 knockdown 
on growth of MCF7 cells. D) Barplot showing confluence of TET2 knockdown cells as a 
% of the confluence of corresponding control cells at 24, 48, 72 and 96 hours after 
treatment. E) Growth experiment demonstrating the effect of ER knockdown on MCF7 
growth. F) Barplot showing confluence of ER knockdown cells as a % of the confluence 
of corresponding control cells at 24, 48, 72 and 96 hours after treatment. 
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4.2.4 Genes repressed by loss of TET2 are also repressed by tamoxifen 
treatment 
As described in Chapter 3, higher expression of TET2 is associated with improved 
outcome in ER+ breast cancer. The finding that loss of TET2 inhibits the growth of ER+ 
MCF7 cells reinforces the idea that TET2 contributes to the proper function of the driving 
transcription factor, ER, which stimulates growth in these cells. The presence of a 
functional and hormone-sensitive ER complex is crucial to the success of targeted 
therapies for ER+ breast cancer. One of the current standard-of-care therapies, tamoxifen, 
binds ER and antagonises the effects of oestrogen on target genes (Clarke et al. 2001). 
To assess whether TET2 modulates growth through regulating similar proliferative 
pathways to those affected in the clinical setting, genes downregulated by TET2 depletion 
were compared with those repressed by tamoxifen treatment using data from 
Papachristou et al. (2018). As an ER target gene, TET2 is itself repressed by tamoxifen, 
with significant loss of both mRNA and protein observed after 24 hours’ tamoxifen 
treatment according to data from Papachristou et al. (2018). However, acute tamoxifen 
treatment (6 hours) does not significantly affect TET2 protein levels, allowing the 
identification of gene expression changes in response to tamoxifen treatment only. Within 
genes significantly repressed by TET2 knockdown (p < 0.05), a subset of 175 genes was 
identified that are also acutely and significantly repressed by tamoxifen (6 hours 100 nM 
tamoxifen, p < 0.01). GO analysis using DAVID revealed that this subset of genes was 
enriched for functions relating to the ‘cellular stress response’ and ‘DNA damage’ 
pathways (FDR = 1.2e-7 and 2.4e-7, respectively) and several categories linked to cell 
cycle progression (‘cell cycle phase’, ‘cell cycle process’ and ‘mitotic cell cycle’, FDR = 
1.4e-3, 2.3e-2 and 3.4e-3, respectively). These results further reinforce that TET2 regulates 
key ER target genes, including those targeted by agents proven to be effective in the clinic. 
In terms of therapy, an extension of this logic might be that targeting TET2 in ER+ breast 
cancer could provide clinical benefit in conjunction with current hormone therapies by 
potentiating their effects. However, it is still unclear precisely which aspects of TET2 
function might be important for the ER complex, and furthermore, there are currently no 
known specific inhibitors of TET2 catalytic activity. Nonetheless, these studies illustrate 
that investigating the involvement of TET2 in ER function holds potential for developing a 
better knowledge of both basic and translational aspects of breast cancer biology.  
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Having established that TET2 is linked to expression of ER target genes, the next step will 
be to unravel the mechanisms behind this. As described in Chapter 1, TET2 oxidises 
methylated cytosines (5mC) to further DNA modifications 5hmC, 5fC and 5caC, with this 
process an intermediate step in DNA demethylation pathways (He et al. 2011; Inoue and 
Zhang 2011; Ito et al. 2011; Tahiliani et al. 2009). Dynamic regulation of these marks has 
been implicated in transcriptional control. If TET2 has a role in maintenance and turnover 
of these modifications at ER sites, this could contribute to the gene expression changes 
observed in response to loss of TET2. Whilst the work in this thesis was in progress, Wang 
et al. (2018) demonstrated that TET2 knockout MCF7 cells show changes in oestrogen-
induced gene expression compared to wild-type cells. This was concurrent with 
differences in levels of methylation at ER binding sites in knockouts compared to controls, 
and this indeed may contribute to the changes observed in the acute knockdown system 
studied here. In addition, the TET2 RIME data discussed in Chapter 3, in conjunction with 
reports in the literature, suggest TET2 can interact with transcriptional regulators such 
HDAC2 and p300, as well as members of both the NCOA and NCOR families (Zhang et 
al. 2015; Zhang et al. 2017). This reinforces the idea that TET2 could have a role in 
stabilising transcriptional complexes in addition to its catalytic role regulating DNA 
modifications. The concept of TET2 providing stability to ER-chromatin interactions is 
explored in the sections below, whilst investigations into the role of TET2 in regulating 
DNA modifications at ER sites are carried out in Chapter 5. 
4.2.5 TET2 knockdown affects global ER binding 
To further investigate the relationship between TET2 and ER gene expression, the impact 
of TET2 loss on ER binding to chromatin was assessed. Firstly, TET2 ChIP-seq was 
performed after 48 hours of TET2 knockdown in asynchronous MCF7 cells to confirm that 
TET2 silencing effectively depletes TET2-chromatin interactions. Four biological 
replicates were performed, and peaks were called using MACS2 (Zhang et al. 2008). Valid 
peaks were defined as those occurring in all four replicates. A robust global reduction in 
TET2 binding was observed in siTET2-treated cells compared to controls (Figure 4.8). 
Specifically, 12,728 valid TET2 peaks were detected under control conditions, but only 
3,098 TET2 peaks were called after TET2 silencing, validating the efficacy of the 
knockdown, and the specificity of the antibody.  
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To assess the effect of these depleted TET2-chromatin interactions on genome-wide ER 
binding, samples for ER ChIP-seq were harvested at 72 hours after TET2 siRNA 
treatment. A drop in overall ER binding was observed as a result of TET2 silencing (Figure 
4.8). As demonstrated by the full proteome analysis in Figure 4.3, TET2 knockdown does 
not affect total ER protein levels. This result therefore strongly implies a role for TET2 in 
stabilising ER-chromatin interactions. Notably, despite the fact that TET2 binding was 
previously shown to occur at a large subset of, but not all, ER sites (Chapter 3), the profile 
of the MA plot in Figure 4.9A suggests that ER binding appears to be depleted, if modestly, 
at a large proportion of ER sites. This could suggest that the TET2 ChIP has not captured 
the full range of TET2 sites, and that TET2 is in fact present at many of the apparently 
TET2-independent ER sites, where it stabilises ER binding. Alternatively, this could imply 
that TET2 exerts secondary effects that stabilise ER-chromatin interactions in an indirect 
manner. Overall, these results imply that the loss of proper ER binding as a result of TET2 
knockdown contributes to impaired regulation of ER target genes. 
 
There are multiple mechanisms through which TET2 might impact ER-chromatin 
interactions. As previously mentioned, TET2 is a large protein (~223 kDa), and it is 
possible that it confers stability to the ER complex in a scaffolding capacity, recruiting 
additional cofactors and bridging connections between different parts of the complex. The 
absence of TET2 may therefore have a destabilising effect on the complex, contributing 
to the observed depletion of ER-chromatin interactions. A similar role has been suggested 
for ER cofactors RARα (Ross-Innes et al. 2010) and GREB1 (Mohammed et al. 2013), 
and the interaction of TET2 with a large number of other ER complex proteins and 
transcriptional regulators in RIME reinforces this idea. Interestingly, it has been shown 
that another TET family member, TET3, can stabilise the chromatin interactions of thyroid 
hormone receptors TRα1 and TRβ1, both of which are members of the nuclear receptor 
superfamily. Specifically, enrichment of both TRs in the chromatin fraction of HEK293T 
cells was dependent on the expression of TET3 (Guan et al. 2017). Notably, whilst a 
truncated form of TET3 lacking the catalytic and CXXC domains failed to achieve the same 
effect, the stabilising effect on TR-chromatin interactions was maintained in the presence 
of a TET3 mutant lacking dioxygenase ability, suggesting the stabilising function of TET3 
may be independent from its catalytic role. 
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Figure 4.8. TET2 knockdown depletes global TET2 binding. 
A) MA plot showing log2 fold change in TET2 binding in control versus TET2 knockdown 
conditions against log2 mean intensity of ChIP-seq signal for all TET2 sites (12,728 
peaks). B) Boxplot showing the normalised tag density of TET2 ChIP-seq signal in control 
(non-targeting control siRNA, siNT) and TET2 knockdown (siTET2) conditions within all 
TET2 peaks. **** = p ≤ 0.0001. C) Average plot showing normalised signal enrichment of 
TET2 ChIP-seq under control (siNT) or TET2 knockdown (siTET2) conditions within all 
TET2 peaks. TET2 knockdown was performed for 48 hours. 
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Figure 4.9. TET2 knockdown depletes global ER binding. 
A) MA plot showing log2 fold change in ER binding in control versus TET2 knockdown 
conditions against the log2 mean intensity of ChIP-seq signal for all ER sites (20,386 
peaks). B) Boxplot showing the normalised tag density of ER ChIP-seq signal in control 
(non-targeting control siRNA, siNT) and TET2 knockdown (siTET2) conditions within all 
ER peaks. **** = p ≤ 0.0001. C) Average plot showing normalised signal enrichment of 
ER ChIP-seq under control (siNT) or TET2 knockdown (siTET2) conditions within all ER 
peaks. TET2 knockdown was performed for 72 hours. 
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However, it remains possible that the effects of TET2 loss on ER binding may also be 
attributable to changes in TET2-mediated regulation of DNA modifications at ER sites. As 
described in Chapter 1, 5mC is generally considered to repress interactions of many DNA-
binding proteins and transcription factors with their DNA motifs (Yin et al. 2017). As TET2 
has been suggested to protect enhancers from aberrant methylation (Jeong et al. 2014; 
Rasmussen et al. 2015), loss of TET2 might result in an accumulation of 5mC at ER sites 
which could potentially destabilise ER binding, or the binding of other ER cofactors which 
might have a knock-on effect on the complex. Consistent with this, Rasmussen et al. 
(2019) showed that TET2 appears to mediate demethylation of enhancers in 
haematopoietic cells, and based on observations of increased chromatin accessibility, and 
the motifs consequently exposed at these sites, suggested this facilitates recruitment of 
lineage-specific transcription factors. However, 5mC may not solely destabilise protein-
DNA interactions, and indeed some transcription factors may rather bind preferentially at 
motifs containing 5mC (Yin et al. 2017). It is hypothetically possible that increased binding 
or stabilisation of additional proteins near ER sites could also have a disruptive effect on 
the ER complex, and hence ER binding. The potential effects of DNA modifications on the 
binding of transcription factors are not confined to 5mC, as TET-oxidised 5mC 
intermediates 5hmC and 5fC have also each been shown to attract the binding of distinct 
“readers” in a sequence context-dependent manner (Iurlaro et al. 2013; Spruijt et al. 2013; 
Song & Pfeifer, 2016). Although speculative, it is possible that changes in the levels of 
these marks as a result of TET2 loss could also alter the binding of certain ER complex 
proteins. The reduced ER binding in response to TET2 loss could therefore be contributed 
to by changes in the dynamic regulation of 5mC and its oxidised forms at ER sites, a 
certain profile of which may be required for the assembly of a stable ER complex. Further 
investigations, including examination of DNA modification dynamics at these sites, will be 
required to assess this. 
4.2.6 Acute ER depletion reduces TET2 binding at a subset of sites 
As previously described, TET2 appears to lack a sequence-targeted DNA binding domain 
(Ko et al. 2013). It thus remains poorly understood how it is recruited to specific genomic 
regions. Wang et al. (2018) demonstrated a link between the ER complex and TET2 
recruitment by showing that disruption of the ER complex with tamoxifen treatment over 
72 hours reduces TET2-chromatin interactions. However, as TET2 is an ER target gene, 
Chapter 4 
90 
 
this was associated with significant depletion of TET2 protein levels. Although this result 
clearly demonstrates a role for ER in regulating TET2 chromatin occupancy, this approach 
renders it difficult to decouple the effects of TET2 protein-level regulation versus direct 
stabilisation on chromatin through ER. Furthermore, although ER-chromatin associations 
are decreased by acute (45 minutes) tamoxifen treatment, as shown by Hurtado et al. 
(2011), increased durations of tamoxifen treatment (6–24 hours) result in significant 
upregulation of global ER protein levels (Papachristou et al. 2018), and the effect of 
tamoxifen treatment on ER binding at later timepoints, such as at the 72 hour timepoint 
measured by Wang et al. (2018), is unclear. To assess a role for ER in directly stabilising 
TET2 on chromatin, it would therefore be useful to decouple depletion of ER-chromatin 
interactions from dramatic changes in TET2 protein levels. 
 
The aim of this experiment was to deplete genome-wide ER binding to assess whether 
ER directly contributes to stabilisation of TET2 on chromatin, but to simultaneously 
minimise any effect on TET2 protein levels that would confound interpretation of the 
results. To this end, cells were treated with the SERD fulvestrant for an acute duration of 
three hours, with the assumption that promoting active degradation of existing ER protein 
would provide rapid depletion of ER-chromatin interactions whilst minimising protein-level 
changes in target genes, including TET2. Targeted proteomics (PRM) was then used to 
measure the levels of ER and TET2 in response to fulvestrant treatment. Within this 
timeframe, although only one ER peptide was detected due to technical limitations, a 
significant drop in ER total protein levels was observed using PRM (Figure 4.10), and 
ChIP-qPCR at several key ER regulatory sites confirmed effective depletion of ER-
chromatin interactions (Figure 4.11). Illustrating the sensitivity of TET2 as an ER target 
gene, despite the short treatment duration, fulvestrant produced a modest depletion of 
TET2 total protein levels, assessed through measurement of five different TET2 peptides. 
However, this depletion was significant for only one of the peptides measured 
(corresponding to a ~20% reduction compared to control), with changes in levels of the 
other four TET2 peptides remaining non-significant (Figure 4.10). 
 
ER depletion through acute fulvestrant treatment resulted in significantly reduced TET2 
binding at a distinct subset of TET2 binding events (1,810 out of 20,599 peaks, ~9%), as 
assessed using DiffBind (Stark & Brown 2011) (Figure 4.12A). This indicates that the 
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modest depletion of global TET2 protein levels observed using PRM was not reflected by 
a global drop in TET2 chromatin occupancy. In contrast, TET2 binding remained 
unchanged at the majority (~90%) of sites, which could imply a particularly important 
function for ER in recruiting TET2 at the depleted subset of sites. When investigated more 
closely, TET2 “lost” sites corresponded to ER/TET2 shared sites with higher ER binding 
intensity and significantly greater frequencies of ER motifs, and motifs for key ER cofactors 
FOXA1 and GATA3, than the TET2 binding sites that did not change in response to 
treatment (Figure 4.12B and C). Furthermore, genes in proximity to these lost sites 
included key ER target genes that are also repressed in response to TET2 knockdown, 
including PGR, CCND1, XBP1, and members of the EGR and E2F protein families. 
Examples of significantly depleted TET2 binding sites in proximity to the PGR and XBP1 
genes are shown in Figure 4.13. Taken together, these results demonstrate that the sites 
where TET2 targeting is disrupted are the ER binding sites that are most robustly detected 
using ChIP-seq. This indicates these peaks as the ER sites that occur most frequently in 
the cell population, and likely those where ER target gene expression is immediately and 
directly modulated by the complex. 
 
 
Figure 4.10. The effect of fulvestrant treatment on ER and TET2 total protein levels. 
PRM targeted proteomics was used to measure levels of ER- and TET2-specific peptides 
in MCF7 cells. Barplots depict levels of unique ER (left) or TET2 (right) peptides in 
response to vehicle (ethanol, 3 hours) or fulvestrant (100 nM, 3 hours). Results represent 
mean ± SD peptide levels relative to an actin control (n=4). ** = p ≤ 0.01, **** = p ≤ 0.0001. 
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It is of note that TET2 occupancy was significantly affected only at a subset of sites, 
despite the fact that (as shown in Chapter 3) almost all TET2 sites are co-occupied by ER 
in these cells. Whether ER is important for TET2 recruitment at the remainder of sites, or 
whether other mechanisms might target TET2 to these regions is unclear. Though a 
significant and robust depletion of total ER levels was observed (Figure 4.10), and ER 
binding was dramatically depleted at the key sites tested (Figure 4.11), it is possible that 
many sites retain levels of ER occupancy after 3 hours fulvestrant treatment that are 
sufficient for TET2 binding to remain unaffected. Longer durations of fulvestrant treatment 
might be required to disrupt TET2 binding at these remaining ER regions, at which point 
reduced TET2 expression due to ER depletion may become the dominant factor affecting 
TET2 occupancy. Having uncovered the sensitivity of TET2 as an ER target gene, it is 
clear that decoupling TET2-chromatin interactions from depletion of TET2 protein levels 
is challenging using this particular approach. Nevertheless, these investigations reinforce 
the association between ER and TET2, and demonstrate that, irrespective of whether 
through protein-level regulation or direct stabilisation on chromatin, ER has a key role in 
mediating TET2-chromatin interactions at direct ER binding sites. 
Figure 4.11. Fulvestrant treatment reduces ER chromatin occupancy. 
ChIP-qPCR results showing reduction of ER-chromatin interactions in response to 
treatment with vehicle (ethanol, 3 hours) or fulvestrant (100 nM, 3 hours) at several key 
ER binding sites (error bars indicate mean ± SD, n=4). * = p ≤ 0.05, ** = p ≤ 0.01, *** = p 
≤ 0.001. 
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Figure 4.12. Acute ER depletion reduces TET2 binding at a subset of sites. 
A) MA plot showing log2 fold change in TET2 binding in response to fulvestrant treatment 
(100 nM, 3 hours) against the log2 mean intensity of TET2 ChIP-seq signal for all TET2 
sites (20,599 peaks). “Lost” sites (n = 1,810) and “gained” sites (n = 64) according to 
DiffBind analysis (p ≤ 0.05) are highlighted in red. B) Boxplot showing the normalised tag 
density of ER ChIP-seq signal at unchanging (“common”) (n = 18,725) and “lost” (n = 
1,810) TET2 sites in response to fulvestrant treatment. C) Barplot showing motif frequency 
(number of motifs divided by the total number of peaks in each category) of ER, FOXA1 
and GATA3 motifs for lost, common and background sites. Background values were 
obtained using random open chromatin regions from an MCF7 MNase dataset (EBI Array 
Express E-MTAB-1958) and are expressed as the average ± SD of two separate 
background values calculated matched to the number of sites in the lost and common 
cohorts. Significance against background is indicated * = p ≤ 0.05, ** = p ≤ 0.01, **** = p 
≤ 0.0001. 
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Figure 4.13. Fulvestrant-mediated depletion of TET2 binding at ER target genes 
PGR and XBP1. 
A) UCSC genome browser tracks showing TET2 binding in response to treatment with 
vehicle (ethanol, 3 hours) or fulvestrant (100 nM, 3 hours) at significantly (p ≤ 0.05) 
depleted sites according to Diffbind analysis, within 50 kb of the TSS of two key ER target 
genes (PGR and XBP1). B) UCSC genome browser tracks showing TET2 binding in 
response to treatment with vehicle (ethanol, 3 hours) or fulvestrant (100 nM, 3 hours) at 
unchanged sites according to Diffbind analysis. Tracks represent merged data from four 
biological replicates. For the gene schematics below each track, lines indicate introns, 
boxes indicate exons, and arrowheads indicate the direction of transcription. 
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4.3 Summary 
The work in this chapter has shown that TET2 knockdown modulates gene expression in 
MCF7 cells, and that the TET2 gene regulatory programme includes a large proportion of 
genes also co-regulated by both GATA3 and ER. The effects of TET2 silencing included 
reduced activation of gene pathways related to cell proliferation, and consistent with this, 
MCF7 cell growth was inhibited by TET2 knockdown. Furthermore, a subset of the genes 
repressed by loss of TET2 coincide with those repressed in the therapeutic setting, as 
demonstrated by comparison with gene expression data from tamoxifen-treated MCF7 
cells.  
 
Whilst Chapter 3 demonstrated that ER and TET2 operate as part of the same complex 
and co-localise at chromatin, work in this chapter built on these findings by investigating 
the interdependence of these two factors in their ability to bind their target sites. It appears 
that TET2 has a role in stabilisation of the ER complex at chromatin, as ER-chromatin 
interactions were depleted, if modestly, in a global manner by TET2 knockdown. This is 
consistent with observations of the role of other oestrogen-regulated ER cofactors (such 
as FOXA1, GREB1 and NCOA3) in ER-chromatin interactions (Hurtado et al. 2011; 
Mohammed et al. 2013; Tikkanen et al. 2000), and likely contributes to the influence of 
TET2 loss on the expression of ER-regulated genes. Nevertheless, the precise 
mechanism behind the potential TET2-mediated stabilisation of the ER complex remains 
unclear, and aspects of this response, for example the apparent loss of ER binding at sites 
that may not be co-occupied by TET2, merit further investigation.  
 
Reinforcing the association between ER and TET2, it was also shown that ER depletion 
through fulvestrant treatment affects TET2-chromatin interactions. The function of TET2 
as an ER target gene renders it difficult to decipher the full extent of the role of ER in 
targeting TET2 to chromatin at all ER/TET2 shared sites. Further investigations would be 
required to decipher whether this effect might be a result of direct or indirect tethering of 
TET2 through the ER complex, or whether TET2 occupancy mainly reflects its protein-
level control by ER. It is possible that both these scenarios operate. Nevertheless, this 
result indicates an important role for ER in stabilising TET2 at chromatin as part of the ER 
complex. Coupled with the RNA-seq data demonstrating crossover between ER and 
Chapter 4 
96 
 
TET2-regulated genes, the observations of the interdependence of TET2 and ER 
chromatin interactions paint a picture of a firmly interconnected transcriptional network, 
where disruption of either of these proteins perpetuates destabilisation of the complex as 
a whole, with associated effects on gene expression. 
 
Of the TET2 gene regulatory programme, it was the genes repressed by TET2 knockdown 
that displayed the strongest association with proliferation. This could imply that TET2 acts 
as an activator in the ER complex, contributing to oestrogen-driven cell growth. 
Nevertheless, TET2 knockdown resulted in significant upregulation of an equal number of 
genes to those that were repressed. It is therefore possible that TET2 may act as a 
transcriptional repressor at some sites, though these may be less directly related to the 
ER gene programme. Further work is needed to determine the precise mechanisms of 
TET2 transcriptional regulation, and to unravel any aspects of context-dependency at 
different sites. One proposed mechanism of TET2 transcriptional control is through 
regulation of DNA modifications, and the potential relevance of this process at ER/TET2 
sites is investigated in Chapter 5. 
 
Overall, these investigations into of the effects of acute TET2 disruption have yielded 
important insights regarding the role of TET2 in ER signalling. A different type of 
investigation that could help to further establish the role of TET2 in the ER complex would 
be to use stable TET2 knockouts to examine the effects of chronic TET2 loss on 
ER/GATA3 gene expression and ER binding profiles in breast cancer cells. As a 
continuation of the work detailed in this thesis, characterisation of in-house generated 
TET2 knockout MCF7 cells is currently underway, and will provide a useful tool for further 
investigations into TET2-mediated gene expression, and the functional effects of TET2 
loss in ER+ cells. 
 
For the work in this chapter, full proteome analysis was performed by the Proteomics Core 
Facility, with further bioinformatic analysis performed by Dr Kamal Kishore of the 
Bioinformatics Core Facility. PRM analysis was performed by Dr Carmen Gonzalez 
Tejedo of the Proteomics Core Facility. Sequencing was performed by the Genomics Core 
Facility, and RNA-seq and ChIP-seq data processing and analysis were performed by Dr 
Igor Chernukhin. 
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TET2-mediated regulation of DNA 
modifications in ER+ breast cancer cell 
lines 
5.1 Introduction 
The work in Chapters 3 and 4 showed that TET2 is a key component of the ER complex, 
with TET2 binding events a near-total subset of ER sites in several ER+ breast cancer 
models, and TET2 itself subject to expression-level regulation by ER. RNA-seq 
demonstrated that TET2 also appears to have a role in the ER gene regulatory 
programme, and TET2 silencing abrogates growth in ER+ MCF7 cells. Whilst these 
knockdown studies showed that TET2 appears to stabilise ER on chromatin, and this likely 
contributes to its apparent influence on ER-mediated gene expression, the precise 
mechanisms behind this remain unclear. Moreover, TET2 possesses intrinsic enzymatic 
functions that warrant investigation with respect to its role in the ER complex. 
 
As described in Chapter 1, TET2 is an Fe(II)/α-ketoglutarate-dependent dioxygenase, and 
can oxidise methylated cytosines (5mC) to produce the additional DNA modifications 
5hmC, 5fC and 5caC. By way of these steps, TET2 can also contribute to active DNA 
demethylation, as 5fC and 5caC can be removed through TDG-mediated base-excision 
repair and replaced with unmodified cytosine (He et al. 2011; Ito et al. 2011; Maiti & Drohat 
2011; Tahiliani et al. 2009). Unlike 5mC, which is heritable across cell divisions (Bostick 
et al. 2007; Hermann et al. 2004), it is unclear whether oxidised forms of 5mC are 
maintained during DNA replication. Therefore, TET2-mediated conversion of 5mC to 
5hmC, 5fC and 5caC likely also contributes to replication-dependent loss of these marks. 
As described in Chapter 1, whilst 5mC has an established role in transcriptional repression 
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in many contexts, a role for 5hmC in regulation of gene expression is also emerging, and, 
although less-investigated, some studies suggest 5fC and 5caC may also have specific 
functional roles related to transcription (Iurlaro et al. 2013; Iurlaro et al. 2016; Kellinger et 
al. 2012; Spruijt et al. 2013). Together, this implies diverse ways in which TET2 might act 
to modulate gene expression. 
 
Genome-wide, the distribution of 5mC appears to be relatively stable across different 
mammalian cell types, but notably varies at gene regulatory regions (Ziller et al. 2013). 
Coupled with the finding that TET2 appears to preferentially localise at ER-regulated 
enhancers in ER+ breast cancer models (Chapter 3), and the broad evidence that 
differential DNA methylation patterns can predict breast cancer classification (and in 
particular ER status) (Fackler et al. 2011; Hill et al. 2011; Ronneberg et al. 2011), this led 
to the hypothesis that TET2 may contribute aspects of the ER+ phenotype through 
controlling DNA modifications at ER sites. The work in this chapter sought to investigate 
this, first through examination of the dynamics of these epigenetic marks in ER+ MCF7 
cells in response to TET2 knockdown, and secondly by investigating these changes in the 
context of TET2-regulated gene expression. 
 
5mC and 5hmC are the most abundant cytosine modifications, with 5mC present as 
approximately 4-5% of total cytosines, and 5hmC levels ranging between 0.03-0.7% of 
total cytosines, dependent on the cellular context (Globisch et al. 2010; Lister et al. 2009; 
Szwagierczak et al. 2010). The final products of TET metabolism, 5fC and 5caC, are 
present at levels at least 1000 times lower than 5hmC (Globisch et al. 2010; Ito et al. 
2011), and are more difficult to reliably detect using current methods. The studies in this 
chapter therefore focused on measurements of 5mC and 5hmC in response to TET2 
knockdown to assess the role of TET2 at ER sites, with a combination of techniques 
employed for this purpose. DNA mass spectrometry was used to measure global levels of 
these modified nucleotides in genomic DNA, quantifying 5mC/5hmC as a percentage of 
total cytosines. For site-specific analysis of 5mC and 5hmC, two sequencing-based 
techniques were employed, Methyl Midi-seq (MMS), and Reduced Representation 
Hydroxymethylation Profiling (RRHP). Both methods rely on restriction digest-based 
enrichment of areas of the genome containing high levels of modifiable CpG dinucleotides, 
and as both promoters and enhancers exhibit heightened GC content (ENCODE Project 
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Consortium 2012; Fenouil et al. 2012) these methods facilitate the investigation of gene 
regulatory regions. Furthermore, the restricted coverage of these techniques avoids the 
prohibitive sequencing costs of genome-wide methods and decreases the time required 
for data processing and analysis, allowing more rapid identification of potential features of 
interest.  
 
The workflows for MMS and RRHP are described in Figures 5.1 and 5.2, respectively. 
MMS relies on a bisulfite sequencing approach, which, due to the chemical effect of 
bisulfite treatment on 5mC and 5hmC, does not distinguish these two marks. This assay 
therefore provides a combined measurement of total 5mC and 5hmC. In contrast, the 
RRHP method profiles 5hmC exclusively. The use of these two techniques in combination 
facilitates a more detailed insight into the levels of 5mC/5hmC at specific sites than the 
measurement of net 5mC/5hmC provided by the bisulfite-based MMS method alone. 
Using these methods described, the role of TET2 in regulating DNA modifications in ER+ 
cell lines was thus examined. Global measurements of 5mC/5hmC using DNA mass 
spectrometry facilitated initial, broad assessment of the effects of TET2 loss on 5mC and 
5hmC, and subsequent genomic analysis allowed specific assessment of ER sites. 
Following this, TET2-mediated changes in DNA modifications at ER/TET2 sites were 
examined in the context of TET2-regulated gene expression. 
  
Chapter 5 
100 
 
 
  
Figure 5.1. Methyl Midi-seq workflow. 
Genomic DNA is digested with MspI (consensus site CCGG) and TaqαI (consensus site 
TCGA) to enrich for CG-rich areas of the genome. Fragments are then ligated to pre-
annealed adapters containing 5mC instead of unmodified cytosine, such that their 
sequence will be preserved through subsequent bisulfite treatment. Bisulfite treatment 
results in deamination of unmodified cytosine to uracil, whilst 5mC and 5hmC are 
unaffected. Further modifications 5fC and 5caC, like unmodified cytosine, are also 
converted to uracil (not shown). Changes in the DNA sequence that depend on the 
methylation or hydroxymethylation status of individual cytosine residues are amplified by 
PCR and sequenced, providing single-nucleotide resolution of DNA modifications. 
Chapter 5 
101 
 
  
Figure 5.2. Reduced Representation Hydroxymethylation Profiling workflow. 
Genomic DNA is digested with MspI (consensus site CCGG) to enrich for CG-rich areas 
of the genome. Fragments are then ligated to pre-annealed adapters P5 and P7. Homo-
adapterised fragments form an inhibitory stem-loop hairpin which will prevent further 
amplification, so only hetero-adapterised fragments are ultimately sequenced. The P5 
adapter regenerates an MspI site at the adapter-fragment junction, whereas the P7 
adapter does not. All ligated library fragments are next subject to a β-glucosyltransferase 
reaction, whereby 5hmC residues become glucosylated. Fragments presenting a 
glucosylated 5hmC at the CCGG at the P5-adapter junction are resistant to a second MspI 
digestion while fragments without 5hmC are cleaved, removing the P5 adapter. Only the 
fragments with both P5 and P7 adapters after the second MspI digestion, and thus 
possessing 5hmC at the P5-adapter junction, are amplified and sequenced. Adapted from 
Petterson et al. (2014). 
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5.2 Results 
5.2.1 TET2 knockdown induces loss of global 5hmC, but has no effect 
on global 5mC levels cells according to mass spectrometry  
To investigate the mechanistic role of TET2 in ER biology, mass spectrometry was used 
to measure total levels of 5mC and 5hmC in response to TET2 knockdown in MCF7 cells. 
TET2 protein levels were confirmed as robustly depleted at both 48 and 72 hours after 
TET2 knockdown using PRM, with four high confidence TET2 peptides detected, and all 
of these reduced by at least 85% compared to control (Figure 5.3B). As expected, the 
overall abundance of 5mC was much greater than that of 5hmC, with 5mC present as 
~3% of total cytosines, and 5hmC present as ~0.02% of total cytosines, under control 
conditions. TET2 knockdown for 48 hours resulted in a dramatic decrease (~50%) in 
global levels of 5hmC in MCF7 cells, with this augmented to a ~75% drop after 96 hours 
of knockdown (Figure 5.3A), indicating that the effects of TET2 silencing on 5hmC are 
preserved across cell divisions (the doubling time of MCF7 cells is ~28 hours). Despite 
the robust drop in 5hmC in response to TET2 knockdown, no significant change in global 
5mC was detected. Validation of these findings in additional ER+ cell lines T47D and 
ZR75-1 demonstrated similar effects (Figure 5.4), where, despite some variability in the 
measurements for the T47D cell line, an average drop of ~50% in global 5hmC levels was 
measured in response to TET2 knockdown for 48 hours, whilst global 5mC appeared 
largely unchanged (Figure 5.4A). PRM again confirmed effective depletion of TET2 protein 
levels in these cell lines (Figure 5.4B). Due to technical constraints imposed by the 
apparently lower levels of TET2 in T47D and ZR75-1 cells, only one of the five TET2 
peptides probed using PRM was detected with high confidence. Nevertheless, qRT-PCR 
(Figure 5.4C) further confirmed expression-level depletion of TET2 in these cell lines.  
 
The dramatic global decrease in 5hmC in response to TET2 loss is consistent with reports 
in the literature, with Hon et al. (2014) observing a global drop of 5hmC to ~10% of control 
levels in TET2 knockout mESCs. This finding is backed up by studies in other cell lines, 
with the extent of 5hmC depletion varying in different systems, but generally appearing 
robust in response to TET2 loss (Li et al. 2011; Li et al. 2018). It is possible that 
compensatory activity of TET1 or TET3 could prevent an even more dramatic drop in 
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5hmC in response to TET2 silencing in MCF7 cells. However, as shown in Figure 5.5, 
neither TET1 nor TET3 mRNA levels demonstrated robust changes in response to TET2 
knockdown according to RNA-seq in MCF7 cells, and indeed TET1 appeared very lowly 
expressed. Some redundancy between TET enzymes may still occur, and protein-level 
measurements and functional studies would be required to further validate these 
observations. Nevertheless, these findings suggest that of all three TET proteins, TET2 
may exert the major control over 5hmC levels in these cells. These results indicate a key 
role for TET2 in the production and/or maintenance of 5hmC in ER+ breast cancer cells. 
 
 
Figure 5.3. TET2 knockdown in MCF7 cells induces a global drop in 5hmC levels, 
but no change in overall 5mC levels. 
A) Mass spectrometry was used to assess global levels of 5mC (top) or 5hmC (bottom) 
in DNA isolated from MCF7 cells treated with either non-targeting control siRNA (siNT) or 
siRNA targeting TET2 (siTET2) for various durations. Data represent mean ± SD (n≥4). 
Results are expressed as % of total cytosines. B) PRM confirmed effective TET2 
knockdown in MCF7 cells. Barplots depict levels of different TET2 peptides in response 
to siNT or siTET2, with data representing mean ± SD peptide levels relative to an actin 
control (n=3). ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. 
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Figure 5.4. TET2 knockdown in T47D and ZR75-1 cells induces a global drop in 
5hmC levels, but no change in overall 5mC levels. 
A) Mass spectrometry was used to assess global levels of 5mC (left) or 5hmC (right) in 
DNA isolated from T47D cells and ZR75-1 cells treated for 72 hours with either non-
targeting control siRNA (siNT) or siRNA targeting TET2 (siTET2). Measurements from 
two independent biological replicates are plotted separately. Results are expressed as % 
of total cytosines. B) PRM confirmed effective TET2 knockdown in T47D cells (top) and 
ZR75-1 cells (bottom) Barplots depict levels of the TET2 peptide VSDVDEFGSVEAQEEK 
in response to siNT or siTET2 treatment (72 hours), with data representing mean ± SD 
peptide levels relative to an actin control (n=3). ** = p ≤ 0.01. C) To validate the PRM 
results, TET2 mRNA levels in T47D cells (top) and ZR75-1 cells (bottom) in response to 
siNT or siTET2 treatment (48 hours) were assessed using qRT-PCR. Data are expressed 
as enrichment relative to a housekeeping control gene (UBC) (n=1, average of three 
technical replicates). 
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The lack of a visible change in global 5mC levels in response to TET2 knockdown may be 
partly due to the bulk nature of these measurements. Specifically, whilst reports in the 
literature, cited above, show that TET2 loss results in global depletion of 5hmC, the picture 
appears to be more complex regarding loss of TET2 and 5mC. A recent study by López-
Moyado et al. (2019) showed that TET2 knockout in a range of cell types causes localised 
increases in 5mC in active euchromatic regions, but a loss of 5mC in heterochromatic 
regions, implying that the effects of TET2 depletion on 5mC levels can vary dependent on 
chromatin state. It is therefore possible that the apparently stable readout of 5mC 
measured here masks site-specific variations. An alternative explanation could be that 
5mC may only undergo regulation at discrete sites as a result of TET2 loss, consistent 
with dynamic modulation of this mark being observed mainly at selected regulatory regions 
across different cell types (Bird 2002; Ziller et al. 2013). If TET2 only impacts 5mC at a 
subset of sites, these changes may be subtle as a fraction of total 5mC, such that their 
detection is limited by the sensitivity of this technique. As the focus of this work is ER 
regulatory regions, subsequent investigations were aimed towards providing ER site-
specific resolution of the effects of TET2 loss. 
Figure 5.5. Expression of TET1, TET2 and TET3 mRNA in MCF7 cells in response to 
TET2 siRNA treatment. 
Barplot shows the average Reads Per Kilobase of transcript per Million (RPKM) for TET1, 
TET2 and TET3 in MCF7 cells according to RNA-seq, in response to treatment with either 
non-targeting control siRNA (siNT) or siRNA targeting TET2 (siTET2) for 48 hours. 
Results represent mean ± SD (n=6). 
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5.2.2 TET2 knockdown regulates DNA modifications at ER sites 
according to mass spectrometry 
To focus on the effects of TET2 knockdown on 5mC and 5hmC at ER regulatory regions, 
ER ChIP was performed in asynchronous MCF7 cells and the DNA obtained was analysed 
using mass spectrometry. This showed that the global drop in 5hmC in response to TET2 
loss was recapitulated at ER regulatory regions, where a ~50% loss of 5hmC was 
observed (Figure 5.6). Although very modest, there also appeared to be a concomitant 
increase in 5mC at ER sites in response to TET2 knockdown, indicating that TET2 loss 
may also impact 5mC levels at genomic regions bound by ER. Since only two biological 
replicates were conducted, statistical analysis was not performed on these results. This 
work therefore remains preliminary, and further replicates would be required to validate 
these findings. Nevertheless, this local increase in 5mC in response to TET2 knockdown 
would be consistent with studies indicating a role for TET2 in modulating 5mC specifically 
at enhancers (Hon et al. 2014; Wang et al. 2018), and potentially providing a protective 
effect against aberrant hypermethylation at these sites (Rasmussen et al. 2015).  
Figure 5.6. Analysis of ER ChIP DNA from MCF7 cells reveals changes in DNA 
modifications at ER sites in response to TET2 knockdown. 
Mass spectrometry was used to measure 5mC or 5hmC levels in either A) input DNA or 
B) DNA from ER ChIP in MCF7 cells treated with either non-targeting control siRNA (siNT) 
or siRNA targeting TET2 (siTET2) for 72 hours. Measurements from two independent 
biological replicates are plotted separately. Results are expressed as % of total cytosines. 
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5.2.3 GATA3 knockdown reduces TET2 expression, but does not affect 
global 5mC or 5hmC according to mass spectrometry 
As described in Chapters 3 and 4, GATA3 regulates the participation of TET2 in the ER 
complex. RNA-seq after GATA3 knockdown in MCF7 cells indicated that this is likely due 
to loss of TET2 expression, implicating TET2 as a GATA3 target gene. Having shown that 
TET2 knockdown results in changes in the levels of 5hmC (and, potentially, though more 
modestly, 5mC) at ER regulatory sites, it was reasoned that GATA3 might provide indirect 
modulation of these pathways. Mass spectrometry to measure global 5mC and 5hmC was 
therefore performed after GATA3 knockdown in MCF7 cells. As expected, GATA3 loss 
resulted in a robust reduction of TET2 protein levels according to PRM, with four high 
confidence TET2 peptides detected, and three of these depleted significantly by GATA3 
knockdown (Figure 5.7C). However, this loss of TET2 did not translate into an effect on 
global 5mC or 5hmC (Figure 5.7A). There are several possible explanations for why TET2 
depletion via GATA3 knockdown might not phenocopy direct TET2 silencing with regards 
to 5hmC changes. Firstly, the depletion of TET2 protein levels as a result of GATA3 
knockdown is not as robust as the effect of TET2 knockdown itself. Whilst the TET2 
peptides measured by PRM were reduced to less than 15% of control after direct TET2 
silencing (Figure 5.3B), their levels ranged between 20-56% of control in response to 
GATA3 knockdown (Figure 5.7C). This indicates that there may be a threshold of TET2 
loss required for disruption of 5hmC levels that is not achieved via GATA3 silencing. 
Another possibility is that any changes in 5mC/5hmC in response to GATA3 knockdown 
are both less dramatic than those induced by direct loss of TET2, and/or occur in a site-
specific manner, and the bulk nature of these mass spectrometry measurements prevents 
resolution of these events. A more speculative explanation for the lack of 5hmC depletion 
is that GATA3 knockdown may simultaneously induce compensatory changes that 
stabilise 5hmC in response to reductions in TET2 protein levels. For example, increases 
in the levels or activity of TET1 or TET3 in response to TET2 loss could hypothetically 
facilitate increased 5hmC generation. However, as neither TET1 or TET3 mRNA levels 
were increased in response to GATA3 knockdown (data not shown), functional studies 
would be needed to explore this, or any other compensatory changes that might protect 
from loss of 5hmC in response to GATA3 knockdown. Off-target effects of the GATA3 
siRNAs used could be a further confounding feature that may affect this facet of the 
response to GATA3 knockdown, although similarly, further in-depth investigations would 
be required to assess this. 
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Figure 5.7. GATA3 knockdown results in depletion of TET2 protein levels, but no 
effect on global 5mC or 5hmC in MCF7 cells. 
A) Mass spectrometry was used to assess global levels of 5mC (top) or 5hmC (bottom) 
in DNA isolated from MCF7 cells treated with either non-targeting control siRNA (siNT) 
or siRNA targeting GATA3 (siGATA3) for 72 hours. Measurements from two independent 
biological replicates are plotted separately. Data are expressed as a % of total cytosines. 
B) PRM confirmed effective GATA3 knockdown. Barplots depict levels of different GATA3 
peptides in response to siNT or siGATA3 treatment (48 hours). C) PRM showing TET2 
levels in response to GATA3 knockdown. Barplots depict levels of different TET2 peptides 
in response to siNT or siGATA3 treatment (48 hours). Results represent mean ± SD 
peptide levels relative to an actin control (n=3). ** = p ≤ 0.01, **** = p ≤ 0.0001. 
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5.2.4 Sequencing-based measurements of 5mC and 5hmC confirm that 
TET2 regulates DNA modifications at ER sites 
To obtain greater resolution of TET2-mediated changes in DNA modifications at ER sites, 
sequencing-based measurements of 5mC and 5hmC were performed. A modified form of 
bisulfite sequencing, MMS, was used to profile total 5mC and 5hmC, and 5hmC was 
uniquely profiled using RRHP. These methods are outlined in Section 5.1 (Figures 5.1 and 
5.2). Both these techniques use the methylation-insensitive enzyme MspI (consensus site 
CCGG) to enrich for regions with a high frequency of CpG dinucleotides, with MMS 
coverage enhanced through further digestion with TaqαI (consensus site TCGA). Both 
promoters and enhancers display heightened GC content (Consortium, 2012; Fenouil et 
al., 2012), although promoters overall more so due to the abundance of CGIs within these 
sequences. To confirm that MMS and RRHP would provide adequate representation of 
ER regulatory regions, bioinformatic analysis was performed to assess the number of ER 
peaks covered by theoretical MspI-generated fragments of sequencing-appropriate size. 
Using an MCF7 dataset of 29,149 ER peaks from Mohammed et al. (2015), and size-
selecting for fragments between 100-400bp (as per the MMS and RRHP protocols) it was 
shown that 20% of ER peak regions overlapped with these MspI fragments, the majority 
(13%) of which were outside promoters. This indicated that these techniques could 
provide sufficient coverage of ER sites to allow investigation of 5mC/5hmC dynamics in 
response to TET2 loss, and ultimately, assessment of whether any observed changes 
might correlate with TET2-regulated gene expression. 
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Using DNA obtained from MCF7 cells, 720,837 modifications were profiled using MMS, 
and 849,892 modifications were profiled using RRHP. The restriction digest methods of 
both techniques enrich for similar regions of the genome, whilst the bisulfite sequencing 
approach of MMS detects both 5mC and 5hmC. As a result, the modified sites profiled by 
each of these techniques demonstrated a high degree of residue-for-residue overlap 
(Figure 5.8). This indicates that the majority of sites detected using MMS are either stable 
5hmC sites, or, more likely, present as 5mC modifications at some loci and 5hmC at 
others. Cell-to-cell variation in the type of modifications present at specific positions, and 
possibly allele-specific differences in 5mC/5hmC within the same cell (Song et al. 2019; 
Stern et al. 2017), may both account for this overlap. As TET-mediated oxidation of 5mC 
is a requirement for 5hmC generation, overall this implies that many of these sites are 
subject to dynamic regulation by TET proteins under normal conditions.  
 
Figure 5.8. Venn diagram showing residue-for-residue overlap of modified bases 
detected using MMS and RRHP in MCF7 cells. 
Numbers correspond to the number of sites exhibiting modifications in either MMS or 
RRHP in DNA obtained from MCF7 cells treated with non-targeting siRNA for 72 hours. 
MMS measures both 5mC and 5hmC, whilst RRHP detects 5hmC exclusively. 
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The MA plots in Figure 5.9 show the global changes in response to TET2 knockdown 
reported by the MMS and RRHP assays. A dramatic drop in 5hmC was observed at the 
vast majority of sites where this modification was profiled using RRHP (Figure 5.9B), 
consistent with the mass spectrometry data (Figures 5.3 and 5.6). In contrast, most sites 
displayed no change in combined 5mC/5hmC levels (Figure 5.9A). The lack of a significant 
global shift at sites profiled by MMS (the vast majority of which, as implied in Figure 5.8, 
appear to be found both methylated and hydroxymethylated in the cell population) could 
suggest that, reflective of its higher genomic abundance, the frequency of 5mC at these 
sites is much higher than that of 5hmC. This would mean that the incidence of 5hmC 
measured by RRHP reflects a very small fraction of the total modifications detected by 
MMS for a specific residue, and the sensitivity of the MMS assay is not sufficient to 
distinguish loss of 5hmC at these sites from the stable overall 5mC signal. However, it is 
possible that the relative frequency 5mC and 5hmC could be more balanced at some of 
the regions profiled by MMS and RRHP, and Pastor et al. (2013) have suggested that at 
least at promoters, 5hmC may be enriched in absolute terms compared to 5mC. If this is 
Figure 5.9. Residue-specific changes in 5mC and 5hmC in response to TET2 
knockdown in MCF7 cells. 
MA plots showing log2 fold change in 5mC + 5hmC (left, MMS readout) and 5hmC 
exclusively (right, RRHP readout) in control versus TET2 knockdown conditions. Each 
datapoint represents an individual 5mC or 5hmC residue. Knockdowns were performed 
for 72 hours. 
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the case, the stability of the MMS signal in response to TET2 knockdown could imply that 
any loss of 5hmC equals a corresponding gain in 5mC at these individual sites. In either 
case, the clear depletion of 5hmC in response to TET2 loss, observed using both mass 
spectrometry and RRHP, is consistent with an important role for TET2 in dynamic 
regulation of the 5mC to 5hmC conversion in these cells.  
 
Focusing on ER and TET2 co-bound genomic loci, 29% of total ER sites and 24% of 
ER/TET2 shared sites were found to contain at least one 5mC/5hmC residue as measured 
by MMS, whilst 35% of total ER sites and 28% of ER/TET2 sites possessed at least one 
5hmC modification according to RRHP. Figure 5.10 shows MMS (5mC + 5hmC) and 
RRHP (5hmC) readouts under control or TET2 knockdown conditions at all ER sites, and 
at the subset of ER sites co-occupied by TET2. Interestingly, the overall drop in 5hmC as 
measured by RRHP was the same at both groups of sites, and hence the magnitude of 
5hmC loss appears not to rely on the presence of TET2. This is somewhat consistent with 
the findings of Rasmussen et al. (2019), who showed that most differentially methylated 
regions identified in TET2 -/- mESCs did not demonstrate detectable TET2 binding. This 
could imply that the TET2 antibodies used for ChIP, both in the work reported here, and 
the Rasmussen et al. (2019) study, did not effectively capture all TET2 sites. Alternatively, 
TET2 may regulate DNA modifications at these alternative sites in the absence of robust 
and persistent binding. This could imply a “scanning” mechanism whereby TET2 exerts 
its catalytic effects rapidly and with minimal interaction with chromatin. Another 
explanation is that some of these DNA modification changes may occur as secondary 
events to TET2 depletion, pointing to an indirect role for TET2 in regulating 5mC/5hmC 
levels. 
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5.2.5 5mC/5hmC changes reveal no direct correlation with TET2-
regulated gene expression  
To investigate a potential relationship between TET2-mediated regulation of DNA 
modifications at ER sites, and changes in the expression of nearby genes, the 500 most 
induced and 500 most repressed genes in response to TET2 silencing (sorted based on 
p-value, all p ≤ 0.05) were selected. A further 500 genes with unchanged expression in 
response to TET2 knockdown were selected as controls, and the average MMS and 
RRHP readouts at ER/TET2 shared sites within ± 50 kb of the TSSs of these genes were 
examined (Figure 5.11).  
Figure 5.10. The effect of TET2 knockdown on DNA modifications at ER sites in 
MCF7 cells. 
MMS signal (5mC + 5hmC) and RRHP signal (5hmC) was assessed at ER peak regions 
(left) or ER/TET2 overlapping peak regions (right) under control (siNT) or TET2 
knockdown (siTET2) conditions. The total numbers of sites analysed within each category 
are: ER MMS sites = 8,463; ER RRHP sites = 10,104; ER/TET2 MMS sites = 3,762; 
ER/TET2 RRHP sites = 4,512.  
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Figure 5.11. TET2 knockdown in MCF7 cells shows a uniform effect on DNA 
modifications at ER/TET2 shared sites in proximity to genes regulated by TET2 
knockdown, and genes with unchanged expression. 
MMS signal (5mC + 5hmC) and RRHP signal (5hmC) was assessed under (siNT) or 
TET2 knockdown (siTET2) conditions (72h) at ER/TET2 shared sites within ± 50 kb of 
the TSSs of the top 500 induced or repressed genes (sorted based on p-value, all p ≤ 
0.05) in response to TET2 knockdown in MCF7 cells. Unchanging genes (n = 500) were 
defined as those with p > 0.1 and log2 fold change < 0.05. 
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Subdivision of ER/TET2 sites according to the TET2-mediated regulation of nearby genes 
did not reveal differences in the MMS readouts at these different groups of regions. 
Specifically, the net levels of 5mC + 5hmC remained similar in magnitude and unchanged 
between control and TET2 knockdown at sites near induced, repressed and unchanging 
genes. In terms of 5hmC, whilst a robust depletion of 5hmC was measured across all three 
classes of sites in response to TET2 knockdown, reflecting the global measurements, no 
overall differences in the magnitude of this change were observed in proximity to induced, 
repressed and unchanging genes. Although, as shown in Chapter 3, both ER and TET2 
express a preference for binding to enhancers in these cells, they also interact at 
promoters, and it has been suggested that 5mC and 5hmC may have distinct 
transcriptional contributions at these two classes of sites. However, separate examination 
of ER/TET2-occupied promoter regions (within 2 kb upstream and 1 kb downstream of the 
TSS) compared to enhancers did not distinguish the MMS and RRHP readouts nearby 
induced, repressed or unchanging genes from those at ER/TET2 shared sites as a whole 
(data not shown). Genes regulated in response to TET2 loss therefore showed no clear 
bias towards differential regulation of DNA modifications at ER/TET2 sites. As these 
analyses, although more targeted than global measurements, nevertheless involve 
averaged signal over groups of sites, it remains possible that divergent effects in the 
direction or magnitude of any changes in DNA modifications might be observed at 
individual sites. In addition, as this investigation focuses on the most significantly 
regulated genes, there may be differences in the extent to which these may be affected 
by changes in DNA modifications, compared to genes undergoing subtler regulation in 
response to TET2 loss. TET2-mediated regulation of 5mC/5hmC may therefore provide a 
regulatory contribution at subsets of these genes, or in a subtler manner, in concert with 
other mechanisms. 
 
Overall, these results imply that complex and potentially divergent mechanisms might be 
involved in regulation of these different groups of genes in response to TET2 loss, with a 
more granular relationship existing between TET2-regulated gene expression and 
changes in DNA modifications. As described in Chapter 1, whilst many studies have 
demonstrated a correlation between gene expression and 5mC/5hmC levels at certain 
genomic elements, this relationship appears to be non-uniform, with several mechanisms 
of context-dependency reported for these effects. For example, CpG content can define 
the transcriptional effects of methylation at different types of promoters. Specifically, whilst 
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methylation of high and intermediate CpG density promoters is associated with 
repression, methylation of low CpG density promoters appears to have less of an effect 
on gene expression (Marchal & Miotto 2015), and it is possible that a similar concept may 
apply to enhancers. Similarly, the existing levels of 5mC or 5hmC within different regions 
might influence both the impact of TET2 loss on the modifications at these sites, and any 
effects on the expression of associated genes. Additional variables could include the 
histone modifications present at these sites, as it has been shown in mESCs that the 
profiles of histone modifications at active versus bivalent promoters correlates with 
differential changes in gene expression in response to hypermethylation of these regions 
(Lu et al. 2014). Furthermore, dynamic interplay between cytosine modifications and 
transcription factors or chromatin remodellers (a variety of which participate in the ER 
complex) may also play a role in the relationship between 5mC/5hmC levels and gene 
expression. It is emerging that a range of proteins may be capable of interacting with 5mC 
and 5hmC, and that these may be capable of diverse transcriptional functions, further 
reinforcing that the profiles of these 5mC/5hmC readers at specific sites are likely to be 
important in dictating the effects of these epigenetic marks on gene expression (Iurlaro et 
al. 2013; Spruijt et al. 2013; Spruijt & Vermeulen 2014). The affinity of certain 5mC and 
5hmC readers may also vary dependent on the DNA sequence surrounding these marks 
(Iurlaro et al. 2013), and it is also possible that differential post-translational modifications 
of 5mC/5hmC readers might affect their affinity for their sites of interest, resulting in 
different functional outcomes (Spruijt et al. 2013). Finally, several additional roles of TET2 
were described in Chapter 1, for example TET-mediated stabilisation of the histone 
methyltransferase complex SET1/COMPASS (Deplus et al. 2013). Some of these 
functions may be catalytic-independent, and may also contribute to context-dependent 
effects of TET2 on gene expression, to fine-tune the role of TET2 at different sites (Lian 
et al. 2016). Taken together, these findings paint a potentially complex picture of the role 
of TET2 in transcriptional regulation. 
 
5.3 Summary 
The work in this chapter demonstrates that TET2 regulates DNA modifications in several 
ER+ breast cancer cell lines, and shows more specifically in MCF7 cells that this process 
occurs at ER binding sites. Given that ER sites mainly constitute distal regulatory 
elements, this is consistent with the finding that these are amongst the key regions where 
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DNA modifications appear to undergo TET2-mediated dynamic regulation (Ziller et al. 
2013; Rasmussen et al. 2015; 2019; Wang et al. 2018). 
 
Regarding the precise nature of these DNA modification changes, DNA mass 
spectrometry indicated a global depletion of 5hmC in response to TET2 loss, indicating a 
key role for TET2 in regulation of this mark in ER+ breast cancer cells. No effect was 
observed on global 5mC, and further sequencing-based measurements of 5mC and 5hmC 
using a bisulfite approach (MMS) revealed no overall changes in response to TET2 
knockdown, both at the global level and at ER sites specifically. In the absence of a direct 
measure of 5mC, whether TET2 may prevent aberrant methylation at ER sites is not 
completely clear. The preliminary mass spectrometry data following ER ChIP (Figure 5.6) 
suggests that TET2 loss may indeed result in hypermethylation at some ER sites, although 
further replicates are required to validate this. Nevertheless, it appears clear that TET2 
has an important role in the conversion of of 5mC to 5hmC at these regions, with the 
possibility that 5hmC then remains stable and functional in its own right. Investigating 
whether TET2 activity at some ER sites might also involve demethylation in the classic 
sense (i.e. restoration of unmodified cytosine) may require further site-specific 
examination of these results. Whilst this work was in progress, a study was published by 
Wang et al. (2018) examining the effects of stable TET2 knockout in MCF7 cells. 
Consistent with measurements obtained using the acute TET2 knockdown system 
employed in this thesis, Wang et al. (2018) observed no global change in overall bisulfite 
sequencing signal in TET2 knockouts compared to control cells. However, an increase in 
bisulfite signal, suggesting an overall gain in 5mC, was observed at a subset of ER sites. 
This increase in 5mC occurred to different extents at different clusters of ER sites, with no 
changes seen at the promoters analysed, suggesting that some ER enhancers, but not 
all, may undergo demethylation as a result of TET2 activity. These observations validate 
the association between ER and TET2 shown in this work, and also suggest that bona 
fide TET2-mediated demethylation may occur at some ER sites in response to TET2 loss. 
The measurements of 5hmC provided in this chapter build on existing findings by 
demonstrating direct evidence of TET2-mediated regulation of 5hmC levels at ER 
enhancers in breast cancer cells. 
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In terms of the functional effects of these changes in DNA modifications, subdividing 
differentially hydroxymethylated (and by inference, potentially differentially methylated) 
sites into those near genes repressed, induced or unchanged in response to TET2 loss 
revealed no direct correlation between DNA modification changes and gene regulation. 
Therefore, while it is possible that TET2-mediated regulation of DNA modifications has a 
role in controlling gene expression at ER sites, work in this chapter indicates that this 
appears to be a more nuanced relationship than that of 5mC/5hmC gain/loss equating to 
transcriptional control in a particular direction. In the above-cited study from Wang et al. 
(2018), comparison of TET2 knockout cells and wild-type controls revealed that the 
observed changes in DNA methylation at subsets of ER sites were associated with 
changes in oestrogen-regulated expression of nearby genes. It is therefore possible that 
more detailed sub-classification of regulated genes, or inspection of individual loci, may 
reveal an association between the dynamics of TET2-regulated gene expression and 
changes in 5mC/5hmC in the acute knockdown system employed in this work. 
 
Of further interest, TET2 loss appeared to coincide with 5hmC depletion throughout the 
regions profiled using MMS and RRHP, irrespective of the presence of TET2. This implies 
either that not all TET2-chromatin interactions have been captured using ChIP, or that loss 
of 5hmC can somehow occur secondary to TET2 depletion. This could also imply that the 
role of TET2 at ER/TET2 shared sites is unique to its contribution at other sites, related to 
an increased occupancy time of TET2 on chromatin, reflected in TET2 being capturable 
by ChIP at these regions. In addition, catalytic-independent functions, in combination with 
the observed regulation of 5mC/5hmC, may help to distinguish the potential effects of 
TET2 at ER sites from its putative role at other genomic regions. Selective inactivation of 
the catalytic domain of TET2 (e.g. through CRISPR) would facilitate decoupling of TET2 
enzymatic function from its role in the ER complex and could provide the first step towards 
answering this complex question. 
 
For the work in this chapter, DNA mass spectrometry analysis was performed by Dr 
Shiqing Mao. PRM analysis was performed by Dr Carmen Gonzalez Tejedo of the 
Proteomics Core Facility, and ChIP-seq data processing and analysis was performed by 
Dr Igor Chernukhin. MMS and RRHP data was obtained through Zymo Research (Irvine, 
California), and was analysed by Dr Kamal Kishore of the Bioinformatics Core Facility. 
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Discussion 
6.1 GATA3, TET2 and the ER complex 
In Chapter 3, quantitiative proteomics was used to assess the composition of the ER 
complex in response to knockdown of GATA3, with the aim of investigating the 
contribution of this key ER-associated transcription factor to ER signalling. As a result of 
GATA3 silencing, several proteins with links to DNA methylation exhibited altered 
interactions with the ER complex. Specifically, the dioxygenase enzyme TET2 was 
depleted from the ER complex, whilst the transcription factors LHX4 and ZBTB34 were 
enriched. TET2 is thought to be capable of mediating DNA demethylation through its 
iterative oxidiation of 5mC to 5hmC, 5fC and 5caC (He et al. 2011; Ito et al. 2011; Tahiliani 
et al. 2009), as, unlike 5mC, which is heritable, these marks are likely lost through 
replication-dependent dilution (Hackett et al. 2013; Inoue & Zhang, 2011). Moreover, 5fC 
and 5caC may additionally be actively removed via base excision repair (He et al. 2011; 
Shen et al. 2013; Song et al. 2013). Meanwhile, LHX4 and ZBTB34 are transcription 
factors thought to be capable of binding to methylated DNA (Filion et al. 2006; Qi et al. 
2006; Yin et al. 2017). The altered levels of these proteins in response to GATA3 
knockdown implies that GATA3 might provide a functional link to writing and reading of 
DNA methylation as part of the ER complex. Specifically, these results might suggest that 
changes in DNA methylation through loss of TET2 could cause altered LHX4 and ZBTB34 
binding to ER regions. Subsequent work (discussed further in sections 6.2 and 6.3 below) 
explored the relationship between TET2, the ER complex, and ER-regulated gene 
expression in more detail. TET2- and GATA3-mediated regulation of DNA modifications 
in ER+ breast cancer cells was investigated in Chapter 5, with TET2 demonstrating a role 
in regulating 5hmC levels at ER sites. 
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In Chapter 3, TET2-ER interactions were characterised using both RIME and ChIP-seq, 
and TET2 was shown to co-localise with ER on chromatin at a subset of sites in four 
different ER+ breast cancer models (two cell lines and two PDXs). Of note regarding the 
profile of TET2 genomic binding, it was shown in Chapter 5 that TET2 silencing in MCF7 
cells results in loss of 5hmC at sites where no TET2 binding is detected. The presence of 
indirect TET2-regulated 5hmC events could be due to the nature of TET2 action, for 
example a sampling or scanning mechanism whereby TET2 does not fully interact with 
chromatin when oxidising cytosine modifications. A further, more speculative explanation 
could be that some of these apparently indirect TET2-mediated 5hmC events are the 
result of chromatin looping. Alternatively, the TET2-regulated 5hmC changes in the 
absence of TET2 binding could imply that not all TET2 sites are captured by ChIP-seq in 
these cells, despite the antibody chosen for these studies emerging as the most robust 
and specific TET2 antibody tested in both ChIP and RIME. The profile of TET2 binding in 
the models examined might also insinuate the presence of additional, uncaptured TET2 
binding events, as TET2 binding was seen to correlate very closely with that of ER, but 
only at a subset of sites. Additionally, in all four models, very few ER-independent TET2 
sites were observed. Whilst the latter may be a biological property of TET2 action in these 
cells, consistent for a stabilising role of ER in TET2-chromatin interactions (as discussed 
in Chapter 4), this finding merits further investigation. Any hypothetically uncaptured TET2 
binding sites, whether ER co-occupied or ER-independent, likely correspond to lower-
affinity binding sites that exhibit weaker TET2 enrichment and hence cannot be captured 
with the antibody used. One method to circumvent this, and to additionally test the 
specificity of the TET2 antibody, could be to express the TET2 protein tagged with an 
epitope that can be robustly and specifically detected in ChIP, for example FLAG or HA. 
Expression of this tagged TET2, in either in untreated cells or after knockdown of the 
endogenous protein, could provide validation of the existing TET2 sites and might point to 
additional sites where TET2 is found at low levels but cannot be captured in its 
endogenous form. This could also enable the detection of ER-independent TET2 binding 
events, which might aid in dissecting the precise role of TET2 in the ER complex as 
opposed to at other loci. 
 
TET2 is an ER target gene, induced in response to oestrogen and repressed by tamoxifen 
in MCF7 cells (Papachristou et al. 2018; Wang et al. 2018). The ER qPLEX-RIME 
experiment in Chapter 3, coupled with the subsequent RNA-seq investigations, showed 
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that TET2 is also a GATA3 target gene. As GATA3 forms part of the ER complex at many 
sites, and is linked to ER function, the expression-level control of TET2 by GATA3 may 
be a correlate of its regulation by the ER complex as a whole. This would reinforce that 
the basis of the functional interplay between these three proteins is to sustain the 
transcriptional activity of the ER complex. Having detected TET2 as a GATA3-regulated 
ER interactor, an area that remains to be explored is the precise relationship between 
GATA3 and TET2 genomic binding. Notably, like TET2, GATA3 also associates with a 
distinct subset of ER sites (Theodorou et al. 2013). It would therefore be informative to 
assess how GATA3 and TET2 genomic binding compares and to what extent they 
participate in the same complex. Indeed, if the presence of GATA3 additionally helps to 
stabilise the TET2 protein in the ER complex, GATA3/TET2 overlap could account for the 
specific profile of TET2 binding. 
 
Future work to establish the consequences of GATA3 and TET2 loss from the ER complex 
could also include investigating the factors enriched in response to GATA3 knockdown. 
For example, as previously mentioned, the recruitment of LHX4 and ZBTB34 to the ER 
complex may partly reflect their upregulation in response to GATA3 knockdown, but could 
also be a result of aberrant methylation, due to the concurrent loss of TET2, that attracts 
the binding of these proteins to ER sites. Indeed, TET2 has been suggested to protect 
against hypermethylation of enhancers (Jeong et al. 2014; Rasmussen et al. 2015),. 
Increased methylation of certain ER sites is observed in stable TET2 knockout cells (Wang 
et al. 2018), and preliminary mass spectrometry data in this thesis points to increased 
overall methylation at ER sites in response to acute TET2 knockdown, assessed through 
bulk analysis of ER ChIP DNA (Chapter 5). Nevertheless, an examination of DNA 
modifications at ER sites specifically in response to GATA3 knockdown remains a 
requirement of these investigations. Indeed, in notable contrast to the robust changes in 
5hmC levels induced by TET2 silencing, loss of TET2 secondary to GATA3 knockdown 
had no visible effects on global 5hmC levels (Chapter 5). This implies a more nuanced 
relationship between GATA3 knockdown and TET2-mediated control of DNA 
modifications, and suggests that loss of GATA3 does not phenocopy loss of TET2. An 
opposing suggestion might therefore be that the binding of LHX4 and ZBTB34, or the 
additional factor GREB1L, also enriched in response to GATA3 knockdown, could protect 
against loss of 5hmC and/or aberrant methylation as a result of TET2 depletion through 
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this pathway. Further functional studies, including a detailed examination of the profiles of 
5mC and 5hmC at ER sites after GATA3 knockdown, would be required to assess this. 
 
In contrast to LHX4 and ZBTB34, which are transcription factors, the specific function of 
the third factor enriched in the ER complex in response to GATA3 loss, GREB1L, is 
currently unknown. However, Brophy et al. (2017) suggested this protein may have a role 
in renal development through interactions with RAR, implying it may be a general nuclear 
receptor cofactor. Indeed, GREB1L bears 51% protein sequence identity with the ER 
cofactor GREB1 using Protein BLAST (https://blast.ncbi.nlm.nih.gov) (Mohammed et al. 
2013). Notably, proteins of this clade may also have a link to DNA modifications, with 
structural and comparative genomics analyses by Iyer et al. (2013) suggesting GREB1-
like proteins may be capable of glycosylating 5hmC. However, no direct evidence of this 
has yet been shown. ChIP-seq for GREB1L, LHX4 and ZBTB34 under normal conditions 
and in response to GATA3 knockdown in ER+ breast cancer cells could help establish 
whether they are enriched at other regions prior to GATA3 loss, before being recruited to 
ER sites. In this way, a better understanding of the transcriptional role of these factors 
could shed further light on the contribution of GATA3 to the ER complex, and identify any 
potential consequences of TET2 loss at ER binding sites. 
 
6.2 TET2 as an ER cofactor and potential prognostic factor in 
breast cancer 
TET2 is an ER target gene in MCF7 cells (Papachristou et al. 2018; Wang et al. 2018), 
and ChIP-seq presented in Chapter 3 demonstrated robust ER binding sites 20-30 kb 
upstream of the TET2 promoter in these cells. The observation that ZR75-1 cells and the 
two PDXs examined also possess similarly-located ER binding sites suggests TET2 also 
functions as an ER target gene in these models. Work in Chapter 4 further reinforced the 
association between ER and TET2 by demonstrating that global ER binding is affected by 
TET2 silencing, and that this is associated with dysregulated expression of several ER 
and GATA3 target genes and reduced growth of ER+ MCF7 cells. These findings are 
consistent with those of Wang et al. (2018), who showed that in stable TET2 knockout 
MCF7 cells, oestrogen-induced recruitment of ER to chromatin, and oestrogen-driven cell 
Chapter 6 
123 
 
growth, are both attenuated compared to wild-type controls. The identification of TET2 as 
an ER cofactor therefore suggests the existence of a feed-forward loop in which co-
regulators such as TET2 are expressed to support the transcriptional activity of the ER 
complex. 
 
Consistent with the notion of TET2 as a key component of a functional ER complex, higher 
TET2 expression predicts improved relapse-free survival in ER+ breast cancer (Chapter 
3), indicating TET2 as a potential prognostic factor. Having demonstrated the role of TET2 
in ER-driven proliferation in MCF7 cells, the exploration of other malignant phenotypes, 
for example migration and invasion, could be of use in further characterising the role of 
TET2 in ER biology. Given the hypothesis that TET2 contributes to functionality of the ER 
complex, this protein could also have a role in the response to antihormone therapy. As 
ER+ breast cancer relapse is often associated with drug resistance, it would be pertinent 
to explore the effect of TET2 loss or overexpression in the context of long-term tamoxifen 
treatment. Transwell or scratch-wound assays could be used to examine proliferative, 
migratory and invasive phenotypes in cell lines, and mammary intraductal injection-based 
approaches using the MIND technique (Sflomos et al. 2016) could be used to investigate 
the behaviour of TET2-overexpressing or knockout cells in vivo. 
 
TET2 expression is repressed in response to tamoxifen treatment in MCF7 cells 
(Papachristou et al. 2018), and it is also possible that loss of TET2 from the ER complex 
might result in transcriptional changes that, in a long-term clinical setting, could eventually 
contribute to resistance. Interestingly, Takayama et al. (2015) have shown that the 
androgen antagonist bicalutamide differentially regulates TET2 expression in hormone-
dependent versus hormone refractory prostate cancer cells. Specifically, TET2 expression 
was induced by bicalutamide in the sensitive setting but repressed in resistance, which 
led to speculation that TET2 may have a role in clinical complications associated with the 
withdrawal of anti-hormone treatment in prostate cancer. Although reported in a different 
cancer type, this provides further evidence of a connection between TET2 and nuclear 
receptor activity in hormone-dependent cancers, and suggests that this relationship may 
become dysfunctional in the resistant setting. It would therefore be of interest to explore 
how TET2 levels are regulated in the context of long-term tamoxifen treatment in breast 
cancer cell lines or patient-derived xenograft systems. 
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In terms of DNA modifications in cancer progression, global depletion of 5hmC is observed 
in several cancers, and is associated with loss of TET2 (Kudo et al. 2012; Lian et al. 2012; 
Takayama et al. 2015; Yang et al. 2013). Moreover, lower levels of 5hmC may be 
specifically associated with more aggressive phenotypes, as has been shown in prostate 
cancer (Takayama et al. 2015). Dysregulated control of DNA modifications in response to 
TET2 loss could therefore play a role in antihormone resistance. Indeed, differentially 
methylated genes have been identified in tamoxifen-resistant versus wild-type MCF7 cells, 
and this differential methylation was associated with changes in the expression of genes 
related to proliferative control (Fan et al. 2006; Stone et al. 2012). Profiling 5mC and 5hmC 
in hormone-sensitive versus hormone-resistant breast cancer cell lines could help to 
solidify the relationship between TET2 loss and breast cancer progression.  
 
Regarding TET2 in the context of cancer progression, it may also be useful to consider 
the breast cancer models used in this work. The MCF7 cell line is derived from a metastatic 
pleural effusion, and genome-wide analysis of ER binding in MCF7 cells compared to 
clinical samples has suggested that this cell line more closely resembles a poor 
outcome/metastatic tumour than tumours of earlier stages, despite its responsiveness to 
tamoxifen (Ross-Innes et al. 2012). The observation that TET2 expression may be low in 
both this cell line (based on the issues detecting this protein using Western blot), and in 
similarly metastasis-derived T47D and ZR75-1 cells (based on the technical difficulties in 
PRM analysis of TET2 in these cell lines), further implies that TET2 may be lost during 
breast cancer progression. The PDX models employed in Chapter 3 demonstrated co-
localisation of TET2 and ER on chromatin, providing evidence of TET2 activity in an 
additional breast cancer system. However, it may be of interest to assess TET2 
expression directly in clinical samples, which could represent earlier stages of breast 
cancer. Method development is currently underway to measure ER and TET2 levels in 
various clinical samples using PRM, combined with global 5mC and 5hmC measurements 
using mass spectrometry. Comparing these features with the clinical status of these 
tumours could provide an indication of the role of TET2 in these different settings, and any 
association between ER levels, TET2 levels, and 5mC/5hmC. 
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6.3 Mechanisms linking TET2 and ER biology 
To assess the role of TET2 in regulating DNA modifications, global levels of 5mC and 
5hmC were examined in response to TET2 loss in MCF7, T47D and ZR75-1 cells using 
mass spectrometry. Consistent with observations in other cell lines (Hon et al. 2014; Li et 
al. 2011; Li et al. 2018), loss of TET2 resulted in a dramatic global drop in 5hmC, indicating 
a key role for TET2 in regulation of 5hmC in these models. No effect was observed on 
global 5mC levels in the three ER+ cell lines tested. This may be partly due to TET2 loss 
resulting in site-specific changes in 5mC that are averaged out using these global mass 
spectrometry measurements, resulting in a stable overall signal. Alternatively, TET2 
knockdown may rather induce 5mC changes only at discrete sites, resulting in alterations 
in 5mC levels that are subtle relative to its global abundance. Detection of these changes 
might therefore be limited by the sensitivity of the mass spectrometry technique. 
 
To examine the potential role of TET2 at specifically ER sites, 5mC and 5hmC were 
profiled using MMS and RRHP in ER+ MCF7 cells. Reflecting the global mass 
spectrometry measurements, 5hmC was robustly depleted at ER sites in response to 
TET2 loss. In contrast, the exact nature of any 5mC regulation in response to TET2 loss 
could not be precisely quantified. This is because the assay used to assess 5mC levels 
(MMS) provides a composite measure of both 5mC and 5hmC, rather an an isolated 5mC 
readout, and this overall signal remained unchanged across ER sites in control and TET2 
knockdown conditions. It is possible this signal, averaged over groups of ER sites, masks 
subtly divergent site-specific effects. Mass spectrometry analysis of ER ChIP DNA, which 
provides a measurement of 5mC alone, showed that loss of TET2 may cause increased 
5mC levels at overall ER regions, although this requires further replicates for validation 
(Chapter 5). Nevertheless, this could indicate a role for TET2 in either protection of ER 
sites from aberrant methylation by conversion of 5mC to 5hmC, and/or in triggering full 
demethylation to unmodified cytosine at these sites. Indeed, Wang et al. (2018) suggested 
that stable knockout of TET2 in MCF7 cells may mediate demethylation of subsets of ER 
enhancers. However, emerging evidence also suggests that 5hmC, rather than being a 
transient intermediate in an enzymatic process leading to DNA demethylation, is instead 
created and remains stable in genomic DNA for an extended period of time (Bachman et 
al. 2014). TET2 activity might therefore facilitate maintenance of 5hmC at ER sites, where 
it acts as a stable epigenetic mark in its own right. 
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Distinction between 5mC and 5hmC can be attained through oxidative bisulfite 
sequencing (OxBS-seq). This is achieved by comparing sequencing results obtained from 
traditional bisulfite sequencing (5mC + 5hmC) with those obtained from a bisulfite 
sequencing method incorporating an oxidation step, which allows 5hmC to be sequenced 
as thymine whilst 5mC is read as cytosine (Booth et al. 2013). Comparison of the resulting 
sequences allows distinction between 5mC and 5hmC. As the 5hmC profiling method 
used in this thesis (RRHP) relies on enrichment-based detection of 5hmC rather than 
detecting specific changes to the DNA sequence as a proxy for the presence of these 
modifications, further investigation would be required to establish the feasibility of 
‘subtracting’ the RRHP 5hmC readout from the MMS readout in this way. However, to 
investigate the dynamics of 5mC alone, OxBS-seq could be used to isolate the 5mC 
readout from 5hmC and interrogate these marks at base-resolution. This could be of 
importance to these studies, as this may help provide a clearer indication of which 
functions of TET2 are most important ER sites; whether TET2 activity predominantly 
involves turnover of 5mC to stable 5hmC, or whether this enzyme may mediate DNA 
demethylation at ER sites. This could provide a more comprehensive view of the 
contribution of TET2 to transcriptional regulation at ER regulatory regions. Performing 
investigations such as these after GATA3 knockdown could also help delineate any 
relationship between the loss of GATA3 and DNA modifications at specific ER sites. 
 
Despite a clear role for TET2 in regulating 5hmC in ER+ breast cancer cell lines, no direct 
correlation was observed between these changes at overall ER sites in response to TET2 
loss, and the directionality of the expression changes of nearby TET2-regulated genes. 
The approach of grouping ER/TET2 sites into those near upregulated, downregulated and 
unchanging genes, although providing a broad overview, may average out any site-
specific differences in 5mC/5hmC that could contribute to differential gene expression at 
different sites. In addition, several factors may contribute to a more nuanced relationship 
between gene expression and changes in DNA modifications. Some of these (such as 
CpG content of differentially methylated promoters, and differential assembly of chromatin 
remodellers and other transcriptional regulators at different sites) were discussed in 
Chapter 5. An alternative approach could be to first subclassify ER/TET2 sites based on 
their different properties, then examine any changes in DNA modifications at these sites 
in conjunction with changes in the expression of nearby genes. Specific properties of the 
ER/TET2 sites could then be taken into account when assessing the impact of any DNA 
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modification changes on gene expression. For example, categorising ER/TET2 sites 
based on their profile of histone modifications could provide an alternative starting point. 
The finding that increases in 5mC at promoters bearing H3K4me3 and/or downstream 
H3K79me2/3 (initiated or active promoters) and their associated enhancers is linked to 
gene repression, whilst increases in 5mC at promoters bearing H3K4me3 and H3K27ac 
(bivalent promoters) and their associated enhancers is linked to gene activation (Lu et al. 
2014) implies that the combined effects of histone marks and changes in DNA 
modifications could be important in defining gene regulatory outcomes at different sites.  
 
Additional factors to consider in the potentially nuanced relationship between 5mC/5hmC 
changes and gene expression could include the strength of ER/TET2 binding, and the 
profile of additional ER cofactors present at specific loci. For example, in Chapter 3 it was 
shown that ER interacts with both TET2, which may be involved in maintaining low 5mC 
at its target sites, and DNMT1, which methylates cytosines to produce 5mC. It is possible 
that DNMT1 and TET2 could participate in the ER complex to exert opposite effects on 
DNA methylation, and at sites where their levels or activity in the ER complex do not 
counter one another equally, the changes in DNA modifications might result in a fine-
tuning of transcriptional control, at a subset of sites and in a locus-specific manner. Indeed, 
a study by Ariazi et al. (2017) suggested ER may direct methylation of certain target genes 
through an association with DNMTs. In addition, oestrogen-induced methylation and 
silencing of the CYP1A1 promoter in ER+ MCF7 cells was associated with recruitment of 
DNMT3B to this locus (Marques et al. 2013). Comparison of the levels of TET2 and 
DNMT1 at different ER sites, for example through ChIP-seq, could provide insights into 
the potential balance between methylation and any demethylation occurring at these loci. 
 
As part of future work, it may also be important to confirm which ER/TET2 sites are directly 
associated with TET2-regulated genes. This study has taken a proximity-based approach, 
assessing all TET2-regulated genes within a ± 50 kb window as potentially regulated by a 
particular ER/TET2 site. This is based on the finding that the majority of ER enhancers 
appear to lie within 10-100 kb of their target genes (Fullwood et al. 2009), however, many 
enhancers may be further away from their associated promoters. In addition, as described 
in Chapter 1, some ER binding events may not be functional, but may rather be the result 
of opportunistic ER binding (Carroll et al. 2006). Enhancers that are active in these cells 
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could be determined by performing ChIP-seq for active histone marks or monitoring the 
production of eRNAs. In conjunction with this, ER/TET2 sites could be linked to TET2-
regulated genes through mapping chromatin loops before and after TET2 knockdown. 
These approaches might provide additional perspectives on the relationship between 
changes in DNA modifications and TET2-regulated expression of ER target genes. 
Furthermore, in addition to investigating coding genes, changes in the expression of non-
coding RNAs could also be examined as endpoints of TET2 activity. 
 
Adding further complexity to the potential relationship between TET2 and ER-mediated 
gene expression, as described in Chapter 1, TET2 may have additional functions related 
to transcription. These might include mediating protein-protein interactions between 
transcriptional regulators, or stabilising histone modifying complexes at gene regulatory 
sites (Deplus et al. 2013; Zhang et al. 2015; Zhang et al. 2017). It is possible that these 
additional functions of TET2 may contribute to its role in gene regulation and fine-tune its 
effects at different loci. To distinguish the catalytic and non-catalytic functions of TET2, 
the activity of TET2 lacking dioxygenase functions could be examined in ER+ breast 
cancer cells. To complement the acute knockdown system used in this work, this could 
involve TET2 silencing followed by overexpression of a catalytically dead TET2 mutant to 
assess whether this rescues the effects of TET2 loss on ER-regulated gene expression 
and global ER binding. In addition, with work to develop TET2 knockout MCF7 cells using 
CRISPR currently in progress, CRISPR-generated TET2 catalytic mutants could provide 
a stable system for comparison. Overall, the findings summarised in this chapter provide 
novel insights into the mechanisms of ER biology. Placing these studies into the context 
of wider developments in both basic and translational research reveals several routes to 
build upon the work outlined in this thesis, towards the ultimate aim of developing more 
effective treatments for ER+ breast cancer. 
 
6.4 Conclusions 
In summary, the key points revealed by this study are: 
 TET2 is a GATA3-regulated member of the ER complex in MCF7 cells, and is also 
an ER target gene. 
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 TET2 binding events constitute a near-total subset of ER binding events in ER+ 
breast cancer cell lines and PDX models according to ChIP-seq, implying potential 
genomic co-operation between these two proteins. 
 Knockdown of TET2 in ER+ breast cancer cells depletes global ER binding and is 
associated with reduced cell growth and disrupted expression of several ER target 
genes. This suggests that TET2, as an ER-regulated component of the ER 
complex, may help to sustain ER-regulated transcription in breast cancer. 
 TET2 knockdown does not appear to result in changes to global DNA methylation 
in ER+ breast cancer cells. However, oxidation of methylated DNA to 5-
hydroxymethylcytosine (5hmC) is significantly reduced after TET2 depletion. This 
indicates a key role for TET2 in the production and maintenance of 5hmC at ER 
sites, providing a potential mechanism for TET2-mediated regulation of ER target 
genes. 
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